Page 1 Extracted Terms:
- anticoagulation therapy  
- aortic regurgitation  
- aortic stenosis  
- bicuspid aortic valve  
- cardiac surgery  
- guidelines  
- infective endocarditis  
- mitral regurgitation  
- mitral stenosis  
- mitral transcatheter edge-to-edge repair  
- prosthetic valve  
- pulmonic regurgitation  
- pulmonic stenosis  
- transcatheter aortic valve replacement or implantation  
- tricuspid regurgitation  
- tricuspid stenosis  
- valvular heart disease

Page 2 Extracted Terms:
- Valvular Heart Disease  
- Aortic Stenosis  
- Aortic Regurgitation  
- Bicuspid Aortic Valve  
- Mitral Stenosis  
- Mitral Regurgitation  
- Tricuspid Valve Disease  
- Tricuspid Regurgitation  
- Pulmonic Valve Disease  
- Mixed Valve Disease  
- Prosthetic Valves  
- Antithrombotic Therapy  
- Bridging Therapy  
- Anticoagulation for Atrial Fibrillation in Valve Disease  
- Infective Endocarditis Prophylaxis  
- Valve Prosthesis Selection (Bioprosthetic vs Mechanical)  
- Prosthetic Valve Thrombosis  
- Prosthetic Valve Stenosis  
- Prosthetic Valve Regurgitation  
- Valve Disease Severity Assessment  
- Multidisciplinary Heart Valve Team  
- Diagnostic Testing (e.g., Echocardiography, Cardiac Catheterization)  
- Timing of Valve Intervention  
- Medical Therapy for Valve Disease  
- Secondary Prevention of Rheumatic Fever  
- Acute Mitral Regurgitation  
- Chronic Primary Mitral Regurgitation  
- Chronic Secondary Mitral Regurgitation  
- Acute Aortic Regurgitation  
- Chronic Aortic Regurgitation  
- Rheumatic Mitral Stenosis  
- Nonrheumatic Calcific Mitral Stenosis  
- Surgical and Transcatheter Interventional Risk Evaluation  
- Routine Follow‑Up Imaging after Valve Intervention  

Page 3 Extracted Terms:
- Valvular Heart Disease (VHD)  
- Infective Endocarditis  
- Aortic Stenosis  
- Aortic Regurgitation  
- Mitral Stenosis  
- Mitral Regurgitation  
- Tricuspid Regurgitation  
- Pulmonary Regurgitation (if applicable)  
- Coronary Artery Disease (CAD) in VHD patients  
- Transcatheter Aortic Valve Implantation (TAVI)  
- Surgical valve replacement/repair  
- Valve surgery  
- Atrial Fibrillation (AF) in VHD  
- Oral anticoagulation therapy  
- Vitamin K antagonist (e.g., warfarin)  
- Non‑vitamin K antagonist oral anticoagulants (NOACs)  
- CHA₂DS₂‑VASc score  
- Valve intervention (timing, type, approach)  
- Mechanical prosthetic heart valves  
- Bioprosthetic (tissue) valves  
- Multidisciplinary valve team  
- Primary Valve Center  
- Comprehensive Valve Center  
- Transcatheter edge‑to‑edge mitral repair (MitraClip)  
- Isolated tricuspid regurgitation surgery  
- Pregnancy in VHD (management/anticoagulation)  
- Stages of valve disease (A, B, C, D)  
- Noncardiac surgery in VHD patients  
- Symptomatic vs. asymptomatic patient management  
- Prevention of valve disease  
- Disease progression therapy  
- Optimal timing of intervention  
- Imaging modalities: ECG, chest X‑ray, TTE, CT, CMR, stress testing, TEE, cardiac catheterization  
- Ventricular systolic function assessment  
- Left ventricular volume overload  
- Stroke prevention in AF/VHD  

These terms capture the core concepts and clinical focus areas discussed in the guideline text.

Page 4 Extracted Terms:
- Valvular heart disease  
- Cardiac valve dysfunction  
- Bioprosthetic valve dysfunction  
- Bioprosthetic leaflet degeneration  
- Valve thrombosis  
- Prosthetic valve dysfunction  
- Paravalvular leak  
- Right ventricular dysfunction  
- Cardiovascular disease  
- End‑organ damage (liver and kidney)  
- Cardiovascular health  
- Bioprosthetic valve  
- Valve degeneration  
- Cardiovascular care (clinical context)

Page 5 Extracted Terms:
- Valvular heart disease  
- Aortic stenosis  
- Aortic regurgitation  
- Bicuspid aortic valve  
- Mitral stenosis  
- Mitral regurgitation  
- Tricuspid stenosis  
- Tricuspid regurgitation  
- Pulmonic stenosis  
- Pulmonic regurgitation  
- Prosthetic valves  
- Anticoagulation therapy  
- Infective endocarditis  
- Cardiac surgery  
- Transcatheter aortic valve replacement  
- Transcatheter aortic valve implantation  
- Percutaneous mitral clip  

Page 6 Extracted Terms:
- Valvular Heart Disease  
- Aortic Valve Stenosis (AS)  
- Aortic Regurgitation (AR)  
- Bicuspid Aortic Valve (BAV)  
- Mitral Regurgitation  
- Tricuspid Regurgitation  
- Atrial Fibrillation (AF)  
- Heart Failure (HF)  
- Hypertrophic Cardiomyopathy  
- Infective Endocarditis (IE)  
- Congenital Heart Disease  
- Prosthetic Valve  
- Percutaneous Valve Repair / Replacement  
- Coronary Artery Disease (CAD)  
- Coronary Artery Bypass Graft (CABG)  
- Angiotensin‑Converting Enzyme (ACE) Inhibitors  
- Angiotensin Receptor Blockers (ARB)  
- B‑Type Natriuretic Peptide (BNP)  
- Low‑Molecular‑Weight Heparin (LMWH)  
- International Normalized Ratio (INR)  
- Activated Partial Thromboplastin Time (aPTT)  
- Electrocardiogram (ECG)  
- Computed Tomography (CT)  
- Cardiac Magnetic Resonance Imaging (CMR)  
- Echocardiography (2‑D & 3‑D)  
- Doppler Echocardiography  
- Guideline‑Directed Medical Therapy (GDMT)  

**Key Guideline Terms**  
- ACC/AHA Guideline for the Management of Valvular Heart Disease  
- ACC/AHA/ESC Guidelines for Atrial Fibrillation  
- ACCF/AHA Guideline for the Management of Heart Failure  
- ESC/EACTS Guidelines on Valvular Heart Disease  
- ESC/EAC Guidelines for Congenital Heart Disease  
- ACCP Antithrombotic and Thrombolytic Therapy for Valvular Disease

Page 7 Extracted Terms:
- Valvular heart disease (VHD)  
- Valvular lesions/valve dysfunction  
- Heart murmur  
- Electrocardiogram (ECG)  
- Chest X‑ray  
- Transthoracic echocardiography (TTE)  
- Transesophageal echocardiography (TEE)  
- Computed tomography (CT)  
- Cardiac magnetic resonance (CMR) imaging  
- Positron emission tomography (PET)  
- Holter monitoring  
- Diagnostic hemodynamic cardiac catheterization  
- Transcatheter aortic valve implantation (TAVI)  
- Surgical aortic valve replacement (SAVR)  
- Transcatheter edge‑to‑edge repair (TEER)  
- Valve‑in‑valve (ViV) procedures  
- Mitral regurgitation (MR)  
- Mitral stenosis (MS)  
- Tricuspid regurgitation (TR)  
- Atrial fibrillation (AF)  
- Pulmonary hypertension  
- Stroke (as a VHD‑related complication)  
- Left ventricle (LV)  
- Right ventricle (RV)  
- Left ventricular ejection fraction (LVEF)  
- Left ventricular end‑diastolic dimension (LVEDD)  
- Left ventricular end‑systolic dimension (LVESD)  
- NYHA functional class  
- Non‑vitamin K oral anticoagulant (NOAC)  
- Vitamin K antagonist (VKA)  
- Unfractionated heparin (UFH)  
- Percutaneous coronary intervention (PCI)  
- Percutaneous mitral balloon commissurotomy (PMBC)  
- Randomized controlled trial (RCT)  
- Multidisciplinary team (MDT)  
- Level of Evidence (LOE)  
- Stages A–D of VHD progression  
- Symptom evaluation (e.g., dyspnea, chest pain)  
- Valve anatomy and hemodynamics assessment  
- Ventricular and vascular function impact  
- End‑organ damage criteria  
- Surgical or transcatheter intervention criteria  
- Periodic monitoring and patient education  
- Comorbidities, frailty, patient preferences, and values.

Page 8 Extracted Terms:
- TTE (transthoracic echocardiography)  
- Valve anatomy  
- Valve disease  
- Aortic dilation  
- Left ventricular (LV) anatomy  
- Linear dimensions  
- 2D volumes  
- 3D volumes  
- Ejection fraction (LVEF)  
- Sequential studies  
- Measurement variability  
- Doppler echocardiography  
- Valve hemodynamics  
- Stenotic lesions  
- Maximum velocity  
- Mean gradient  
- Valve area  
- Regurgitant lesions  
- Regurgitant orifice area  
- Regurgitant volume  
- Regurgitant fraction  
- Multiparameter severity grade  
- Color Doppler imaging  
- Continuous‑wave Doppler  
- Pulsed‑wave Doppler  
- Distal flow reversals  
- Pulmonary systolic pressure  
- Right ventricular (RV) size  
- Right ventricular function  
- Stress testing  
- TEE (transesophageal echocardiography)  
- Cardiac catheterization  
- CT imaging  
- CMR imaging  
- Cardiac imaging  
- Hemodynamics  
- Echocardiography (as primary evaluation tool)  
- Valvular heart disease (VHD)  
- ACC/AHA guideline for valvular heart disease  
- Intersocietal Accreditation Commission (IAC) accreditation  
- Class of Recommendation and Level of Evidence (clinical strategies, interventions, treatments, or diagnostic testing)

Page 9 Extracted Terms:
- Valvular Heart Disease (VHD)  
- Transthoracic Echocardiography (TTE)  
- Transesophageal Echocardiography (TEE)  
- Cardiac Magnetic Resonance (CMR)  
- Positron Emission Tomography–Computed Tomography (PET‑CT)  
- Stress Testing (exercise treadmill, stress echo)  
- Cardiac Catheterization  
- Echocardiographic Strain Imaging (TTE strain)  
- Pulmonary Circulation  
- Ventricular Response  
- Left Ventricular Function  
- Heart Failure (HF)  
- Electrocardiogram (ECG)  
- Biomarkers (filling pressures, myocardial damage)  
- Intracardiac Pressures  
- Valve Morphology  
- Valve Severity  
- Valve Deterioration  
- Progressive Valve Dysfunction  
- Volume Overload  
- Pressure Overload  
- Aortic Disease  
- Intracardiac Mass  
- Intracardiac Abscess  
- Left Atrial Thrombus  
- Fibrosis (gadolinium enhancement)  
- Frailty Score  
- Surgical Risk (STS Score)  
- Transcatheter Aortic Valve Implantation (TAVI)  
- Coronary Angiography (CT or invasive)  
- Peripheral Access (CT Peripheral)  
- Cardiac CT (CT Cardiac)  
- Dental Examination (infection source)  
- Chest X‑ray  
- History and Physical Examination  
- Symptom Status  
- Physical Examination  
- Stages C2 and D Disease  
- Interventional Candidates  
- Clinical Follow‑up Schedule  
- Intrinsic Myocardial Performance  
- Prognostic Markers  
- Risk Stratification  
- Timing of Intervention

Page 10 Extracted Terms:
Valvular heart disease (VHD)  
Hemodynamic catheterization  
Transvalvular pressure gradients  
Cardiac output measurement  
Valvular stenosis  
Valve regurgitation  
Doppler beam alignment/velocity jet  
Contrast angiography  
Pulmonary vascular resistance  
Dobutamine infusion (low‑flow states)  
Pulmonary vasodilators  
Pulmonary hypertension  
Exercise hemodynamics  
Exercise stress testing  
Exercise capacity assessment  
Blood pressure response to exercise  
Prognostic value in asymptomatic valve disease  
Standard guideline‑directed medical therapy (GDMT)  
Hypertension  
Diabetes mellitus  
Hyperlipidemia  
Heart‑healthy lifestyle factors  
Aerobic exercise  
Left ventricular (LV) afterload  
Resistive training with light weights  
Risk factors for development of VHD  
Stage A: At risk (risk factors present)  
Stage B: Progressive (mild‑to‑moderate, asymptomatic)  
Stage C1: Asymptomatic severe, LV/RV compensated  
Stage C2: Asymptomatic severe, LV/RV decompensation  
Stage D: Symptomatic severe  
Left ventricle (LV)  
Right ventricle (RV)  
Aortic stenosis (AS)  
Aortic regurgitation (AR)  
Mitral stenosis (MS)  
Mitral regurgitation (MR)  
Maximum velocity (Vmax)  
Mitral valve (MV) area  
Serial echocardiographic surveillance intervals (3–5 y, 1–2 y, 6–12 mo, 1 yr)

Page 11 Extracted Terms:
- Valvular heart disease (VHD)  
- Left ventricular (LV) systolic dysfunction  
- Guideline‑directed medical therapy (GDMT)  
- Diuretics  
- Angiotensin‑converting enzyme (ACE) inhibitors  
- Angiotensin receptor blockers (ARBs)  
- Beta blockers  
- Aldosterone antagonists  
- Sacubitril/valsartan  
- Biventricular pacing  
- Heart failure (HF)  
- Stenotic valve lesions  
- Abrupt lowering of blood pressure  
- Rheumatic fever prophylaxis  
- Infective endocarditis (IE) prophylaxis  
- Oral health maintenance  
- Influenza vaccination  
- Pneumococcal vaccination  
- Atrial fibrillation (AF)  
- Anticoagulation therapy  
- Rheumatic heart disease  
- Strep A pharyngitis (group A streptococcus)  
- Antibiotic prophylaxis  
- Dental procedures (gingival manipulation, periapical manipulation, mucosal perforation)  
- Prosthetic cardiac valves  
- Transcatheter‑implanted prostheses  
- Homografts  
- Prosthetic material for valve repair (annuloplasty rings, chords, clips)  
- Previous infective endocarditis (IE)  
- Unrepaired cyanotic congenital heart disease  
- Repaired congenital heart disease with residual shunts or valvular regurgitation  
- Prosthetic patch or prosthetic device  
- Cardiac transplant with valve regurgitation caused by an abnormal valve  
- Non‑dental invasive procedures (transthoracic/ transesophageal echocardiography, esophagogastroduodenoscopy, colonoscopy, cystoscopy)  
- Penicillin G benzathine (intramuscular)  
- Penicillin V potassium (oral)  
- Sulfadiazine (oral)  
- Macrolide or azalide antibiotics (for penicillin‑allergic patients)  
- Lifelong or extended prophylaxis (≥ 10 years or until 40 years of age)  
- Group A streptococcus exposure risk  
- Clinical or echocardiographic evidence of residual valvular heart disease.

Page 12 Extracted Terms:
- Infective Endocarditis (IE)  
- Prophylactic Antibiotics  
- Prosthetic Valve  
- Prior Infective Endocarditis  
- Congenital Heart Disease (with residual flow disturbances)  
- Transcatheter Aortic Valve Implantation (TAVI)  
- Surgical Aortic Valve Replacement (SAVR)  
- Valve Repair with Prosthetic Material  
- Heart Transplant Recipients  
- Endothelial Disruption  
- High‑Intensity Immunosuppressive Therapy  
- Central Venous Catheter Access  
- Endomyocardial Biopsies  
- Oral Health / Oral Hygiene (brushing teeth, flossing)  
- Transient Bacteremia  
- Clostridium difficile Colitis  
- Anticoagulation for Atrial Fibrillation (AF) in Valvular Heart Disease (VHD)  
- Native Valve Heart Disease (excluding rheumatic mitral stenosis)  
- Rheumatic Mitral Stenosis (MS)  
- Bioprosthetic Valve (≥ 3 months post‑implantation)  
- CHA₂DS₂‑VASc Score  
- Vitamin‑K Antagonist (VKA) Anticoagulation  
- Non‑Vitamin‑K Oral Anticoagulant (NOAC)  
- Mechanical Heart Valves  
- Valve Thrombosis Prevention  
- Atrial Fibrillation (AF)  
- Valvular Heart Disease (VHD)  

Page 13 Extracted Terms:
**Key heart‑disease related terms from the text**

1. Valvular heart disease (VHD)  
2. Bioprosthetic valves  
3. Rheumatic mitral stenosis (MS)  
4. Non‑vitamin K oral anticoagulants (NOACs)  
5. Warfarin  
6. Vitamin K antagonist (VKA)  
7. Mechanical heart valves  
8. Atrial fibrillation (AF)  
9. CHA₂DS₂‑VASc risk score  
10. Thromboembolic events (e.g., stroke)  
11. Post‑operative AF after VHD intervention  
12. Bioprosthesis (bioprosthetic valve prosthesis)  
13. Transcatheter valve implantation  
14. Target international normalized ratio (INR)  
15. Stroke and mortality risks associated with AF/VHD  
16. Phase II RE‑ALIGN study (dabigatran vs. warfarin in valve replacement)  

These terms capture the key clinical concepts and disease entities discussed in the guideline excerpt.

Page 14 Extracted Terms:
Valvular heart disease (VHD)  
Mechanical heart valve  
Bleeding (in anticoagulation)  
Dabigatran  
Non‑vitamin K antagonist oral anticoagulants (NOACs)  
Evaluation of surgical and interventional risk  
Transcatheter aortic valve implantation (TAVI)  
Aortic stenosis (AS)  
Valve durability  
Permanent pacemaker implantation  
Surgical bioprosthesis  
Valve‑in‑valve (ViV) procedure  
Reoperation  
Surgical aortic valve replacement (SAVR)  
Mitral valve repair  
Mitral regurgitation (MR)  
STS risk calculator (STS‑Predicted Risk of Death)  
EuroSCORE II risk calculator  
Frailty assessment (frailty indices)  
Organ system compromise  
Cardiac dysfunction  
Left‑ventricular dysfunction (systolic or diastolic)  
Right‑ventricular dysfunction  
Pulmonary hypertension  
Risk assessment tools  
Shared decision‑making process

Page 15 Extracted Terms:
- Valvular Heart Disease (VHD)  
- Multidisciplinary Heart Valve Team (MDT)  
- Primary or Comprehensive Heart Valve Center  
- Aortic Valve Replacement (AVR)  
- Surgical Aortic Valve Replacement (SAVR)  
- Transcatheter Aortic Valve Implantation (TAVI)  
- Transcatheter Edge‑to‑Edge Repair (TEER)  
- Mitral Valve Repair  
- Mitral Valve Replacement  
- Coronary Artery Bypass Grafting (CABG)  
- Society of Thoracic Surgeons (STS) score  
- Chronic Obstructive Pulmonary Disease (COPD)  
- Pulmonary Hypertension  
- Right Ventricular (RV) Dysfunction  
- Hepatic Dysfunction  
- Frailty (including Katz Activities of Daily Living Score)  
- Life expectancy < 1 year  
- Poor candidate for rehabilitation  
- Multivalve disease  
- Aorto‑iliac occlusive disease (precluding transfemoral approach)  
- Ascending aortic calcification (porcelain aorta)  
- Aortic arch atherosclerosis (protuberant lesions)  
- Severe mitral regurgitation (MR)  
- Severe tricuspid regurgitation (TR)  
- Basal septal hypertrophy  
- Valve morphology (bicuspid, unicuspid, thickening, perforations, clefts, calcification, stenosis)  
- Extensive left‑ventricular outflow tract calcification  
- Prior mediastinal radiation  
- Prior sternotomy  
- Prior mitral valve surgery  
- Risk prediction tools (tool‑specific)  
- Operator/institutional case volume  
- Perioperative mortality rates  
- Surgical procedure‑specific mortality (e.g., AVR, AVR+CABG, mitral repair, etc.)

Page 16 Extracted Terms:
- TAVI (transfemoral)  
- Percutaneous aortic valve balloon dilation  
- TAVI – alternative access (transthoracic, transapical, subclavian, carotid, caval)  
- Valve‑in‑valve procedures  
- TEER (transcatheter edge‑to‑edge repair)  
- Prosthetic valve paravalvular leak closure  
- Percutaneous mitral balloon commissurotomy  
- SAVR (surgical aortic valve replacement)  
- Valve‑sparing aortic root procedures  
- Aortic root procedures for aneurysmal disease  
- Concomitant septal myectomy with AVR  
- Root enlargement with AVR  
- Mitral repair for primary MR (posterior leaflet)  
- Mitral valve replacement  
- Multivalve operations  
- Reoperative valve surgery  
- Isolated or concomitant tricuspid valve repair or replacement  
- Concomitant tricuspid valve repair or replacement with mitral surgery  
- Echocardiographer (valve disease expertise)  
- Expertise in CT (valve assessment and procedural planning)  
- Interventional echocardiographer (imaging guidance)  
- Expertise in cardiac MRI (valve disease assessment)  
- Valve echocardiographer (pre‑ and post‑procedural assessment)  
- Expert in CT (pre‑procedural assessment of valve disease)  
- Interventional echocardiographer (formalized role)  
- Multidisciplinary team (MDT)  
- Valve coordinator (dedicated role)  
- Cardiac anesthesia support  
- Palliative care team  
- Vascular surgery support  
- Neurology stroke team  
- Consultative services with cardiovascular subspecialties  
- Consultative services with other medical and surgical subspecialties  
- Echo 3D TEE (transesophageal echocardiography)  
- Comprehensive TTE (transthoracic echocardiography)  
- Cardiac CT  
- ICU (intensive care unit)

Page 17 Extracted Terms:
- Valvular heart disease (VHD)  
- Heart valve programs  
- Multidisciplinary team (MDT)  
- Cardiologists (including valve disease specialists)  
- Interventional cardiologists  
- Cardiovascular imaging specialists  
- Heart failure (HF) specialist  
- Cardiovascular nurses  
- Cardiovascular anesthesiologists  
- Intensivists  
- Primary clinical cardiologist  
- Secondary mitral regurgitation (MR)  
- Tricuspid regurgitation (TR)  
- Operative mortality  
- Perioperative morbidity  
- Institutional volume  
- Surgical aortic valve replacement (SAVR)  
- Transcatheter aortic valve implantation (TAVI)  
- Mitral valve repair (surgical)  
- Primary/Comprehensive heart valve center  
- Multiple comorbidities  
- Cardiac surgical care  
- Cardiac catheterization laboratory  
- Hybrid catheterization laboratory  
- Hybrid operating room (OR) laboratory  
- Permanent pacemaker (PPM) implantation  
- Implantable cardioverter‑defibrillator (ICD) implantation  
- Temporary mechanical support (e.g., intra‑aortic balloon pump, temporary peripheral ventricular assist device, ECMO)  
- Left‑ventricular assist device (LVAD)  
- Right‑ventricular assist device (RVAD)  
- Intersocietal Accreditation Commission (IAC) echocardiography laboratory accreditation  
- Intensive care unit (ICU) coverage  
- Fixed radiographic imaging system and flat‑panel fluoroscopy  
- Aortic valve replacement (AVR)  
- Computed tomography (CT)  
- Extracorporeal membrane oxygenation (ECMO)  
- Implantable cardioverter defibrillator (ICD)  
- Intersocietal Accreditation Commission (IAC)  
- Intensive care unit (ICU)  
- Multidisciplinary team (MDT)  
- Mitral regurgitation (MR)  
- Magnetic resonance imaging (MRI)  
- Operating room (OR)  
- Permanent pacemaker (PPM)  
- Surgical aortic valve replacement (SAVR)  
- Transcatheter aortic valve implantation (TAVI)  
- Transesophageal echocardiography (TEE)  
- Transcatheter edge‑to‑edge repair (TEER)  
- Transthoracic echocardiography (TTE)  
- Valvular heart disease (VHD)  
- Valve‑in‑valve (ViV) procedures

Page 18 Extracted Terms:
- Valvular heart disease (VHD)  
- Prosthetic valve  
- Valve replacement (surgical & transcatheter)  
- Valve repair (mitral)  
- Aortic valve replacement (AVR)  
- Bicuspid aortic valve disease  
- Mechanical valve (surgical)  
- Bioprosthetic valve (surgical & transcatheter)  
- Atrial fibrillation (post‑operative AF)  
- Pulse‑wave and conduction abnormalities (heart block, permanent pacing)  
- Stroke and embolic events  
- Vascular complications (access‑site, systemic)  
- Bleeding complications  
- Pericarditis  
- Infection (prosthetic valve endocarditis)  
- Endocarditis prophylaxis  
- Antithrombotic therapy for prosthetic valves  
- Valve thrombosis  
- Valve stenosis  
- Valve regurgitation (including paravalvular leak)  
- Residual valve dysfunction  
- Coronary artery disease (CAD) – concurrent with VHD  
- Primary prevention of CAD  
- Secondary prevention of CAD  
- Cardiovascular outcomes and coronary events  
- Heart failure (HF) – symptom management, GDMT  
- Left‑ventricular (LV) systolic dysfunction  
- Left‑ventricular (LV) diastolic dysfunction  
- Right‑ventricular (RV) dysfunction  
- Pulmonary hypertension  
- Renal dysfunction (post‑operative)  
- Transthoracic echocardiography (TTE) – baseline, periodic imaging  
- Timing of periodic imaging (baseline, 1 yr, 5 yr, 10 yr, annual)  
- Valve degeneration (early bioprosthetic degeneration)  
- Risk factors for valve degeneration (younger age, diabetes, renal failure)  
- Hemodynamic monitoring after valve intervention  
- Clinical follow‑up (annual, pregnancy)  
- Primary Valve Center, Comprehensive Valve Center, Valve surveillance programs



Page 19 Extracted Terms:
- Valve intervention  
- Baseline transthoracic echocardiography (TTE)  
- Prosthetic valve  
- Transaortic maximum velocity  
- Mean pressure gradient  
- Low‑flow, low‑gradient severe aortic stenosis (AS)  
- Stage D2 (low LVEF)  
- Stage D3 (normal LVEF)  
- Bicuspid aortic valve (BAV)  
- Doppler echocardiography  
- Transesophageal echocardiography (TEE)  
- Cardiac magnetic resonance (CMR)  
- Cardiac computed tomography (CT)  
- Positron emission tomography (PET)  
- Endocarditis  
- Aortic valve hemodynamics  
- Left ventricular (LV) systolic function  
- LV size  
- Pulmonary systolic pressure  
- Left ventricular ejection fraction (LVEF)  
- Contractile reserve  
- Valve anatomy and motion  
- Valve obstruction  
- Residual valve dysfunction  
- Concurrent cardiac conditions  
- Blood pressure control  
- Low‑dose dobutamine stress testing  
- Valvular heart disease (VHD)  
- Aortic valve calcium score  
- Hemodynamic severity  
- Ventricular size  
- Cardiac catheterization  
- Fluoroscopy  
- Clinical history and physical examination  
- Periodic imaging schedule  
- Valve repair/valve prosthesis type  
- Symptom‑based monitoring  
- Systemic hypertension  
- Blood pressure management  
- Transaortic volume flow rate  
- Stroke volume  
- Systolic function assessment  
- Valve replacement recommendations  
- Valve surveillance guidelines  

Page 20 Extracted Terms:
**Key heart‑disease terms extracted**

- Aortic stenosis (AS)  
- Aortic valve area (AVA)  
- Aortic valve area indexed (AVAi)  
- Aortic valve sclerosis  
- Bicuspid aortic valve (BAV)  
- Aortic regurgitation (AR)  
- Left ventricular ejection fraction (LVEF)  
- Left ventricular hypertrophy (LVH)  
- Left ventricular systolic dysfunction  
- Left ventricular diastolic dysfunction  
- Forward stroke volume  
- Stroke volume index (SVi)  
- Transaortic pressure gradient  
- Mean pressure gradient (ΔP)  
- Maximum velocity (Vmax)  
- Severe AS  
- Low‑gradient AS  
- High‑gradient AS  
- Symptomatic severe AS  
- Asymptomatic severe AS  
- Low‑flow AS  
- Paradoxical low‑flow severe AS  
- Pulmonary hypertension  
- Exercise tolerance  
- Exertional dyspnea  
- Exertional angina  
- Syncope / presyncope  
- Heart failure (HF)  
- Stage A, B, C, D of AS progression  
- Doppler velocity data  
- Invasive pressure measurements  
- Valve anatomy  
- Valve hemodynamics  
- Valve calcification/fibrosis  
- Commissural fusion  
- Stroke‑volume index <35 mL/m²  
- Small left‑ventricular chamber  
- Restrictive diastolic filling  
- Aortic Vmax ≥4 m/s or ≥5 m/s  
- Aortic Vmax <4 m/s or 2.0–2.9 m/s  
- Mean ΔP ≥40 mm Hg or <20 mm Hg  
- Small, low‑flow, low‑gradient AS  
- Symptomatic low‑gradient AS with preserved LVEF.

Page 21 Extracted Terms:
- Valvular heart disease  
- Aortic stenosis (AS)  
- Moderate aortic stenosis  
- Severe aortic stenosis  
- Aortic valve calcification  
- Bicuspid aortic valve (BAV) disease  
- Dobutamine stress echocardiography  
- Aortic velocity  
- Mean pressure gradient  
- Trans‑aortic velocity  
- Valve area (effective orifice area)  
- Valve area measurement by continuity equation  
- Outflow tract‑to‑aortic velocity ratio  
- Lateral velocity ratio threshold (≤0.25)  
- Stroke volume reserve (≥20% increase with dobutamine)  
- Lack of contractile reserve / flow reserve  
- Aortic valve calcium volume (CT imaging)  
- Sex‑specific Agaston unit thresholds (1300 women, 2000 men)  
- Annulus area (CT measurement for TAVI planning)  
- Leaflet length (CT measurement for TAVI planning)  
- Annular‑to‑coronary ostial distance (CT measurement for TAVI planning)  
- Aortic murmur characteristics (loudness, onset, peak, A2 component)  
- Aortic valve stenosis progression metrics (velocity, gradient, area changes)  
- Aortic sclerosis (velocity <2.0 m/s)  
- Transaortic pressure gradient (cardiac catheterization)  
- Left ventricular (LV) outflow tract diameter/area  
- Left ventricular ejection fraction (LVEF)  
- Cardiac output  
- Hemodynamic demands (surgery, pregnancy, infection, anemia, bleeding)  
- Symptom onset in severe AS  
- Event‑free survival percentages for severe AS  
- Follow‑up intervals for asymptomatic severe or moderate AS  
- Diagnostic transthoracic echocardiography (TTE)  
- Doppler echocardiography (velocity, gradient measurement)  
- Non‑invasive imaging limitations (parallel intercept angle, image quality)  
- Angiographic assessment of aortic valve stenosis severity.

Page 22 Extracted Terms:
- Aortic Stenosis (AS)  
- Valvular Heart Disease (VHD)  
- Exercise Testing  
- Exercise‑induced Angina  
- Excessive Dyspnea  
- Syncope  
- Ventricular Tachycardia  
- Asystole  
- Gorlin Formula  
- Fick Method  
- Thermodilution  
- Cardiac Output  
- Aortic Velocity  
- Mean Pressure Gradient  
- Hypertension  
- Hypertensive Therapy  
- Statin Therapy  
- Renin–Angiotensin System Blocker  
- ACE Inhibitor  
- ARB (Angiotensin‑II Receptor Blocker)  
- TAVI (Transcatheter Aortic Valve Implantation)  
- Calcific Aortic Stenosis  
- Disease Staging (Stage A; Stage B; Stage C; Stage D)  
- GDMT (Guideline‑Directed Medical Therapy)  
- Coronary Angiography  
- Hemodynamic Compromise  
- Blood Pressure Monitoring  
- ECG Monitoring  
- Functional Capacity  
- Clinical Outcome  
- Guideline for Management of Valvular Heart Disease  
- ACC/AHA Guideline for Valvular Heart Disease  
- Circulation (journal)  
- Diagnostic Testing  
- Physiological Changes  
- Hemodynamics  
- Complications (e.g., syncope, ventricular tachycardia, death)

Page 23 Extracted Terms:
- Aortic stenosis (AS)  
- Asymptomatic aortic stenosis  
- Severe aortic stenosis  
- Very severe aortic stenosis  
- Aortic valve replacement (AVR)  
- Surgical aortic valve replacement (SAVR)  
- Transcatheter aortic valve implantation (TAVI)  
- Left ventricular ejection fraction (LVEF)  
- Low‑flow, low‑gradient severe AS  
- Low surgical risk  
- High‑gradient severe AS  
- Elevated B‑type natriuretic peptide (BNP)  
- Ischemic cardiovascular events  
- Cardiovascular mortality  
- Hypertension (high blood pressure)  
- Renin–angiotensin system blockers  
- Angiotensin‑converting enzyme (ACE) inhibitors  
- Diuretics  
- LV fibrosis  
- Hypercholesterolemia  
- Coronary artery disease (CAD)  
- Statin therapy  
- Lipid‑lowering therapy  
- Experimental models of calcific AS  
- Randomized controlled trials (RCTs)  
- Observational and registry data  
- Clinical guideline statements (ACC/AHA, 2020)  
- Low‑flow versus high‑flow states in AS  
- Systolic blood pressure fall during exercise  
- Exercise testing (stress test)  
- Progressive decline in LVEF  
- Progressive increase in aortic velocity  
- Aortic valve event rates  
- Perioperative management of AS patients.

Page 24 Extracted Terms:
- Aortic stenosis (AS)  
- Severe high‑gradient AS  
- Low‑gradient AS  
- Symptomatic AS  
- Asymptomatic AS  
- Stage C, Stage D1, D2, D3 (AS staging)  
- Aortic valve replacement (AVR)  
- Surgical aortic valve replacement (SAVR)  
- Transcatheter aortic valve implantation (TAVI/TAVR)  
- Mechanical valve  
- Bioprosthetic valve  
- Left ventricular ejection fraction (LVEF)  
- Left ventricular systolic function  
- Exertional dyspnea  
- Decreased exercise tolerance  
- Heart failure (HF)  
- Syncope  
- Angina  
- Sudden death risk  
- B‑type natriuretic peptide (BNP)  
- Blood pressure (BP)  
- Dobutamine stress echocardiography (DSE)  
- Exercise treadmill test (ETT)  
- Mean systolic pressure gradient (∆Pmean)  
- Stroke volume index (SVI)  
- Aortic valve area (AVA)  
- Aortic valve area index (AVAi)  
- Maximum velocity (Vmax)  
- Afterload mismatch  
- Symptomatic survival benefit of AVR  
- Transcatheter versus surgical AVR choice  
- Palliative care in prohibitive surgical risk patients  
- RCT (randomized controlled trial)  

(Note: All terms are extracted from the guideline excerpt and pertain to heart disease, particularly aortic valve disease and its management.)

Page 25 Extracted Terms:
- Aortic valve replacement (AVR)  
- Transcatheter aortic valve implantation (TAVI)  
- Aortic stenosis (AS)  
- Severe aortic stenosis  
- Very severe aortic stenosis  
- Low‑flow, low‑gradient severe AS  
- High‑gradient AS  
- Mean pressure gradient (mm Hg)  
- Aortic velocity (m s⁻¹)  
- Stroke volume (mL)  
- Stroke volume index (mL m⁻²)  
- Left ventricular ejection fraction (LVEF)  
- Contractile reserve  
- Dobutamine stress testing  
- Echocardiographic assessment of valve stenosis  
- Valve area (cm²)  
- Valve area indexed to body size  
- Valve area index (cm² m⁻²)  
- Aortic valve calcium score (CT)  
- B‑type natriuretic peptide (BNP)  
- Cardiovascular mortality  
- Surgical risk (e.g., low, high)  
- Patient‑prosthesis mismatch  
- Anticoagulation considerations  
- Symptom onset (clinical, exercise‑provoked)  
- Afterload mismatch  
- Left‑ventricular systolic dysfunction  
- Left‑ventricular diastolic dysfunction  
- Hypertension (blood‑pressure control)  
- Doppler imaging  
- Two‑dimensional (2D) imaging  
- Guideline recommendations (ACC/AHA, 2020)  
- Surgical aortic valve replacement (SAVR)  
- Exercise testing (symptom clarification)

Page 26 Extracted Terms:
- BNP (Brain Natriuretic Peptide)  
- Aortic valve stenosis (AS)  
- Aortic valve replacement (AVR)  
- Left ventricular ejection fraction (LVEF)  
- Left‑ventricular systolic function  
- Hemodynamic progression  
- Aortic velocity  
- Mean gradient  
- Valve area  
- Valve calcification  
- Severe AS (asymptomatic or symptomatic)  
- Symptom onset  
- Sudden death  
- All‑cause mortality  
- Cardiovascular mortality  
- Hazard ratio (HR)  
- BNP level >300 pg/mL  
- Mechanical prosthetic valve  
- Bioprosthetic valve  
- Ross procedure (pulmonic autograft)  
- TAVI (transcatheter aortic valve implantation)  
- VKA anticoagulation  
- Anticoagulant therapy  
- Valve reintervention  
- Shared decision‑making  
- Serial imaging studies  
- Valve durability  
- Clinical risk factors (age, comorbid conditions)  

(Note: The list captures key heart‑disease‑related terms from the guideline excerpt.)

Page 27 Extracted Terms:
- Valvular heart disease  
- Aortic valve replacement (AVR)  
- Mitral valve replacement  
- Bioprosthetic valve  
- Mechanical valve prosthesis  
- Transcatheter aortic valve implantation (TAVI)  
- Valve durability  
- Structural valve deterioration (SVD)  
- Reintervention / reoperation  
- Valve prosthesis mismatch  
- Anticoagulation therapy  
- Vitamin K antagonist (VKA)  
- Low‑molecular‑weight heparin (LMWH) – alternative anticoagulant (not directly mentioned but relevant)  
- New‑generation direct oral anticoagulants (DOACs)  
- Thromboembolic events  
- Bleeding risk (intracranial, gastrointestinal)  
- International Normalized Ratio (INR) monitoring  
- Long‑term anticoagulation  
- Age stratification in valve choice (<50, 50–65, >65 years)  
- Patient values and preferences  
- Shared decision‑making process  
- Pregnancy‑related anticoagulation considerations  
- Surgical vs interventional risk  
- Hemodynamics of valve type and size  
- Post‑implant monitoring  
- Implantation‑related complications  
- Structural deterioration probability (15‑year risk %)  
- Survival advantage with mechanical valves  
- Late mortality associated with bioprosthetic valves  

   (All terms are directly related to heart valve disease management and outcomes as described in the guideline excerpt.)

Page 28 Extracted Terms:
**Key heart‑disease terms identified**

- Valvular heart disease  
- VKA therapy  
- Bleeding complications  
- Anticoagulation  
- Bioprosthetic valve  
- Prosthetic heart valve  
- Ross procedure  
- Aortic valve replacement  
- Pulmonary autograft (Ross procedure)  
- Pulmonic homograft  
- Valve degeneration  
- Valve calcification  
- Valve re‑intervention  
- Severe aortic stenosis (AS)  
- Aortic valve (AV)  
- Pulmonary valve (PV)  
- Valve durability  
- Aortic valve (AV) replacement (SAVR)  
- Transcatheter aortic valve implantation (TAVI)  
- Transfemoral TAVI  
- Life expectancy  
- Symptomatic vs. asymptomatic AS  
- LVEF (<50%)  
- BNP  
- Exercise test (exercise‑testing)  
- High or prohibitive surgical risk  
- Palliative care  
- Critical illness  
- Percutaneous aortic balloon dilation  
- Shared decision‑making  
- Comprehensive valve center  
- Valve hemodynamics  
- Valve failure (regurgitation of the neoaortic valve)  
- Valve position (pulmonic, aortic)  
- Valve anatomy  
- Valve durability data (≥10 years)  
- Post‑TAVI survival  
- Post‑SAVR survival  
- Quality of life (QoL)  

These terms capture the major concepts and interventions related to heart valve disease discussed in the provided guideline excerpt.

Page 29 Extracted Terms:
- ACC/AHA Guideline for the Management of Valvular Heart Disease  
- Valvular Heart Disease  
- Surgical Aortic Valve Replacement (SAVR)  
- Transcatheter Aortic Valve Implantation (TAVI)  
- Aortic Valve Replacement (AVR)  
- Aortic Stenosis (AS)  
- Bioprosthetic Valve  
- Mechanical Valve  
- Valve Durability  
- Lifelong Anticoagulation  
- Vitamin K Antagonist (VKA)  
- Transfemoral Delivery  
- Aortic Root Dilation  
- Annulus Size and Shape  
- Leaflet Number  
- Calcification  
- Coronary Ostial Height  
- Left Ventricular Ejection Fraction (LVEF)  
- Quality of Life (QOL)  
- Society of Thoracic Surgeons (STS)  
- ACC Expert Consensus Statement  
- Valvular Anatomy   
- Transcatheter Valve Placement  
- Age-Related Longevity and Valve Selection  
- Vascular Anatomy Compatibility



Page 30 Extracted Terms:
- Valvular Heart Disease  
- Aortic Valve Replacement (AVR)  
- Surgical Aortic Valve Replacement (SAVR)  
- Transcatheter Aortic Valve Implantation (TAVI)  
- Aortic Stenosis (AS)  
- Severe Aortic Stenosis  
- Low‑flow, low‑gradient Severe AS  
- High‑velocity Severe AS (Stage D1)  
- Left Ventricular Ejection Fraction (LVEF)  
- Paravalvular Leak / Regurgitation  
- Valve Durability  
- Transfemoral TAVI Approach  
- Balloon‑Expandable Valve  
- Self‑Expanding Valve  
- Valve‑in‑Valve TAVI  
- Permanent Pacemaker Implantation  
- Vascular Complications  
- Stroke  
- Major Bleeding  
- Atrial Fibrillation (AF)  
- Hospital Length of Stay  
- Post‑operative Pain  
- Symptomatic Patients  
- Surgical Risk (High, Low, Intermediate)  
- Life Expectancy  
- Comorbid Cardiac Conditions  
- Noncardiac Conditions  
- Frailty  
- Dementia  
- Shared Decision‑Making  
- Mortality Risk  
- Paravalvular Leakage  
- Stroke Risk (HR)  
- Bleeding Risk  
- AF Risk  
- Paravalvular Regurgitation  
- Durability Beyond 5–6 Years  
- Age‑Based Recommendations (≤65 yr, 65–80 yr, >80 yr)

Page 31 Extracted Terms:
- Valvular heart disease  
- Aortic stenosis (AS)  
- Severe aortic stenosis  
- Left ventricular ejection fraction (LVEF)  
- Left ventricular systolic dysfunction  
- Transcatheter aortic valve implantation (TAVI)  
- Surgical aortic valve replacement (SAVR)  
- Percutaneous aortic balloon dilation (balloon aortic valvuloplasty)  
- New York Heart Association (NYHA) functional class  
- Stroke  
- Major vascular complications  
- Pulmonary hypertension  
- Anemia  
- Chronic obstructive pulmonary disease (COPD)  
- Liver disease  
- Frailty  
- Porcelain aorta  
- Chest radiation damage  
- Valve reintervention  
- STS (Society of Thoracic Surgeons) surgical risk score

Page 32 Extracted Terms:
- Percutaneous aortic balloon dilation  
- Aortic stenosis (AS)  
- Calcific valve deposits  
- Aortic annulus  
- Valve commissures  
- Hemodynamics  
- Surgical aortic valve replacement (SAVR)  
- Transcatheter aortic valve implantation (TAVI)  
- Aortic valve palliation  
- Bicuspid aortic valve (BAV)  
- Subaortic (LV outflow tract) calcification  
- Rheumatic valve disease  
- Aortic annulus size  
- Calcific AS of a trileaflet valve  
- Mechanical prosthetic valve  
- Bioprosthetic valve  
- Patient–prosthesis mismatch  
- Valve durability  
- Primary mitral regurgitation (MR)  
- Coronary artery disease (CAD)  
- Coronary artery bypass grafting  
- Septal hypertrophy  
- Myectomy  
- Atrial fibrillation (AF)  
- Porcelain aorta  
- Left‑ventricular (LV) systolic dysfunction  
- Severe mitral regurgitation (MR) due to annular calcification  
- Severe lung, liver, or renal disease  
- Mobility issues / procedural risk  
- Severe dementia  
- Frailty  
- Procedural or surgical risk of SAVR/TAVI  
- Vascular access constraints  
- Previous cardiac surgery with at‑risk grafts  
- Previous chest irradiation  
- Goals of care (e.g., symptom relief, quality of life, life prolongation)  
- Permanent pacemaker risk  
- Stroke risk  
- Valve replacement durability data (5‑year TAVI, 20‑year bioprosthetic)  
- Life expectancy / actuarial tables  
- Valve type selection (mechanical vs. bioprosthetic)  
- Valve enlargement procedures  
- Non‑cardiac comorbidities affecting treatment choice.

Page 33 Extracted Terms:
- Aortic valve disease  
- Aortic stenosis (AS)  
- Aortic regurgitation (AR)  
- Transcatheter aortic valve implantation (TAVI)  
- Surgical aortic valve replacement (SAVR / AVR)  
- Percutaneous aortic balloon dilation  
- Acute aortic regurgitation  
- Chronic aortic regurgitation  
- Endocarditis‑related AR  
- Aortic dissection‑related AR  
- Bicuspid aortic valve (BAV) disease  
- Rheumatic heart disease  
- Transcatheter procedures (e.g., transcatheter aortic valve, transcatheter aortic valve replacement)  
- Transcatheter aortic valve replacement (TAVR)  
- Transcatheter aortic valve implantation (TAVI)  
- Valve area (cm²)  
- Transvalvular pressure gradient  
- Left ventricular (LV) volume overload  
- LV chamber dilation  
- LV hypertrophy  
- Pulmonary congestion  
- Pulmonary edema  
- Cardiac output  
- Transthoracic echocardiography (TTE)  
- Transesophageal echocardiography (TEE)  
- Cardiac computed tomography (CT)  
- Cardiac magnetic resonance imaging (MRI)  
- Intra‑aortic balloon counterpulsation  
- Beta blockers (in aortic dissection)  
- Acute severe AR surgical emergency  
- Acute AR diagnosis criteria (deceleration time, pressure half‑time, holodiastolic flow reversal)  
- Aortic root imaging  
- Aortic diastolic pressure equilibration  
- Surgical delay in acute severe AR  
- Acute coronary syndrome (differential diagnosis)

Page 34 Extracted Terms:
- Valvular Heart Disease  
- Aortic Regurgitation (AR)  
- Bicuspid Aortic Valve (BAV)  
- Aortic valve sclerosis  
- Aortic sinuses  
- Ascending aorta  
- Rheumatic fever  
- Rheumatic heart disease  
- Infective endocarditis (IE)  
- Congenital valve anomaly / congenital abnormality  
- Calcific aortic valve disease  
- Left ventricular (LV) systolic function  
- Left ventricular ejection fraction (LVEF)  
- Left ventricular end‑systolic dimension (LVESD)  
- LV dilation / left ventricular dilation  
- LV outflow tract (LVOT)  
- Jet width (percentage of LVOT)  
- Vena contracta (cm)  
- Regurgitant volume (mL/beat)  
- Regurgitant fraction (%)  
- Effective regurgitant orifice (ERO) (cm²)  
- Angiography grade (1–4)  
- Holodiastolic flow reversal in abdominal aorta  
- Exertional dyspnea  
- Angina  
- Heart failure (HF)  
- Mild AR  
- Moderate AR  
- Severe AR  
- Asymptomatic severe AR  
- Symptomatic severe AR  
- Stages of chronic AR (Stage A, B, C, D)  
- LV systolic dysfunction (LVEF ≤ 55%)  
- LV end‑systolic dimension index (mm²/m²)

Page 35 Extracted Terms:
- Chronic aortic regurgitation (AR)  
- Aortic regurgitation severity  
- Valve reparability  
- Transthoracic echocardiography (TTE)  
- Transesophageal echocardiography (TEE)  
- Cardiovascular magnetic resonance (CMR)  
- Cardiac catheterization  
- Aortic angiography  
- Left ventricular (LV) systolic function  
- Left ventricular ejection fraction (LVEF)  
- Fractional shortening  
- LV end‑systolic dimension (LVESD)  
- LV end‑systolic volume (LVESV)  
- LV end‑diastolic dimension/volume (LVEDD/LVEDV)  
- Bicuspid aortic valve (BAV)  
- Aortic sinuses dilation  
- Ascending aorta dilation  
- Symptom staging (Stages B, C, C2, D)  
- Heart failure (HF) symptoms  
- Hypertension (systolic >140 mm Hg)  
- Glycemic‑controlled disease management (GDMT)  
- Angiotensin‑converting enzyme inhibitors (ACE‑I)  
- Angiotensin receptor blockers (ARBs)  
- Sacubitril/valsartan (ARNI)  
- Beta‑blockers  
- Systolic blood pressure (SBP)  
- Diastolic blood pressure (DBP)  
- Pulse pressure  
- Trans‑aortic stroke volume  
- Regurgitant volume  
- Effective regurgitant orifice (ERO) area  
- Regurgitant fraction  
- Aortic valve disease  
- Valve intervention (aortic valve replacement, AVR)  
- Cardiology guidelines  
- Clinical outcomes  
- Survival and functional results  
- Surgical risk assessment  

These terms capture the cardiovascular concepts and therapies discussed in the guideline excerpt.

Page 36 Extracted Terms:
**Key terms related to heart disease extracted from the text**

- Chronic severe aortic regurgitation (AR)  
- Aortic valve surgery / aortic valve replacement (AVR, SAVR)  
- Left ventricular (LV) systolic function  
- Left ventricular ejection fraction (LVEF)  
- LV end‑systolic diameter (LVESD)  
- LV end‑diastolic diameter (LVEDD)  
- LV volume overload / LV volume measurements  
- Mechanical valve (prosthetic)  
- Bioprosthetic valve (prosthetic)  
- Valve‑sparing procedures / valve‑spare surgery  
- Aortic root reconstruction  
- Ascending aorta repair / replacement  
- Transcatheter aortic valve implantation (TAVI)  
- Coronary artery bypass grafting (CABG)  
- Mitral valve surgery  
- Symptomatic patients (with severe AR)  
- Asymptomatic patients (with severe or moderate AR)  
- Severe AR (Stage C1, C2, D)  
- Moderate AR (Stage B)  
- LV systolic dysfunction (LVEF ≤55%)  
- Progressive decline in LVEF (to 55‑60%)  
- Progressive LV dilation (LVEDD >65 mm)  
- Global longitudinal strain (GLS)  
- Circulation biomarkers (e.g., natriuretic peptides)  
- Exercise capacity / exercise testing  
- Survival and functional status after surgery  
- Perioperative period / peri‑operative hemodynamics  
- Mortality rate post‑AVR  
- Clinical evaluation and symptom assessment  
- Risk factors for AVR timing  
- ACC/AHA guideline recommendations  
- Evidence levels (e.g., B‑NR, C‑EO)  
- Clinical outcomes and prognostic markers  
- Imaging modalities: 2‑D echocardiography, 3‑D echocardiography, cardiac MRI (CMR)  
- LVESD index (indexed LVESD, mm/m²)  
- Intervention thresholds (e.g., LVESD >50 mm, indexed >25 mm/m²)  
- Surgical indications: before LVEF falls below 55 %  
- Post‑operative outcomes in asymptomatic patients with LV dysfunction

*(These terms capture the main concepts concerning heart disease, valve pathology, diagnostic imaging, surgical interventions, and guideline‐based recommendations discussed in the text.)*

Page 37 Extracted Terms:
Aortic regurgitation (AR)  
Aortic valve (AV)  
Aortic valve replacement (AVR)  
Valve‑sparing procedure  
Aortic root  
Ascending aorta  
Mitral valve  
Coronary artery bypass grafting (CABG)  
Transcatheter aortic valve implantation (TAVI)  
Left ventricular end‑diastolic dimension (LVEDD)  
Left ventricular end‑systolic dimension (LVESD)  
Left ventricular systolic volume  
Left ventricular ejection fraction (LVEF)  
Effective regurgitant orifice (ERO)  
Regurgitant volume (RVol)  
Regurgitant fraction (RF)  
Vena contracta (VC)  
Cardiac events  
Post‑operative outcomes  
Transcatheter valve migration  
Paravalvular leak  
Transthoracic echocardiography (TTE)  
Transesophageal echocardiography (TEE)  
Cardiac magnetic resonance imaging (CMR)  
Aortic annulus  
Valve calcification  
Valve anatomy  
Aortic root size and shape  
Heart failure (HF)  
Severe regurgitation  
Asymptomatic patients.

Page 38 Extracted Terms:
- Bicuspid aortic valve (BAV)  
- Aortic stenosis (AS)  
- Aortic regurgitation (AR)  
- Aortic aneurysm  
- Aortic dilation  
- Aortopathy  
- Ascending aorta  
- Aortic sinuses (sinuses of Valsalva)  
- Sinotubular junction  
- Aortic coarctation  
- Aortic dissection  
- Transthoracic echocardiography (TTE)  
- Transesophageal echocardiography (TEE)  
- Cardiac magnetic resonance (CMR) angiography  
- Computed tomography (CT) angiography  
- Aortic valve replacement (AVR)  
- Lifelong serial imaging (echocardiography, CMR, CT)  
- Diagnostic imaging of the aorta  
- Screening TTE in first‑degree relatives  
- Genetic inheritance of aortopathy  
- Hemodynamic assessment (Doppler interrogation)  
- Valve morphology evaluation  
- Severity grading of AS and AR  
- Imaging intervals based on aortic size and progression  
- Radiological assessment of aortic annulus, sinuses, and ascending aorta

Page 39 Extracted Terms:
- Bicuspid aortic valve (BAV)  
- Aortic dilation  
- Aortic dissection  
- Aortic grafting  
- Valve surgery / valve replacement  
- Aortic imaging  
- Aortic diameter  
- Aortic sinuses  
- Ascending aorta  
- Surgical intervention  
- Aortic coarctation  
- Aortic growth rate  
- Valvular heart disease  
- Comprehensive Valve Center  
- Computed tomographic angiography (CTA)  
- Cardiac magnetic resonance (CMR)  
- Transthoracic echocardiography (TTE)

Page 40 Extracted Terms:
- BAV (Bicuspid Aortic Valve)  
- SAVR (Surgical Aortic Valve Replacement)  
- TAVI (Transcatheter Aortic Valve Implantation)  
- AVR (Aortic Valve Replacement)  
- AS (Aortic Stenosis)  
- AR (Aortic Regurgitation)  
- Aortic sinuses  
- Ascending aorta  
- Aortic dilation / aortic enlargement  
- Aortic dissection  
- Aortic coarctation  
- Aortic growth rate  
- Valve‑sparing surgery  
- Aortic valve repair  
- Aortic valve reimplantation  
- Comprehensive Valve Center  
- Operative intervention (aortic surgery)  
- Imaging of the aorta (CT, MRI, TEE)  
- Surgical threshold (≥4.5 cm, 5.0–5.5 cm, ≥5.5 cm)  
- Low surgical risk  
- Shared decision‑making  
- Family history of aortic dissection  
- Risk factors for dissection  
- Progressive aortic dilation  
- Retro­active studies on BAV outcomes  
- Aortic valve prosthetic choice (mechanical, bioprosthetic)

Page 41 Extracted Terms:
**Key heart‑disease terms extracted from the text**

- Surgical repair  
- Aortic valve  
- Valve repair  
- Aortic root anatomy  
- Comprehensive Valve Center  
- Transcatheter aortic valve implantation (TAVI)  
- Severe symptomatic aortic stenosis (AS)  
- Bicuspid aortic valve (BAV)  
- Paravalvular leak  
- 30‑day mortality rate  
- 1‑year mortality rate  
- Stroke rate  
- Risk‑benefit ratio (TAVI vs. SAVR)  
- Surgical aortic valve replacement (SAVR)  
- Mitral stenosis (MS)  
- Rheumatic mitral stenosis  
- Female predominance (≈80 % of rheumatic MS cases)  
- Clinical presentation (young age, teenage–30 yr)  
- Aortic replacement intervention  
- Family history of aortic dissection  
- Aortic growth rate (≥ 0.5 cm / year)  
- Aortic coarctation  
- Aortic valve replacement (AVR)  
- Comprehensive Valve Center (CVC)  
- STS/ACC Transcatheter Valve Therapies Registry  

These terms represent the key clinical entities, procedures, outcomes, and populations discussed in the guidelines excerpt.

Page 42 Extracted Terms:
- Mitral stenosis (MS)  
- Rheumatic heart disease  
- Valvular heart disease  
- Commissural fusion  
- Calcific mitral stenosis  
- Mitral valve area  
- Transmitral mean pressure gradient  
- Diastolic pressure half‑time  
- Left atrium (LA)  
- Pulmonary artery systolic pressure (PASP)  
- Pulmonary hypertension  
- Left atrial enlargement  
- Mitral regurgitation (MR)  
- Atherosclerotic disease  
- Hypertension  
- Diastolic dysfunction  
- Transthoracic echocardiography (TTE)  
- Transesophageal echocardiography (TEE)  
- Percutaneous mitral balloon commissurotomy (PMBC)  
- Mitral commissurotomy  
- Valve hemodymamics  
- Valve anatomy  
- Valve obstruction  
- Transvalvular flow rate  
- Heart rate  
- Mitral valve leaflet calcification  
- Mitral valve annulus calcification  
- Continuity equation  
- Gorlin formula  
- Left ventricular (LV) compliance  
- Left atrial (LA) compliance  
- Diastolic filling period  
- LA thrombus  
- Severe MS criteria (≤1.5 cm², >5 mm Hg gradient)  
- Moderate LA enlargement  
- Exertional dyspnea  
- Decreased exercise tolerance

Page 43 Extracted Terms:
**Key terms related to heart disease (valvular and hemodynamic):**

1. Valvular heart disease  
2. Rheumatic mitral stenosis (MS)  
3. Mitral regurgitation (MR)  
4. Percutaneous balloon mitral commissurotomy (PMBC)  
5. Transthoracic echocardiography (TTE)  
6. Transesophageal echocardiography (TEE)  
7. Three‑dimensional echocardiography (3‑D echo)  
8. Doppler echocardiography  
9. Transvalvular gradients  
10. Mean gradient  
11. Mitral valve area  
12. Mitral valve morphology  
13. Commissural fusion  
14. Commissural morphology  
15. Valve thickening  
16. Valve mobility  
17. Valve calcification  
18. Subvalvular chordal fusion  
19. Mitral pressure half‑time  
20. Pulmonary hypertension  
21. Right ventricular (RV) systolic pressure  
22. Tricuspid regurgitation (TR) velocity  
23. Right ventricular enlargement  
24. Left atrial (LA) thrombus  
25. Atrial fibrillation (AF)  
26. Hyperthyroidism  
27. Cardiac catheterization  
28. Left ventricular (LV) diastolic pressure  
29. Pulmonary artery wedge pressure  
30. Gorlin equation (mitral area calculation)  
31. Pulmonary circulation pressure  
32. Hemodynamic load  
33. Exercise hemodynamics  
34. Valve area progression (0.1 cm²/year)  
35. Diastolic dysfunction  
36. LA non‑compliance  
37. Intrinsic pulmonary vascular disease  

These terms capture the primary clinical, diagnostic, and therapeutic concepts discussed in the guideline excerpt.

Page 44 Extracted Terms:
- Rheumatic mitral stenosis (MS)  
- Valvular heart disease  
- Echocardiography  
- Doppler echocardiography  
- Resting echocardiographic findings  
- Exercise testing  
- Treadmill exercise testing  
- Bicycle exercise testing  
- Cardiac catheterization  
- Invasive hemodynamic assessment  
- Mean mitral gradient  
- Pulmonary artery pressure  
- Pulmonary artery wedge pressure  
- Pulmonary artery systolic pressure  
- Valve gradient  
- Diastolic filling period  
- Left atrial (LA) pressure  
- Atrial fibrillation (AF)  
- Rapid ventricular response  
- Sinus tachycardia  
- Anticoagulation  
- Vitamin K antagonist (VKA)  
- Direct oral anticoagulants (DOACs) – noted as “non‑vitamin K oral anticoagulation”  
- Embolic event  
- Left atrial thrombus  
- Beta‑blockers  
- Calcium‑channel blockers  
- Ivabradine  
- Heart rate control  
- Leg‑lift maneuver  
- Sit‑up maneuver  
- Thromboembolic risk  
- Hemodynamic consequences  
- Exercise capacity  
- Symptomatic response  
- Diagnostic testing  
- Clinical statements  
- Guideline recommendations  
- Hemodynamic mismatch (resting vs. clinical symptoms)

Page 45 Extracted Terms:
- Rheumatic mitral stenosis (MS)
- Mitral valve area ≤ 1.5 cm²
- NYHA functional class II–IV
- Pulmonary artery systolic pressure > 50 mm Hg
- Pulmonary artery wedge pressure > 25 mm Hg
- Mean mitral valve gradient > 15 mm Hg during exercise
- Atrial fibrillation (AF)
- Embolic events
- Left atrial (LA) size / thrombus
- Hemodynamic response
- Valve morphology
- Negative dromotropic agents
- Beta blockers
- Ivabradine
- Chronotropic incompetence
- Stroke volume
- Exercise tolerance
- Symptomatic patients
- Asymptomatic patients
- Comprehensive Valve Center
- Percutaneous mitral balloon commissurotomy (PMBC)
- Mitral valve surgery (repair, commissurotomy, replacement)
- Commissurotomy
- Valve replacement
- Mitral regurgitation (MR) ≤ 2 +
- Doppler echocardiography
- Sellar’s criteria
- Interventional procedures
- Diastolic filling period
- Transmitral mean gradient
- Cardiac output
- Fibrosis of the atria
- Fibrosis of internodal/interatrial tracts
- Damage to the sinoatrial node

Page 46 Extracted Terms:
Mitral valve  
Mitral stenosis (MS)  
Mitral regurgitation (MR)  
Percutaneous mitral balloon commissurotomy (PMBC)  
Mitral valve surgery  
Closed commissurotomy  
Open commissurotomy  
Mitral valve replacement  
Tricuspid regurgitation (TR)  
Tricuspid valve repair  
Rheumatic mitral stenosis  
Atrial fibrillation (AF)  
New York Heart Association (NYHA) class  
Pulmonary artery systolic pressure (PASP)  
Pulmonary hypertension (PH)  
Pulmonary artery pressure  
Doppler echocardiography  
Left atrial (LA) thrombus  
Left ventricular (LV) dysfunction  
Left ventricular diastolic dysfunction  
Left atrial noncompliance  
Net atrial‑ventricular compliance  
Mitral valve area (MVA)  
Valve morphology  
Leaflet calcification  
Subvalvular fusion/fibrosis  
Leaflet tethering  
Valve thickening  
Valve commissures  
Balloon catheter  
Surgical backup  
Long‑term follow‑up  
Survival rate  
Valve repair  
Comprehensive Valve Center  
Mitral valve morphology score  
Pulmonary vascular disease  
Pulmonary circulation  
Pulmonary systolic pressure  
Mitral valve area score  
Mitral valve anatomy  
Mitral subvalvular apparatus  
Valve anatomy assessment  
Mitral valve replacement strategy  
Mitral valve stenosis progression  
Valve surgical outcomes  
Valve replacement outcomes  
Valve replacement indications  
Valve repair outcomes  
Valvular thickening.

Page 47 Extracted Terms:
- Valvular heart disease  
- Mitral valve disease  
- Pulmonary arterial resistance  
- Right ventricular dysfunction  
- Tricuspid regurgitation (TR)  
- Pulmonary hypertension  
- Mitral regurgitation (MR)  
- Atrial fibrillation (AF)  
- Rheumatic mitral stenosis (MS)  
- Left atrial (LA) pressure  
- Percutaneous mitral balloon commissurotomy (PMBC)  
- P‑wave dispersion  
- Mitral valve area  
- Mitral valve gradient  
- Exercise testing  
- Pulmonary artery wedge pressure  
- Commissural calcification  
- Wilkins morphology score  
- New‑onset atrial fibrillation  
- NYHA Class III  
- NYHA Class IV  
- Severe mitral stenosis  
- Stage D mitral stenosis  
- Mitral annular calcification  
- Calcific mitral stenosis (calcific MS)  
- Radiation‑induced mitral stenosis  
- Post‑repair mitral stenosis  
- Annuloplasty ring  
- Mitral leaflet‑base calcification  
- Left‑ventricular compliance  
- Right‑ventricular compliance  
- Left‑atrial compliance  
- High procedural risk  
- Advanced age  
- Multiple comorbidities  
- Five‑year survival rate < 50 %  
- Elevated gradient  
- Planimetric area  
- Diastolic filling interval  
- Rapid ventricular response  
- Thromboembolic events  
- Symptom onset  
- Symptomatic patient  
- Hemodynamics  
- High LA pressure  
- Suboptimal valve anatomy  
- High success rate  
- Low risk  
- Periprocedural complications

Page 48 Extracted Terms:
**Key Heart‑Disease Terms Extracted**

1. Valvular heart disease  
2. Mitral regurgitation (MR)  
3. Acute mitral regurgitation  
4. Chronic mitral regurgitation  
5. Primary (degenerative) MR  
6. Secondary (functional) MR  
7. Mitral valve prolapse  
8. Myxomatous degeneration  
9. Barlow’s valve  
10. Fibroelastic deficiency  
11. Chordal rupture  
12. Papillary muscle rupture  
13. Mitral annular calcification  
14. Valve commissurotomy  
15. Prosthetic valve  
16. Intra‑aortic balloon counterpulsation (IABP)  
17. Vasodilator therapy  
18. Sodium nitroprusside  
19. Nicardipine  
20. Percutaneous circulatory assist device  
21. Catheter‑based therapies  
22. Transthoracic echocardiography (TTE)  
23. Transesophageal echocardiography (TEE)  
24. Pulmonary congestion  
25. Pulmonary hypertension  
26. Left ventricular (LV) systolic dysfunction  
27. Left atrial (LA) dilation  
28. ST‑segment‑elevation myocardial infarction (STEMI)  
29. Inferior infarction  
30. Cardiac output  
31. Aortic afterload  
32. Systemic hypotension  
33. Peripheral resistance  
34. Hemodynamic decompensation  
35. Mitral valve surgery / repair  
36. High surgical risk


Page 49 Extracted Terms:
**Key heart‑disease terms extracted from the guideline text**

- Valvular Heart Disease  
- Chronic Primary Mitral Regurgitation (MR)  
- Severe Primary MR  
- Mitral Intervention (repair or replacement)  
- Valve Repair  
- Valve Replacement  
- Mitral Valve Prolapse  
- Infective Endocarditis (IE)  
- Connective Tissue Disorders  
- Rheumatic Heart Disease  
- Cleft Mitral Valve  
- Radiation Heart Disease  
- Heart Failure (HF)  
- Myocardial Damage  
- Left Ventricular (LV) Size  
- Left Ventricular Function  
- LV Ejection Fraction (LVEF)  
- Right Ventricular (RV) Function  
- Left Atrial (LA) Size  
- Pulmonary Artery Pressure  
- Chamber Volumes  
- Volume Overload  
- Regurgitant Volume  
- Regurgitant Fraction  
- Effective Orifice Area  
- Proximal Isovelocity Surface Area (PISA)  
- Color Jet Area  
- Vena Contracta  
- Continuous‑Wave Doppler Intensity  
- Trans‑Mitral Jet Velocity Curve  
- Transthoracic Echocardiography (TTE)  
- Transesophageal Echocardiography (TEE)  
- Three‑Dimensional TEE  
- Cardiac Magnetic Resonance (CMR)  
- Cardiac Catheterization (invasive evaluation)  
- Intraoperative TEE  
- Stages A–D (valvular disease severity/management stages)  
- ACC/AHA Guideline for the Management of Valvular Heart Disease  
- Clinical Statements & Guidelines  

These terms encompass the diseases, anatomical structures, diagnostic modalities, severity indices, and management strategies discussed in the excerpt.

Page 50 Extracted Terms:
- Intraoperative trans‑esophageal echocardiography (TEE)  
- 3‑dimensional TEE (“surgical view”)  
- Mitral regurgitation (MR)  
- Mitral valve anatomy  
- Mitral valve repair  
- Residual MR  
- Reoperation  
- Left ventricle (LV)  
- Systolic anterior leaflet motion  
- Left ventricular outflow tract obstruction  
- Transcatheter edge‑to‑edge repair  
- Primary severe MR  
- High surgical risk  
- Diagnostic testing: changing signs or symptoms  
- Primary MR stages (B–D)  
- Transthoracic echocardiography (TTE)  
- Mitral valve apparatus  
- Left ventricular ejection fraction (LVEF)  
- Left ventricular end‑systolic dimension (LVESD)  
- Left atrial enlargement  
- Pulmonary hypertension  
- Exertional dyspnea  
- Exercise tolerance  
- Effective regurgitant orifice (ERO)  
- Infective endocarditis (IE)  
- Mitral valve prolapse  
- Flail leaflet  
- Rheumatic valve changes  
- Holosystolic eccentric jet MR  
- Central jet MR  
- Vena contracta  
- Regurgitant volume  
- Regurgitant fraction  
- Mild, moderate, and severe MR definitions  
- Valve thickening  
- Leaflet restriction  
- Normal coaptation  
- Loss of coaptation  
- Left atrium (LA)

Page 51 Extracted Terms:
- Severe mitral regurgitation (MR)  
- Mitral valve surgery  
- Mitral valve repair  
- Left ventricular (LV) function  
- Left ventricular ejection fraction (LVEF)  
- Left ventricular end‑diastolic diameter (LVEDD)  
- Left ventricular end‑systolic diameter (LVESD)  
- Global longitudinal strain  
- LV compliance  
- LV dysfunction  
- LV remodeling  
- Pulmonary artery pressure  
- Pulmonary hypertension  
- Right ventricular (RV) function  
- Tricuspid regurgitation (TR)  
- Atrial fibrillation (AF)  
- Orthopnea  
- Dyspnea on exertion  
- Exercise tolerance  
- Symptom onset  
- Asymptomatic patients  
- Stage B / C1 disease (valvular disease stages)  
- Transthoracic echocardiography (TTE)  
- Cardiac catheterization  
- Left ventriculography  
- Hemodynamic measurements  
- Invasive hemodynamic evaluation  
- Serum biomarkers  
- Natriuretic peptides (BNP, NT‑proBNP)  
- Diuretics  
- Comprehensive valve center  
- Chronic primary MR (valvular heart disease)

Page 52 Extracted Terms:
**Key heart‑disease terms extracted from the text**

- Mitral Regurgitation (MR)  
- Primary MR  
- Chronic Primary MR  
- Acute Severe Symptomatic MR  
- Valvular Heart Disease  
- Pulmonary Hypertension  
- Left Atrial (LA) pressure  
- Pulmonary Artery Wedge pressure  
- Transpulmonary gradient  
- Left Ventricular (LV) systolic dysfunction  
- LV systolic dysfunction  
- LV systolic function  
- Heart Failure (HF)  
- Systolic dysfunction  
- Exercise testing  
- Hemodynamic exercise testing  
- Treadmill exercise test  
- Exercise echocardiography  
- Cardiopulmonary exercise testing  
- Cardiac catheterization  
- Echocardiography (including Doppler)  
- Doppler echocardiography  
- Ventriculography  
- Vasodilator therapy  
- Guideline‑Directed Medical Therapy (GDMT)  
- Beta‑adrenergic blockade  
- ACE inhibitors  
- ARBs (angiotensin‑II receptor blockers)  
- Aldosterone antagonists  
- Transcatheter repair  
- Diagnostic testing  
- Guideline stages B, C, D  
- Lung disease (concomitant)  
- Exercise tolerance  
- Oxygen consumption measurements  
- Dyspnea  
- LV filling pressures  
- Afterload reduction  

These items encompass the principal clinical concepts, diagnostic modalities, therapeutic strategies, and disease stages referenced in the guideline excerpt.

Page 53 Extracted Terms:
**Key Heart‑Disease–Related Terms**

- Mitral valve prolapse  
- Mitral regurgitation (MR)  
- Concomitant hypertension  
- Left‑ventricular (LV) systolic pressure  
- Transmitral gradient  
- Chronic primary MR  
- Mitral valve intervention  
- Mitral valve surgery  
- Mitral valve repair  
- Mitral valve replacement  
- Degenerative mitral‑valve disease  
- Left‑ventricular ejection fraction (LVEF)  
- LV systolic dysfunction  
- LV end‑systolic diameter (LVESD)  
- NYHA functional class III/IV  
- Transcatheter edge‑to‑edge repair (TEER)  
- Rheumatic valve disease  
- Posterior leaflet pathology  
- Bileaflet (anterior‑and‑posterior) prolapse/replacement  
- Papillary‑muscle rupture  
- Infective endocarditis (IE)  
- Cleft mitral valve  
- Mechanical mitral‑valve replacement  
- Anticoagulation (post‑replacement)  
- Hospital mortality rate  
- High‑volume valve‑surgery centers  
- Mixed valve disease (combined MR + aortic stenosis)  
- Heart valve team  
- Surgical risk (high or prohibitive)  
- Severity thresholds for MR (e.g., “severe primary MR”)  
- LV functional thresholds (LVEF ≤ 60 %, LVESD ≥ 40 mm)  
- Stage C1, C2, and D (guideline staging).

Page 54 Extracted Terms:
- Valvular Heart Disease  
- Mitral Regurgitation (MR)  
- Left Ventricular Ejection Fraction (LVEF)  
- Left Ventricular End‑Systolic Diameter (LVESD)  
- Left Ventricular (LV) dysfunction  
- Pulmonary hypertension  
- Mitral Valve Repair  
- Mitral Valve Replacement (MVR)  
- Surgical volume (expertise)  
- Operative mortality  
- Long‑term survival  
- Freedom from reoperation  
- Freedom from recurrent moderate/severe MR  
- Effective Regurgitant Orifice (ERO)  
- End‑Systolic Dimension (ESD)  
- Regurgitant Fraction (RF)  
- Regurgitant Volume (RVol)  
- Vena Contracta (VC)  
- Comprehensive Valve Center (CVC)

Page 55 Extracted Terms:
- Valvular Heart Disease  
- Mitral Regurgitation (MR)  
- Primary MR  
- Secondary MR (chronic secondary MR)  
- Ischemic chronic secondary MR  
- Non‑ischemic chronic secondary MR  
- Left Ventricular (LV) dysfunction  
- Left Ventricular End‑Systolic Diameter (LVESD)  
- Left Ventricular Ejection Fraction (LVEF)  
- Heart Failure (HF)  
- Transcatheter Edge‑to‑Edge Repair (TEER)  
- Mitral Valve Repair  
- Mitral Valve Replacement  
- Rheumatic Mitral Valve Disease  
- Degenerative Mitral Disease  
- Coronary Artery Disease (CAD)  
- Atrial Fibrillation (AF)  
- Mitral Annular Dilation  
- Papillary Muscle Displacement  
- Valve apparatus  
- Valve leaflets  
- Valve chords  
- Valve clip (mitral valve clip)  
- Annuloplasty  
- Valve tethering  
- Valve remodeling (LV remodeling)  
- Valve repair durability  
- Valve repair success rate  
- Valve repair freedom from reoperation  
- Valve replacement freedom from recurrence  
- Operative mortality  
- Mechanical prosthesis  
- Biological prosthesis  
- Valve surgery  
- Valve center (comprehensive valve center)  
- Valve lesion  
- Volume overload  
- LV dilation  
- Valve repair vs. replacement strategy  
- Valve disease progression  
- Valve repair indications (≤½ posterior leaflet)  
- Valve repair criteria (LVEF > 64 %, LVESD < 37 mm)  
- Valve repair thresholds (LVESD ≈ 40 mm, LVEF ≈ 60 %)

Page 56 Extracted Terms:
- Valvular heart disease  
- Mitral regurgitation (MR)  
- Primary MR  
- Secondary MR  
- Regurgitant orifice area (ERO)  
- Regurgitant volume  
- Transthoracic echocardiography (TTE)  
- Transesophageal echocardiography (TEE)  
- Stress nuclear/PET imaging  
- Cardiac magnetic resonance (CMR)  
- Coronary CT angiography  
- Coronary arteriography  
- Myocardial viability  
- Transcatheter mitral valve intervention  
- Transcatheter edge‑to‑edge repair (TEER / MitraClip)  
- Mitral valve morphology  
- Coaptation length  
- Leaflet tethering  
- A2/P2 scallops  
- Valve calcification  
- Cleft in A2/P2 scallops  
- Primary/secondary chordal support  
- Left‑ventricular (LV) remodeling (regional/global)  
- LV systolic dysfunction  
- Left ventricular ejection fraction (LVEF)  
- Pulmonary hypertension  
- Ischemic MR  
- Non‑ischemic MR  
- Coronary artery disease (CAD)  
- Percutaneous coronary intervention (PCI)  
- Coronary artery bypass grafting (CABG)  
- Guideline‑directed medical therapy (GDMT)  
- STICH trial  
- COAPT trial  
- EVEREST trial  
- Heart failure (HF)  
- Functional mitral regurgitation  
- Mitral valve leaflet scallops  
- Hibernating myocardium  
- Viable myocardium  
- 10‑year survival rate  
- Moderate MR (ERO ≥ 20 mm²)  
- Severe MR (ERO ≥ 40 mm² or ≥ 0.4 cm²; regurgitant volume ≥ 60 mL)

Page 57 Extracted Terms:
- Heart Failure (HF)  
- Left Ventricular Ejection Fraction (LVEF)  
- Valvular Heart Disease  
- Mitral Regurgitation (MR)  
- Secondary Mitral Regurgitation (secondary MR)  
- Standard Guideline‑Directed Medical Therapy (GDMT) for HF  
- Angiotensin‑Converting Enzyme (ACE) inhibitors  
- Angiotensin II Receptor Blockers (ARBs)  
- β‑Blockers  
- Aldosterone Antagonists  
- Sacubitril/Valsartan  
- Biventricular Pacing (Cardiac Resynchronization Therapy, CRT)  
- Coronary Revascularization  
- Chronic Severe Secondary MR  
- Staging of Secondary MR (Stages A, B, C, D)  
- Valve Anatomy (leaflets, chordae, annulus)  
- Valve Hemodynamics  
- Effective Regurgitant Orifice area (ERO)  
- Regurgitant Volume  
- Regurgitant Fraction  
- Regional Wall Motion Abnormalities  
- Left Ventricular (LV) Dilation  
- LV Systolic Dysfunction  
- Primary Myocardial Disease  
- Left Atrial (LA) Size/volume  
- Exertional Dyspnea  
- Decreased Exercise Tolerance  
- Multidisciplinary Team (MDT)  
- Cardiologist Expert in Heart Failure  

These terms capture the key clinical concepts, therapies, and anatomical/hemodynamic aspects related to heart disease that are referenced in the provided guideline excerpt.

Page 58 Extracted Terms:
- Secondary mitral regurgitation (MR)  
- Chronic severe secondary MR  
- Severe secondary MR  
- Left ventricular (LV) systolic dysfunction  
- Reduced left ventricular ejection fraction (LVEF < 50 %)  
- Preserved LVEF (≥ 50 %)  
- New York Heart Association (NYHA) class II–IV  
- Heart failure (HF)  
- Stage D heart failure  
- Guideline‑directed medical therapy (GDMT)  
- Transcatheter edge‑to‑edge repair (TEER)  
- Transesophageal echocardiography (TEE)  
- LV end‑systolic dimension (LVESD)  
- LV end‑diastolic dimension (LVEDD)  
- Pulmonary artery systolic pressure  
- Mitral valve surgery (repair/replacement)  
- Coronary artery bypass grafting (CABG)  
- Myocardial ischemia  
- Atrial annular dilation  
- Atrial fibrillation (AF)  
- Chordal‑sparing mitral valve replacement  
- Downsized annuloplasty repair  
- COAPT trial  
- MITRA‑FR study  
- STICH trial  
- Hibernating myocardium  
- LV and left atrial (LA) reverse remodeling  
- MitraClip device  
- Ventricular remodeling  
- Clinical guideline (ACC/AHA)  
- Valvular heart disease  
- Surgical correction of MR  
- Revascularization  
- Optimal GDMT  
- Surgical timing for mixed valve disease  
- Mitral valve repair strategies  
- Mitral valve replacement vs repair  
- Symptom‑based indications for intervention  
- LV dysfunction thresholds for TEER  
- Pulmonary hypertension (moderate)  
- Mitral valve anatomy  
- Mitral valve leaflets malcoaptation  
- Restrictive cardiomyopathy  
- Non‑obstructive hypertrophic cardiomyopathy  
- Sinus‑based atrial maze procedure  
- Observation‐based therapeutic strategies  
- Outcome measures: survival, hospitalization, quality of life  
- Trial inclusion criteria (LVESD ≤70 mm)  
- MR severity (effective regurgitant orifice area)  
- Symptom persistence despite medical therapy  

These terms represent the key concepts and entities related to heart disease discussed in the provided guideline text.

Page 59 Extracted Terms:
**Key heart‑disease related terms extracted from the text**

1. Mitral valve repair  
2. Mitral valve replacement  
3. Mitral regurgitation (MR)  
4. Secondary mitral regurgitation  
5. Primary mitral regurgitation  
6. Ischemic mitral regurgitation  
7. Anterior‑posterior (annular) dilation  
8. Atrial fibrillation (AF)  
9. Coronary artery bypass graft (CABG)  
10. Effective regurgitant orifice (ERO)  
11. Regurgitant fraction (RF)  
12. Regurgitant volume (RVol)  
13. Guideline‑directed medical therapy (GDMT)  
14. Heart failure (HF)  
15. Left ventricular ejection fraction (LVEF)  
16. Left ventricular end‑systolic dimension (LVESD)  
17. Pulmonary artery systolic pressure (PASP)  
18. Ventricular dilation  
19. Left ventricular remodeling  
20. Papillary muscle displacement  
21. Peak oxygen consumption  
22. Survival rate  
23. Quality of life  
24. Chamber size  
25. Recurrent mitral regurgitation  
26. Repeat hospitalization  
27. Medications (Rx)  
28. Chronic severe secondary MR  
29. RCT (Randomized Controlled Trial)  
30. Durability of repair/replacement  

These terms capture the clinical concepts, interventions, measurements, and outcomes discussed in the guidelines excerpt.

Page 60 Extracted Terms:
- Valvular heart disease  
- Tricuspid valve disease  
- Tricuspid regurgitation (TR)  
- Classification and stages of TR  
- Trace, mild, significant, worsening TR  
- Primary disorders of the tricuspid apparatus  
- Rheumatic disease  
- Infective endocarditis (IE)  
- Congenital disease (e.g., Ebstein’s anomaly, levo‑transposition of the great arteries)  
- Myxomatous changes  
- Blunt chest trauma  
- Carcinoid syndrome  
- Drug‑induced TR  
- Radiation‑induced TR  
- Iatrogenic etiologies (device leads, endomyocardial biopsy)  
- Secondary TR  
- Tricuspid annular dilation  
- Leaflet tethering  
- Right‑ventricular (RV) remodeling  
- Pressure overload  
- Volume overload  
- Pulmonary hypertension (primary or secondary to left‑sided heart disease)  
- Dilated cardiomyopathy  
- Atrial fibrillation (AF)  
- Isolated TR (associated with AF, preserved LVEF)  
- RV volume overload (shunts/high‑output states)  
- Central venous pressure  
- End‑organ damage (hepatic failure, renal failure)  
- Survival impact of Stage D TR  
- Pulmonary artery systolic pressure (PASP)  
- Cardiac index  
- Right‑sided diastolic pressures  
- Pulmonary vascular resistance  
- Right ventriculography  
- Physical examination findings in TR  
- Transthoracic echocardiography (TTE)  
- Invasive measurements of pulmonary artery pressures  
- Cardiac catheterization  
- Tricuspid annular plane systolic excursion (TAPSE)  
- Tricuspid annular velocity (S′)  
- RV end‑systolic area  
- Fractional area change  
- 3D transesophageal echocardiography (TEE)  
- Magnetic resonance imaging (MRI)  
- Computed tomography (CT) scan  
- Left ventricular ejection fraction (LVEF)

Page 61 Extracted Terms:
- Tricuspid regurgitation (TR)  
- Right‑sided heart failure (HF)  
- Pulmonary hypertension  
- Pulmonary artery pressure  
- Right atrial pressure  
- Right ventricular pressure  
- Pulmonary vasodilators  
- Invasive measurement (direct invasive measurement)  
- Thermodilution cardiac output  
- Fick cardiac output  
- Guideline‑Directed Medical Therapy (GDMT)  
- Heart failure with reduced left ventricular ejection fraction (LVEF)  
- Diuretics (loop diuretics)  
- Aldosterone antagonists  
- Hepatic congestion  
- Secondary hyperaldosteronism  
- Pulmonary vascular resistance  
- Pulmonary vasomodulators  
- Rhythm control of atrial fibrillation (AF)  
- Annular dilation (associated with AF)  
- Low‑salt diet  
- Compression stockings (support stockings)  
- Stages C and D of tricuspid regurgitation  
- Central jet (≥50% right atrial)  
- Vena contracta width (≥0.7 cm)  
- Effective regurgitant orifice (ERO) (≥0.40 cm²)  
- Regurgitant volume (≥45 mL)  
- Dense continuous‑wave signal (triangular shape)  
- Hepatic vein systolic flow reversal  
- Dilated right ventricle (RV)  
- Dilated right atrium (RA)  
- c‑V wave (systolic positive wave)  
- Right‑ventricular afterload (pulmonary vascular resistance)  
- Systemic congestion (peripheral edema, ascites)

Page 62 Extracted Terms:
**Key heart‑disease terms extracted from the guideline**

- Severe tricuspid regurgitation (TR)  
- Primary TR  
- Secondary TR  
- Tricuspid annular dilation  
- Tricuspid annulus end‑diastolic diameter  
- Tricuspid annulus dilation > 4.0 cm (40 mm)  
- Tricuspid annulus dilation > 40 mm or > 21 mm/m² indexed to BSA  
- Tricuspid annulus dilation > 70 mm intra‑operatively  
- Tricuspid valve surgery (repair or replacement)  
- Tricuspid valve repair  
- Tricuspid valve replacement  
- Left‑sided valve surgery (mitral, aortic)  
- Reoperation with isolated tricuspid valve surgery  
- Right‑sided heart failure (HF)  
- Right ventricular (RV) dilation  
- RV systolic dysfunction  
- RV remodeling  
- Leaflet tethering height  
- Pulmonary hypertension (PH)  
- Pulmonary artery hypertension  
- Severe pulmonary hypertension  
- Left‑sided valve disease  
- Right‑sided HF signs and symptoms  
- Stage B, C, D progression (tricuspid regurgitation stages)  
- End‑organ damage/dysfunction (e.g., renal, hepatic)  
- Operative mortality (8–20 %)  
- Perioperative mortality (10–25 %)  
- Catheter‑based therapies for isolated TR  
- Surgical intervention timing  
- Operative risk reduction (advanced surgical techniques)  
- Tricuspid annulus end‑diastolic diameter > 4 cm  
- Atrial fibrillation (AF) (risk factor for TR progression)  
- Intra‑annular RV pacemaker or implantable cardioverter‑defibrillator leads  
- Functional outcome and survival  
- Tricuspid valve repair vs. replacement selection criteria  

These terms capture the clinical concepts, measurements, stages, procedures, and risk factors central to the management of valvular heart disease as discussed in the guideline.

Page 63 Extracted Terms:
- Tricuspid regurgitation (TR)  
- Tricuspid valve repair  
- Tricuspid valve replacement  
- Right‑sided heart failure (HF)  
- Pulmonary hypertension (PH)  
- Right ventricular (RV) dysfunction  
- Atrial fibrillation (AF)  
- Secondary tricuspid regurgitation  
- Annular dilation  
- Leaflet tethering  
- Carcinoid heart disease  
- Flail tricuspid leaflet  
- Guideline‑directed medical therapy (GDMT)  
- Pulmonary artery pressure (PAP)  
- Left‑sided valve disease  
- Surgical intervention  
- Operative mortality  
- Systemic venous congestion  
- Congestive hepatopathy  
- Cirrhosis  
- Stage D heart failure  
- Right ventricular size assessment  

Page 64 Extracted Terms:
**Key Heart‑Disease Terms Identified**

- Valvular Heart Disease (VHD)  
- Aortic valve  
- Mitral valve  
- Tricuspid valve (TR)  
- Pulmonary valve  
- Tricuspid regurgitation (TR)  
- Right‑ventricular (RV) dysfunction  
- Pulmonary hypertension  
- Right‑sided heart failure (HF)  
- Severe tricuspid regurgitation (severe TR)  
- Reoperative tricuspid surgery  
- Left‑sided valve surgery  
- Reoperative mortality  
- Left‑ventricular (LV) dysfunction  
- Hepatic dysfunction (right‑HF‑related)  
- Renal dysfunction (right‑HF‑related)  
- Mixed valve disease  
- Stenosis  
- Regurgitation (valvular)  
- Concentric hypertrophy  
- Eccentric hypertrophy  
- Right‑ventricular (RV) systolic dysfunction  
- Cardiac remodeling  
- Ventricular function  
- Transthoracic echocardiography (TTE)  
- Biomarkers (e.g., BNP)  
- Invasive hemodynamic measurements  
- Filling pressure / filling pressures  
- Doppler hemodynamics  
- Jet velocities  
- Valve areas  
- Regurgitant flow  
- Regurgitant orifice area  
- Catheterization (exercise/at rest)  
- Comprehensive imaging approach  
- Clinical guidelines (ACC/AHA)  
- Management of congenital heart disease  
- Comprehensive Valve Center  

These terms encapsulate the major concepts related to heart disease, valve pathology, diagnostic modalities, and clinical considerations discussed in the provided guideline excerpt.

Page 65 Extracted Terms:
- Valvular Heart Disease (VHD)  
- Mixed aortic stenosis (AS) and aortic regurgitation (AR)  
- Symptomatic patients  
- Peak transvalvular jet velocity  
- Mean transvalvular gradient  
- Aortic valve replacement (AVR)  
- Surgical aortic valve replacement (SAVR)  
- Transcatheter aortic valve implantation (TAVI)  
- Left ventricular ejection fraction (LVEF)  
- Stage B disease (progressive, no therapeutic action)  
- Mixed moderate AS/AR  
- Mixed severe AS and mitral regurgitation (MR)  
- Primary MR (organic mitral valve disease)  
- Secondary MR (LV‑remodeling‑related)  
- Left ventricular dysfunction (LVEF < 50 %)  
- Surgical risk categories: low, intermediate, high, prohibitive  
- Double valve replacement (AVR + mitral valve replacement)  
- Mitral valve surgery (repair or replacement)  
- Mitral transcatheter edge‑to‑edge repair (TEER)  
- Valve replacement strategy (SAVR vs. TAVI)  
- Multidisciplinary team (MDT) involvement  
- Shared decision‑making with patients  
- Pressure gradient across the aortic valve  
- LV remodeling and its effect on MR  
- Clinical statements and guidelines (ACC/AHA)  
- Sequelae of AVR on MR (improvement vs. persistence)  
- Mortality risk associated with moderate mixed disease  
- Natural history of moderate mixed VHD  
- Decision criteria for valve replacement in symptomatic patients  
- Stage B progressive disease definition  
- Mitral valve repair feasibility  
- Post‑TAVI mitral repair potential  
- Outcomes of staged procedures (TAVI → TEER)  
- Evaluation of short‑ and long‑term outcomes in complex valve disease.

Page 66 Extracted Terms:
- Aortic valve replacement (AVR)  
- Surgical aortic valve replacement (SAVR)  
- Transcatheter aortic valve implantation (TAVI)  
- Transcatheter edge‑to‑edge repair (TEER)  
- Mitral regurgitation (MR)  
- Aortic stenosis (AS)  
- Mitral stenosis (MS)  
- Aortic regurgitation (AR)  
- Rheumatic valve disease  
- Mitral annular calcification  
- Left atrial (LA) pressure  
- Pulmonary artery wedge pressure  
- Left ventricle (LV)  
- Transcatheter approach  
- Surgical approach  
- Prosthetic valve  
- Transthoracic echocardiogram (TTE)  
- Transesophageal echocardiogram (TEE)  
- Cardiac computed tomography (CT)  
- Fluoroscopy  
- Valve hemodynamics  
- Valve dysfunction  
- Bioprosthetic surgical valve  
- Bioprosthetic TAVI  
- Mitral valve replacement  
- Mitral valve repair  
- Mixed mitral stenosis and mitral regurgitation (MS‑MR)  
- Mixed mitral stenosis and aortic regurgitation (MS‑AR)  
- Mixed mitral stenosis and aortic stenosis (MS‑AS)  
- LV filling  
- Stroke volume  
- Transvalvular gradient  
- Valve anatomy  
- Valve disease  
- Valve surgery  
- Valve replacement  
- Valve repair

Page 67 Extracted Terms:
- Prosthetic heart valves  
- Repaired native valves  
- Ventricular function  
- Atrial fibrillation (AF)  
- Pulmonary hypertension  
- Coronary artery disease (CAD)  
- Valve‑related complications  
- Endocarditis prophylaxis  
- Anticoagulation therapy  
- Transthoracic echocardiography (TTE)  
- Transesophageal echocardiography (TEE)  
- Cardiac CT imaging  
- Fluoroscopy  
- Transvalvular velocities  
- Transvalvular pressure gradients  
- Transvalvular leak  
- Paravalvular leak  
- Bioprosthetic valve dysfunction  
- Mechanical valve dysfunction  
- Heart failure (HF) symptoms  
- Shock  
- Thromboembolic events  
- Hemolysis  
- INR monitoring  
- Prosthesis‑patient mismatch  
- Functional stenosis  
- Valve area measurement  
- Left ventricular (LV) volumes  
- Left ventricular ejection fraction (LVEF)  
- Pulmonary artery systolic pressure  
- Right heart function  
- Mitral regurgitation (MR)  
- Pannus formation  
- Vegetation  
- Abscess formation  
- Valve obstruction  
- Reduced valve motion due to pannus or thrombus  
- Structural valve deterioration  
- Valve gradient ≥10 mm Hg  
- Transprosthetic regurgitation severity  
- Early postoperative complications  
- Routine follow‑up visits  
- Valve type (aortic, mitral, bioprosthetic)  
- Residual heart disease  
- Surgical aortic valve bioprosthesis  
- Incidence of valve deterioration after 10 years  
- Risk factors: young age (<60 yr), smoking, diabetes mellitus, chronic kidney disease, initial mean gradient ≥15 mm Hg, valve type.

Page 68 Extracted Terms:
- Aortic valve
- Valve dysfunction
- Prosthetic valve
- Bioprosthetic valve (bioprosthesis)
- Mechanical valve
- Valve replacement
- Valve repair
- Transcatheter aortic valve implantation (TAVI)
- Surgical aortic valve replacement (SAVR)
- Mitral valve replacement
- Pulmonic autograft (Ross procedure)
- Anti‑coagulation therapy
- Vitamin K antagonist (VKA) therapy
- Anticoagulant therapy
- Valve reintervention
- Structural valve deterioration (SVD)
- Transesophageal echocardiography (TTE)
- Hemodynamics
- Atrial fibrillation (AF)
- Pulmonary artery pressure
- Left ventricular (LV) function
- Valve choice
- Shared decision‑making
- Valve durability
- Patient‑prosthesis mismatch
- Invasive monitoring
- Long‑term VKA therapy
- Inconvenience of monitoring
- Dietary restrictions
- Medication interactions
- Athletic activity restrictions
- Radiation exposure risks
- Clinical statements
- Guidelines (ACC/AHA)

Page 69 Extracted Terms:
- Valvular heart disease  
- Aortic valve replacement (AVR)  
- Mechanical valve prosthesis  
- Bioprosthetic valve prosthesis  
- Valve durability  
- Valve type and size  
- Valve hemodynamics  
- Structural deterioration of bioprosthesis  
- Reintervention / reoperation  
- Anticoagulation therapy  
- Vitamin K antagonist (VKA)  
- Warfarin  
- International normalized ratio (INR) monitoring  
- Bleeding risk  
- Thromboembolic events  
- Antithrombotic safety in mechanical valves  
- Atrial fibrillation (AF)  
- Transcatheter aortic valve implantation (TAVI)  
- Valve‑in‑valve (ViV) procedure  
- Small aortic root / patient–prosthesis mismatch  
- Surgical vs. interventional risk  
- Age‑dependent valve choice (≤50 y, 50–65 y, >65 y)  
- Pregnancy‑related anticoagulation considerations  
- Long‑term anticoagulation complications  
- Anticoagulation monitoring accessibility  
- High‑risk reintervention (e.g., porcelain aorta, prior radiation)  
- Access to low‑mortality surgical centers  
- Prosthetic valve selection factors (durability, anticoagulation risk, patient preference)

Page 70 Extracted Terms:
- Bioprosthetic valve replacement  
- Mechanical valve replacement  
- Anticoagulation (VKA therapy)  
- Structural valve deterioration  
- Reoperation / repeat intervention  
- Bleeding complications  
- Thromboembolism / stroke risk  
- Aortic valve replacement (AVR)  
- Surgical aortic valve replacement (SAVR)  
- Transcatheter aortic valve implantation (TAVI)  
- Mitral valve replacement  
- Valve durability  
- Life expectancy / longevity  
- Shared decision‑making  
- Transcatheter bioprosthetic valves  
- Valve durability vs age  
- Mortality rate  
- Bioprosthetic mitral valve  
- Mechanical mitral valve  
- Long‑term VKA anticoagulation  
- Valve type selection  
- Valve durability data (20‑year, 5‑year)

Page 71 Extracted Terms:
- Bioprosthetic mitral valve replacement  
- Mechanical prosthetic valve  
- Ross procedure (pulmonary autograft)  
- Pulmonary homograft  
- Valve degeneration  
- Valve regurgitation  
- Antithrombotic therapy  
- Anticoagulation  
- Vitamin K antagonist (VKA)  
- International Normalized Ratio (INR)  
- Atrial fibrillation (AF)  
- Thromboembolism  
- Left ventricular dysfunction  
- Hypercoagulable state  
- Tissue valve (bioprosthetic)  
- Transcatheter aortic valve implantation (TAVI)  
- Surgical aortic valve replacement (SAVR)  
- Low-dose rivaroxaban  
- Dual antiplatelet therapy (aspirin + clopidogrel)  
- Direct thrombin inhibitor (dabigatran)  
- Anti‑Xa direct oral anticoagulants  
- Aspirin 75‑100 mg daily  
- Clopidogrel 75 mg daily  
- Thrombosis prevention in prosthetic valves  
- Bleeding risk management

Page 72 Extracted Terms:
- Mechanical valve prostheses  
- Bioprosthetic valve  
- Anticoagulant therapy  
- Vitamin K antagonist (VKA)  
- International Normalized Ratio (INR)  
- Thromboembolism  
- Valve thrombosis  
- Embolic events  
- Bleeding complications  
- Hemodynamic shear stress  
- Platelet activation  
- Aortic valve replacement (AVR)  
- Mitral valve replacement  
- Transcatheter Aortic Valve Implantation (TAVI)  
- Percutaneous coronary intervention (PCI)  
- Aspirin  
- Clopidogrel  
- Dual‑antiplatelet therapy  
- Antiplatelet therapy  
- Antithrombin agents  
- Anti‑Xa agents  
- Atrial fibrillation (AF)  
- Venous thromboembolic disease  
- Hypercoagulable state  
- Left‑ventricular (LV) dysfunction  
- Ball‑in‑cage valve  
- Low‑intensity anticoagulation  
- High‑intensity anticoagulation  
- INR target ranges  
- Stroke  
- Myocardial infarction  
- Transient ischemic attack (TIA)  
- Major adverse events  
- Mortality / survival rate  
- Coagulopathy  
- Prosthetic heart valve  
- Thromboembolic risk factors  
- Mechanical valve thrombogenicity  
- Embolism prevention  
- Prothrombotic state  
- Hemorrhage  
- Clinical guidelines  
- ACC/AHA  
- Circulation journal  

Page 73 Extracted Terms:
- Valvular Heart Disease  
- Aortic Valve Replacement (AVR)  
- Mitral Valve Replacement (MVR)  
- Bioprosthetic Valve  
- Biological Valve  
- Mechanical Valve  
- Transcatheter Aortic Valve Implantation (TAVI)  
- Anticoagulation  
- Antiplatelet Therapy  
- Dual Antiplatelet Therapy  
- Single-Anticoagulant Therapy  
- Vitamin K Antagonist (VKA)  
- Aspirin  
- Thromboembolism  
- Thromboembolic Events  
- Stroke  
- Ischemic Stroke  
- Myocardial Infarction  
- Major Bleeding  
- Life‑threatening Bleeding  
- Endothelialization  
- International Normalized Ratio (INR)  
- On‑X AVR  
- Hypercoagulable State  
- Left Ventricular (LV) Systolic Dysfunction  
- Sinus Rhythm  
- Atrial Fibrillation (AF)  
- Bioprosthetic Aortic Valve  
- Bioprosthetic Mitral Valve  
- Antithrombotic Therapy  

Page 74 Extracted Terms:
Valvular heart disease  
Bioprosthetic mitral valve replacement  
Bioprosthetic aortic valve replacement (bioprosthetic AVR)  
Mechanical valve prosthesis  
Transcatheter aortic valve implantation (TAVI)  
Valve‑in‑valve TAVI (ViV TAVI)  
Self‑expanding TAVI device  
On‑X aortic valve  
Anticoagulation therapy  
Vitamin K antagonist (VKA)  
Direct oral anticoagulant (DOAC)  
Low‑dose aspirin  
Aspirin 81 mg daily  
Dual‑antiplatelet therapy (e.g., aspirin + clopidogrel)  
International Normalized Ratio (INR)  
INR target ranges (1.5‑2.0, 2.5, 2.0‑3.0)  
Stroke (ischemic)  
Transient ischemic attack (TIA)  
Myocardial infarction  
Major bleeding  
Minor bleeding  
Cerebrovascular events  
Valve leaflet thrombosis  
Valve perforation  
Mean transvalvular gradient >10 mm Hg  
Low‑dose rivaroxaban  
GALILEO trial  
Antithrombotic strategy  
Antiplatelet strategy  
Bleeding risk  
Mortality (all‑cause, cardiovascular)

Page 75 Extracted Terms:
- Valvular heart disease  
- Low‑dose aspirin  
- Clopidogrel  
- Rivaroxaban  
- Warfarin  
- Dabigatran  
- Mechanical valve prosthesis  
- Oral anti‑Xa agents  
- Bridging therapy  
- Oral anticoagulation  
- Prosthetic heart valves  
- Mechanical heart valves  
- Bileaflet mechanical aortic valve replacement (AVR)  
- Vitamin K antagonist (VKA)  
- Therapeutic INR  
- Subtherapeutic INR  
- 4‑factor prothrombin complex concentrate (4‑PCC)  
- Activated prothrombin complex concentrate (aPCC)  
- Embolic events  
- Valve thrombosis  
- Aortic valve replacement (AVR)  
- Mitral valve replacement (MVR)  
- Thromboembolic complications  
- Bleeding complications  
- Minor procedures (e.g., dental extraction, cataract removal)  
- Invasive procedures  
- Non‑cardiac surgery  
- Transesophageal echocardiography (TEE)  
- Transthoracic echocardiography (TTE)  
- Computed tomography (CT)  
- International normalised ratio (INR)

Page 76 Extracted Terms:
- Valvular heart disease  
- Bioprosthetic heart valves  
- Annuloplasty rings  
- Anticoagulation for atrial fibrillation (AF)  
- CHA₂DS₂‑VASc score  
- Mechanical aortic valve replacement (AVR)  
- Mechanical mitral valve replacement  
- Mechanical bileaflet AVR  
- Bridging anticoagulation therapy  
- Invasive procedures  
- Thromboembolic risk factors  
- International Normalized Ratio (INR)  
- Unfractionated heparin (UFH)  
- Low‑molecular‑weight heparin (LMWH)  
- Prothrombin complex concentrate (PCC)  
- Fresh frozen plasma (FFP)  
- Direct oral anticoagulants (NOACs)  
- Warfarin  
- Moderate to severe rheumatic mitral stenosis  
- Bioprosthetic valve replacement or repair  
- Native valve repair  
- Antithrombotic therapy  
- Anticoagulation reversal  
- Vitamin K  
- Bleeding risk  
- Thrombosis risk  
- Prosthetic heart valves  

Page 77 Extracted Terms:
- Valvular Heart Disease  
- Prosthetic Valves  
- Mechanical Valves  
- Bioprosthetic Valves  
- Annuloplasty Rings  
- Direct Oral Anticoagulants (DOACs)  
- Vitamin K Antagonists (VKA)  
- Four‑factor Prothrombin Complex Concentrate (PCC)  
- Activated Prothrombin Complex (aPCC)  
- Idarucizumab (dabigatran antidote)  
- Andexanet Alfa (anti‑Xa antidote)  
- Intravenous Vitamin K  
- International Normalized Ratio (INR)  
- Supratherapeutic INR (>5.0)  
- Inadequate or excessive anticoagulation  
- Bleeding / Hemorrhage (including uncontrolled bleeding, life‑threatening bleeding)  
- Thromboembolism  
- Stroke (cerebrovascular event)  
- Systemic embolic event  
- Low‑dose Aspirin (75–100 mg)  
- Antiplatelet Therapy  
- Mechanical Aortic Valve Replacement (AVR)  
- Mechanical Mitral Valve Replacement  
- Bioprosthetic Surgical or Transcatheter Aortic Valve  
- Bioprosthetic Mitral Valve  
- Anticoagulation Reversal  
- Therapeutic INR range  

These terms capture the key concepts related to heart disease, particularly valvular heart disease and its management with anticoagulation.

Page 78 Extracted Terms:
- Valvular Heart Disease  
- VKA (Vitamin K antagonist) anticoagulation  
- INR (International Normalized Ratio)  
- Therapeutic range  
- Subtherapeutic INR  
- Thromboembolism  
- Infective Endocarditis (IE)  
- Atrial fibrillation (AF) / new‑onset AF  
- Hypercoagulable state  
- Bioprosthetic valve  
- Transcatheter aortic valve (TAVR)  
- Mechanical valve  
- Leaflet thrombosis  
- Pannus formation  
- Bleeding risk  
- Low‑dose aspirin  
- NOAC (Novel Oral Anticoagulant)  
- Stroke  
- Systemic embolic event  
- Transesophageal echocardiography (TEE)  
- Transthoracic echocardiography (TTE)  
- Fluoroscopy  
- Multidetector CT imaging  
- 3‑D CT scanning  
- Valve function assessment  
- Valve leaflet motion  
- Thrombus detection  
- Valve obstruction  
- Transvalvular gradient  
- Pulmonary edema  
- Stenotic murmur  
- Muffled closing clicks  
- Aortic prosthesis  
- Mitral prosthesis  
- Tricuspid prosthesis  
- Left ventricular (LV) size  
- LV systolic function  
- Estimated pulmonary pressures  
- High‑output state  
- Clinical decision‑making  
- Full neurological evaluation 

Page 79 Extracted Terms:
- Mechanical prosthetic valve thrombosis  
- Valve obstruction  
- Fibrinolytic therapy  
- Low‑dose thrombolytic therapy  
- Slow‑infusion thrombolysis  
- Emergency surgery  
- Left‑sided mechanical prosthetic heart valve  
- NYHA class I  
- NYHA class II  
- Hemodynamic success  
- Embolic events  
- Major bleeding  
- Transvalvular velocity  
- Transcatheter aortic valve implantation (TAVI)  
- Bioprosthetic valve thrombosis  
- Leaflet thrombosis  
- 3D transesophageal echocardiography (TEE)  
- 4D computed tomography (CT) imaging  
- Cardiac magnetic resonance (CMR) imaging  
- Hypoattenuation of valve leaflets  
- Oral anticoagulation  
- Vitamin K antagonist (VKA)  
- Anticoagulation therapy  
- Thrombus burden  
- Recurrent valve thrombosis  
- Surgical expertise  
- Valve stent (bioprosthetic valve)  
- Transvalvular gradient  
- Valve function improvement  

Page 80 Extracted Terms:
- Prosthetic Valve Stenosis  
- Mechanical Valve Stenosis  
- Bioprosthetic Valve Stenosis  
- Trans‑Thoracic Echocardiography (TTE)  
- Trans‑Echocardiographic Echocardiography (TEE)  
- Fluoroscopy  
- Cine‑Computed Tomography (cine‑CT)  
- Three‑Dimensional Trans‑Echocardiographic Imaging (3D TEE)  
- Four‑Dimensional CT Imaging (4D CT)  
- Pulmonary Artery Systolic Pressure  
- Ventricular Function  
- Leaflet Mobility  
- Pannus Ingrew  
- Thrombus Formation  
- Structural Valve Deterioration  
- Leaflet Thinning/Calcification/Tear  
- Stent Creep  
- Valve Academic Research Consortium (VARC) Criteria  
- Patient‑Prosthesis Mismatch  
- Transvalvular Gradient  
- Left Ventricular (LV) Hypertrophy  
- Cardiovascular Events  
- NYHA Class (I–IV)  
- Systemic Fibrinolysis  
- Surgical Therapy (Valve Replacement/Repair)  
- Coronary Artery Disease (CAD)  
- LA Thrombus  
- Intra‑operative Imaging  
- Valve Leaflet Opening/Closing Angles  
- Bioprosthetic Valve Degeneration  
- Endocarditis  
- Non‑Laminar Blood Flow  
- Mechanical Valve Leaflet Imaging  
- Cardiac Output Demands  
- Imaging Diagnostic Criteria for Stenosis Severity  
- Valve Implantation Baseline Hemodynamics  
- Imaging Modality for Pannus Detection  
- Left Ventricular Pressure Gradient  

(Note: All items are key heart‑disease‑related terms extracted from the guideline text.)

Page 81 Extracted Terms:
**Key Terms Related to Heart Disease**

- ACC/AHA Guideline for the Management of Valvular Heart Disease  
- Valvular heart disease  
- Valve stenosis  
- Bioprosthesis  
- Structural valve degeneration  
- Pannus formation  
- Thrombus (valve thrombus, subclinical bioprosthetic valve thrombosis)  
- Calcium deposition (paravalvular calcification)  
- CT imaging (4‑D CT)  
- TAVI (Transcatheter Aortic Valve Implantation)  
- 3‑D TEE (Three‑Dimensional Transesophageal Echocardiography)  
- Prosthetic valve stenosis  
- Surgical intervention (reoperative AVR, SAVR)  
- High or prohibitive surgical risk  
- Transcatheter ViV (Valve‑in‑Valve) procedure  
- Comprehensive Valve Center  
- Oral anticoagulation with a VKA (vitamin K antagonist)  
- Cumulative survival rates  
- Patient‑prosthesis mismatch  
- Paravalvular leak  
- Aortic valve gradients  
- VIVID registry (Valve‑in‑Valve International Data)  
- Stroke and bleeding risks  
- Functional status (NYHA class I/II)  
- Reoperative surgery mortality and morbidity  
- Coronary artery obstruction (specific to aortic ViV)  
- Permanent pacemaker implantation  
- Annulus rupture (not reported)  
- LV outflow obstruction (post‑mitral ViV)  
- Mechanical prosthetic valve complications  
- Transvalvular regurgitation (pannus, thrombus, vegetation)  
- Suture line disruption, annular disruption, endocarditis  
- Severe mitral annular calcification (late paravalvular leak risk)  
- Bioprosthetic valve regurgitation (paravalvular)  

These terms capture the principal concepts, procedures, complications, and clinical decision points discussed in the provided guideline excerpt.

Page 82 Extracted Terms:
- Valvular Heart Disease  
- Prosthetic Valve Regurgitation  
- Prosthetic Valve Stenosis  
- Transvalvular Leak  
- Paravalvular Leak  
- Mechanical Valve  
- Bioprosthetic Valve  
- Calcification  
- Leaflet Perforation  
- Leaflet Flail  
- Hemolysis  
- Heart Failure (HF)  
- Pulmonary Artery Systolic Pressure  
- Transthoracic Echocardiography (TTE)  
- Transesophageal Echocardiography (TEE)  
- 3‑Dimensional TEE (3D TEE)  
- 4‑Dimensional Imaging (4D)  
- Computed Tomography (CT)  
- Comprehensive Valve Center (CVC)  
- Valve‑in‑Valve (ViV)  
- Valve Thrombosis  
- Murmur  
- Auscultatory Findings  
- Echocardiographic Definitions  
- Diagnostic Imaging  
- Transcatheter Procedure  
- Hemodynamic Effects  
- Asymptomatic Presentation  
- New‑Onset Heart Failure  
- Unexplained Hemolysis  
- Estimated Pulmonary Pressure  
- Critical Diagnostic Distinction (Transvalvular vs. Paravalvular)  
- Clinical Presentation of Prosthetic Valve Dysfunction  
- Routine Clinical or Imaging Follow‑up  
- Intraprocedural Guidance  
- 3‑Dimensional Guidance for Transcatheter Procedures  

Page 83 Extracted Terms:
**Key Heart‑Disease Related Terms Extracted**

- Echocardiography (TTE, TEE, 3‑D TEE, real‑time 3‑D TEE)  
- Valve Academic Research Consortium (VARC) – 5‑class grading for paravalvular leak severity  
- Prosthetic valve regurgitation (transvalvular & paravalvular)  
- Prosthetic mitral valve; prosthetic aortic valve  
- Valve thrombosis (see Sections 11.6 & 11.8)  
- Prosthetic valve endocarditis (see Section 12.3)  
- Hemolytic anemia / intractable hemolysis  
- Heart failure (HF) – acute or chronic severe regurgitation; NYHA class III/IV symptoms  
- Transcatheter paravalvular leak closure (catheter‑based, percutaneous repair)  
- Comprehensive Valve Center (recommended site for advanced interventions)  
- Transcatheter valve‑in‑valve (ViV) procedure  
- Bioprosthetic valve degeneration (leaflet calcification, non‑coaptation, tear, perforation)  
- Infection (infective endocarditis, IE) – contraindication to transcatheter therapy, requires antibiotics before surgery  
- Surgical risk (high, prohibitive, low)  
- Anemia management (folic acid, iron supplementation, periodic transfusion)  
- Residual regurgitation assessment post‑device placement  
- Acoustic shadowing, paravalvular leak detection challenges (TTE suboptimal posterior, TEE suboptimal anterior)  

These terms capture the primary disease entities, clinical features, imaging modalities, therapeutic strategies, and risk stratification concepts emphasized in the guideline.

Page 84 Extracted Terms:
- Aortic valve replacement (AVR)  
- Reoperative AVR  
- Surgical reoperation  
- Paravalvular leak  
- Aortic valve  
- Mitral valve  
- Valve replacement  
- Prosthetic valve deterioration  
- Regurgitation  
- Leaflet calcification  
- Leaflet degeneration  
- Leaflet tear / perforation  
- Infective Endocarditis (IE)  
- Watchful waiting  
- Comprehensive Heart Valve Center  
- Percutaneous paravalvular leak closure  
- Multidisciplinary team (MDT)  
- Residual regurgitation  
- Heart failure (HF) symptoms  
- Valve‑in‑Valve (ViV)  
- Transcatheter ViV procedure  
- Stroke  
- Functional status  
- Hemodynamic outcomes  
- Reoperative SAVR (surgical aortic valve replacement)  
- All‑cause mortality  
- Low‑risk patients  
- Endocarditis classification  
- Native valve  
- Prosthetic valve  
- Timing of infection after valve intervention.

Page 85 Extracted Terms:
- Infective Endocarditis (IE)  
- Valvular Heart Disease (VHD)  
- Prosthetic heart valve  
- Left‑sided valve regurgitation  
- Congenital or acquired VHD  
- Injection drug use (risk factor for IE)  
- Blood culture  
- Staphylococcus aureus bacteremia  
- Enterococcal infection  
- Fungal infection  
- Modified Duke Criteria  
- Multispecialty Heart Valve Team  
- Cardiologist  
- Cardiac surgeon  
- Cardiac anesthesiologist  
- Neurologist  
- Transthoracic echocardiography (TTE)  
- Transesophageal echocardiography (TEE)  
- Intraoperative TEE  
- Baseline TEE (before oral therapy)  
- Repeat TEE (before completion of oral therapy)  
- Cardiac imaging (CT, CT/PET)  
- 18F‑fluorodeoxyglucose PET/CT  
- Vegetations  
- Hemodynamic severity of valvular lesions  
- Ventricular function  
- Pulmonary pressures  
- Embolism  
- Heart failure (HF)  
- Abscess  
- Atrioventricular heart block  
- Valve surgery for IE  
- Early change to oral antibiotic therapy for stable IE  
- Nosocomial S. aureus bacteremia  
- Paravalvular infection  
- Diagnostic imaging adjuncts (CT, PET/CT)

Page 86 Extracted Terms:
- Valvular Heart Disease  
- Infective Endocarditis (IE)  
- Culture‑negative Endocarditis  
- New or increased left‑sided valve regurgitation  
- Left‑sided valve  
- Valve regurgitation (mitral, aortic, etc.)  
- Prosthetic valve  
- Valve disease / valve lesions  
- Echocardiography (TTE, TEE)  
- Echocardiogram positive for IE  
- Vegetation  
- Oscillating intracardiac mass  
- Intracardiac abscess  
- Structural heart damage  
- Heart failure (HF)  
- Vascular emboli / embolization (including stroke, septic pulmonary infarcts, mycotic aneurysm)  
- Septic pulmonary infarcts  
- Janeway lesions  
- Osler’s nodes  
- Roth’s spots  
- Glomerulonephritis  
- Immunologic phenomena (immune complex deposition, rheumatoid factor)  
- Blood culture (positive, persistently positive, single positive, etc.)  
- Serological evidence of active infection  
- Polymerase chain reaction (PCR)  
- HACEK organisms (Haemophilus spp., Actinobacillus spp., Cardiobacterium hominis, Eikenella spp., Kingella kingae)  
- Viridans streptococci, Streptococcus bovis, Staphylococcus aureus, enterococci  
- Modified Duke Criteria (major and minor criteria for IE diagnosis)  
- Endocardial involvement  
- New partial dehiscence of prosthetic valve  
- Cardiovascular complications (stroke, intracranial hemorrhage, embolic events)  
- Cardiac imaging findings (e.g., oscillating mass, abscess, valve dehiscence)  
- Infection‑related heart disease indicators (fever >38 °C, vascular phenomena, immunologic phenomena)

Page 87 Extracted Terms:
- Valvular Heart Disease  
- Infective Endocarditis (IE)  
- Valve Vegetation  
- Transthoracic Echocardiography (TTE)  
- Transesophageal Echocardiography (TEE)  
- Prosthetic Valve Endocarditis  
- Aortic Regurgitation  
- Paravalvular Leak  
- Ventricular Size and Systolic Function  
- Pulmonary Pressures / Pulmonary Hypertension  
- Aortic Transvalvular Velocity / Gradient  
- Abscess (intracardiac or paravalvular)  
- Pericardial Effusion  
- Valve Perforation  
- Fistulae (paravalvular or intracardiac)  
- Intracardiac Thrombi  
- Heart Failure (HF)  
- Paravalvular Extension  
- Embolic Events (systemic emboli, stroke)  
- Early Surgical Intervention / Valve Surgery  
- Repeat Echocardiography (TTE/TEE)  
- Air Embolism (intraoperative)  
- Comprehensive Valve Center  
- Telemedicine (remote IE management)  
- Heart Valve Multidisciplinary Team (MDT)  
- Intraoperative TEE  
- Partial Oral Treatment of Endocarditis (POET) trial  
- Infectious Disease Specialists (role in IE care)

Page 88 Extracted Terms:
- Infective endocarditis (IE)  
- S.* aureus bacteremia  
- Transesophageal echocardiography (TEE)  
- Transthoracic echocardiography (TTE)  
- Multidetector‑row computed tomography (CT)  
- 18F‑fluorodeoxyglucose PET/CT  
- Prosthetic valve endocarditis  
- Native valve endocarditis  
- Mechanical prosthetic valve  
- Bioprosthetic valve  
- Valve vegetation  
- Valvular perforation  
- Paravalvular abscess  
- Annular abscess  
- Systemic embolization  
- Septic pulmonary infarct  
- Heart failure (HF)  
- Valvular heart disease  
- Aortic valve involvement  
- Coronary artery evaluation in IE  
- Modified Duke Criteria (major and minor criteria)  
- Intravascular catheter–associated bacteremia  
- Right‑sided infective endocarditis  
- Infective material limiting valve occluder motion  
- Thrombus on prosthetic valve  
- Cardiac fluoroscopy (adjunct imaging modality)

Page 89 Extracted Terms:
- Valvular heart disease  
- Infective endocarditis (IE)  
- Left‑sided infective endocarditis  
- Right‑sided infective endocarditis  
- Mechanical heart valve  
- Intracardiac device  
- Anticoagulation  
- Vitamin‑K antagonist (VKA)  
- Intravenous drug use–associated endocarditis  
- Opioid substitution therapy  
- Paravalvular infection  
- Transesophageal echocardiography (TEE)  
- Blood cultures  
- Antibiotic therapy  
- Antibiotic sensitivity data  
- Cerebral embolism  
- Stroke  
- Intracranial bleeding  
- Systemic emboli  
- Mycotic aneurysm  
- Antimicrobial regimens  
- Heart valve team  
- Antithrombotic therapy  
- Antimicrobial stewardship  
- Hemodialysis dependency  
- Spinal infection or non‑vertebral osteomyelitis  
- Infectious disease specialists (MDT)

Page 90 Extracted Terms:
**Key terms related to heart disease found in the text**

- Valvular heart disease  
- Infective endocarditis (IE)  
- Native valve endocarditis (NVE)  
- Prosthetic valve endocarditis (PVE)  
- Prosthetic valve dysfunction  
- Valve dysfunction  
- Ischemia  
- Hemorrhagic transformation (stroke)  
- Stroke  
- Anticoagulant therapy  
- Vitamin K antagonist (VKA)  
- Unfractionated heparin (UFH)  
- Bridging therapy  
- Antiplatelet therapy  
- Transesophageal echocardiography (TEE)  
- Transthoracic echocardiography (TTE)  
- Computed tomography (CT)  
- Positron emission tomography (PET)  
- 18F‑fluorodeoxyglucose (18FDG)  
- POET study (patient outcome evaluation)  
- Intravenous antibiotic treatment  
- Oral antibiotic treatment  
- Blood culture (diagnostic standard for IE)  
- Heart Valve Team  
- Cardiothoracic surgeon  
- Cardiologist  

These terms capture the primary concepts and interventions discussed in the guideline excerpt that pertain to heart disease management.

Page 91 Extracted Terms:
- Infective endocarditis (IE)  
- Prosthetic valve endocarditis  
- Heart valve dysfunction  
- Heart failure (HF)  
- Left‑sided endocarditis  
- S. aureus endocarditis  
- Fungal endocarditis  
- Highly resistant organisms  
- Heart block  
- Annular abscess  
- Aortic abscess  
- Destructive penetrating lesions  
- Persistent infection (bacteremia, fevers >5 days)  
- Pacemaker or defibrillator infection  
- Complete removal of cardiac electronic device  
- Recurrent endocarditis  
- Intravenous drug use–related endocarditis  
- Embolic events (recurrent emboli)  
- Vegetations (mobile >10 mm)  
- Cerebral embolic events  
- Stroke (ischemic and hemorrhagic)  
- Intracranial hemorrhage  
- Extensive neurological damage  
- Heart Valve Multidisciplinary Team (MDT)  
- Cardiology  
- Cardiothoracic surgery  
- Infectious disease  
- Comprehensive Valve Center  
- STS (Society of Thoracic Surgeons) risk‑scoring system for cardiac surgery  
- Surgical risk in infective endocarditis  

These terms capture the key heart‑disease–related concepts discussed in the guideline excerpt.

Page 92 Extracted Terms:
- Valvular heart disease  
- Infective endocarditis (IE)  
- Native valve endocarditis (NVE)  
- Prosthetic valve endocarditis (PVE)  
- Staphylococcus aureus endocarditis  
- Staphylococcal prosthetic valve endocarditis  
- Viridans streptococci endocarditis  
- Enterococcus faecalis (E. faecalis) endocarditis  
- Coagulase‑negative staphylococci endocarditis  
- Left‑sided infective endocarditis  
- Right‑sided infective endocarditis  
- Heart failure (HF)  
- Moderate to severe heart failure  
- Valve surgery  
- Early surgery (during initial hospital course)  
- Severe valvular dysfunction  
- Transesophageal echocardiography (TEE)  
- Transthoracic echocardiography (TTE)  
- Implantable cardioverter‑defibrillator (ICD)  
- Vitamin‑K antagonist (VKA) therapy  
- Embolic event  
- Central nervous system (CNS) event  
- Stroke  
- Intracranial hemorrhage  
- Drug‑use associated endocarditis (DUA)  
- Opioid substitution treatment (OST)

Page 93 Extracted Terms:
- Endocarditis  
- Valvular Heart Disease  
- Native Valve Endocarditis  
- Prosthetic Valve Endocarditis  
- Paravalvular Abscess  
- Annular Abscess  
- Aortic Abscess  
- Heart Block  
- Cardiac Device Endocarditis  
- Device Extraction  
- Parenteral Antibiotics  
- Methicillin‑Resistant *Staphylococcus aureus* (MRSA)  
- Vegetation  
- Vegetation Size >10 mm  
- Vegetation Mobility  
- Embolic Events  
- Septic Embolism  
- Left‑Sided Infective Endocarditis (IE)  
- Right‑Sided IE  
- Mitral Valve Lesions  
- Aortic Valve Lesions  
- Injection Drug Use–Associated IE  
- Blood Culture Negativity  
- Antifungal Therapy  
- Surgical Intervention  
- Operative Survival (5‑year actuarial survival)  
- Mortality Rate  
- Survival Benefit (device removal)  
- PET/CT Imaging  
- Addiction Therapy  
- Recurrent Fever  
- Recurrent IE  
- Paravalvular Invasion  
- Fistula Formation  
- Destructive Penetrating Lesions  
- Extensive Paravalvular Infections  
- Cardiac Tissue Destruction  
- ICU/Multidisciplinary Team (MDT) Involvement  
- Early Surgery  
- Proportional Hazards Regression  
- Incidence of Drug Use–Associated IE  
- Readmission Rates  
- Cost of Care  
- Antimicrobial Therapy Duration 48 hrs - 1 week  
- Long‑Term Outcomes (8‑year freedom from IE)

Page 94 Extracted Terms:
**Key terms related to heart disease**

- Valvular heart disease (VHD)  
- Infective endocarditis (IE)  
- Stroke (ischemic and hemorrhagic)  
- Embolic events  
- Heart failure (HF)  
- Heart block  
- Paravalvular extension  
- Early surgical intervention  
- Conventional treatment  
- All‑cause mortality  
- Perioperative hemorrhagic conversion  
- Surgical timing (>4 weeks after stroke or hemorrhage)  
- Pregnancy in women with severe valve disease  
- Transthoracic echocardiography (TTE)  
- Bicuspid aortic valve  
- Unicuspid aortic valve  
- Aortic sinus dilation  
- Ascending aorta dilation  
- Aortic dissection  
- Valve lesion staging (Stages C, D; Stage C1)  
- Functional capacity assessment  
- Left ventricular (LV) function  
- Right ventricular (RV) function  
- Pulmonary hypertension  
- Heart Valve Team (cardiologists, surgeons, anesthesiologists, maternal‑fetal medicine obstetricians)

Page 95 Extracted Terms:
- Valvular Heart Disease (VHD)  
- Valve replacement  
- Valve repair  
- Percutaneous aortic balloon dilation  
- Percutaneous mitral balloon dilation  
- Rheumatic mitral stenosis (MS)  
- Aortic stenosis (AS)  
- Severe valve disease  
- Cardiac morbidity  
- Cardiac mortality  
- High‑risk cardiac conditions  
- Stage D heart failure  
- Beta‑blocker medications  
- Diuretic medications  
- Angiotensin‑converting enzyme (ACE) inhibitors  
- Angiotensin‑receptor blockers (ARBs)  
- Arrhythmia  
- Atrial fibrillation (AF)  
- Anticoagulation therapy  
- Pregnancy‑related cardiac complications  
- Low birth weight  
- Fetal malformations  
- Fetal growth retardation  
- Maternal cardiac disease  
- Fetal outcome  
- ROPAC registry (Registry On Pregnancy And Cardiac Disease)  
- Exercise testing (for risk assessment)  
- Cardiac monitoring  

These terms capture the key heart‑disease concepts discussed in the guideline excerpt.

Page 96 Extracted Terms:
**Key Terms Related to Heart Disease**

1. Valvular heart disease (VHD)  
2. Mechanical valve  
3. Bioprosthetic valve  
4. Valve thrombosis  
5. Anticoagulation  
6. Warfarin  
7. International Normalized Ratio (INR)  
8. Pulmonary mitral balloon commissurotomy (PMBC)  
9. Rheumatic mitral stenosis (MS)  
10. Aortic stenosis (AS)  
11. Mitral regurgitation (MR)  
12. Valve repair  
13. Ross procedure  
14. Transcatheter aortic valve implantation (TAVI)  
15. Percutaneous aortic balloon dilation  
16. Valve replacement  
17. Valve intervention  
18. Valve morphology  
19. Valve area  
20. Aortic velocity  
21. Pressure gradient  
22. Hemodynamic changes  
23. Heart failure (HF)  
24. Arrhythmias  
25. Maternal adverse outcome  
26. Fetal complications  
27. Maternal death  
28. Excessive bleeding  
29. Preconception evaluation  
30. Serum brain natriuretic peptide (BNP)  
31. Symptom‑based indications  
32. Shared decision‑making  
33. Stage C / Stage C1 (severity classification)  
34. Preoperative trial of anticoagulation  
35. Mechanical vs. bioprosthetic valve durability in young women  

These terms capture the core concepts, procedures, risks, and clinical considerations discussed in the guideline excerpt.

Page 97 Extracted Terms:
**Key heart‑disease terms extracted from the text**

- Valvular Heart Disease (VHD)  
- Aortic Stenosis (AS)  
- Mitral Regurgitation (MR)  
- Left Ventricular (LV) Systolic Function  
- Biomarkers (in the context of LV function)  
- Mechanical Heart Valve  
- Bioprosthetic Valve  
- Valve Regurgitation (general)  
- Heart Failure (HF)  
- Pulmonary Hypertension (PH)  
- Pulmonary Artery Systolic Pressure (≥ 50 mm Hg)  
- Comprehensive Valve Center  
- Mitral Valve Morphology  
- Valve Repair  
- Surgical Risk (valve surgery)  
- Preconception Management of Valvular Disease  
- Native Valve Disease  
- Transthoracic Echocardiography (TTE) – imaging modality for valvular assessment  

Page 98 Extracted Terms:
**Key terms related to heart disease in the text**

- Valvular Heart Disease (VHD)  
- Severe aortic stenosis (AS)  
- Mean pressure gradient ≥ 40 mm Hg  
- Stage D disease  
- NYHA class III and IV heart‑failure (HF) symptoms  
- Rheumatic mitral stenosis (MS)  
- Mitral valve area ≤ 1.5 cm²  
- Pulmonary‑mural balloon commissurotomy (PMBC)  
- Valve regurgitation (severe)  
- Valve surgery (open heart)  
- Percutaneous balloon dilatation of the aortic valve  
- Percutaneous balloon dilation of the mitral valve  
- High‑risk procedures during pregnancy  
- Multidisciplinary team (cardiologists, interventionalists, cardiac anesthesiologists, obstetricians)  
- Prosthetic (mechanical) heart valves  
- Pre‑pregnancy assessment (echocardiography)  
- Mechanical prosthesis monitoring  
- Tertiary‑care center  
- Maternal‑fetal medicine obstetricians  
- Anticoagulation strategy for mechanical valves  
- Transesophageal echocardiography (TEE)  
- Prosthetic valve obstruction  
- Embolic event  
- Maternal mortality risk (~1 %)  
- Pregnancy risk category III (World Health Organization)  
- Valvular thrombosis risk (~5 %)  

These terms capture the primary heart‑disease concepts and clinical considerations discussed in the guideline excerpt.

Page 99 Extracted Terms:
- Valvular heart disease  
- Prosthetic heart valves  
- Mechanical heart valves  
- Valve dysfunction  
- Valve intervention  
- Preconception transthoracic echocardiography (TTE)  
- Transthoracic echocardiography (TTE)  
- Transesophageal echocardiography (TEE)  
- Transvalvular gradients  
- Valve regurgitation  
- Valve thrombosis  
- Embolic event  
- Heart failure (HF)  
- Pulmonary artery systolic pressure  
- Anticoagulation strategy  
- Vitamin K antagonist (VKA)  
- Warfarin  
- Low‑molecular‑weight heparin (LMWH)  
- Unfractionated heparin (UFH)  
- Activated partial thromboplastin time (aPTT)  
- Anti‑Xa level  
- Hypercoagulable state  
- Maternal mortality  
- Miscarriage  
- Fetal death  
- Congenital abnormalities  
- Maternal‑fetal medicine team  
- Heart Valve Team  
- Cesarean section  
- Vaginal delivery  
- First trimester  
- Second trimester  
- Third trimester  
- Therapeutic anticoagulation  
- Maternal and fetal safety  
- Pregnant women with mechanical prostheses  
- Shared decision‑making  
- Embolic risk  
- Thrombus burden  
- Maternal counseling  
- Fetal counseling  
- Clinical deterioration  
- Valve gradients  
- Valve regurgitation  
- Monitoring of anticoagulation  
- Reversal of anticoagulation  
- Anticoagulation titration  
- Gated cardiac CT  
- Fluoroscopy  
- Thrombus visualization  
- Surgical management of valve disease  
- Valve replacement  
- Valve prosthesis maintenance  
- Thrombus surveillance  
- Anticoagulation adjustment  
- Dose‑adjusted LMWH  
- Dose‑adjusted UFH  
- Target anti‑Xa range (0.8–1.2 U/mL)  
- Therapeutic INR  
- Dose‑adjusted warfarin  
- Anticoagulant safety profile  
- Maternal–fetal outcome optimization  

Page 100 Extracted Terms:
- Mechanical heart valves  
- Valvular heart disease  
- Mechanical valve prosthesis  
- Mechanical valve thrombosis  
- Anticoagulation  
- Warfarin  
- Low‑molecular‑weight heparin (LMWH)  
- Unfractionated heparin (UFH)  
- Direct thrombin inhibitor (dabigatran)  
- Direct oral anticoagulants (DOACs)  
- Anti‑Xa levels  
- International Normalized Ratio (INR)  
- Thromboembolism  
- Thrombosis  
- Hemorrhage  
- Fetal intracranial hemorrhage  
- Fetal intracranial bleeding  
- Warfarin embryopathy  
- Maternal morbidity  
- Maternal mortality  
- Fetal outcomes  
- Spontaneous abortion / miscarriage  
- Loss of pregnancy  
- Teratogenicity  
- Placental crossing of medication  
- Sequential therapy (heparin then warfarin)  
- Continuous warfarin therapy  
- Dose‑adjusted anticoagulation  
- Therapeutic anticoagulation  
- Anticoagulation monitoring  
- Antithrombotic therapy  
- Maternal and fetal risk balance

Page 101 Extracted Terms:
- Valvular heart disease  
- Prosthetic mechanical heart valves  
- Anticoagulation  
- Low‑molecular‑weight heparin (LMWH)  
- Unfractionated heparin (UFH)  
- Vitamin K antagonist (VKA)  
- Anti‑Xa levels  
- Activated partial thromboplastin time (aPTT)  
- Dose‑adjusted LMWH dosing  
- Therapeutic range  
- Pregnancy‑specific anticoagulation strategy  

These are the primary heart‑disease–related terms extracted from the text.

Page 102 Extracted Terms:
- Valvular Heart Disease  
- Mechanical heart valve  
- Prosthetic valve  
- Valve thrombosis (incl. mechanical valve thrombosis)  
- Low‑dose warfarin  
- Warfarin embryopathy / teratogenicity  
- Low‑dose LMWH (Low‑molecular‑weight heparin)  
- Unfractionated heparin (UFH)  
- Intravenous heparin infusion (continuous or slow‑infusion)  
- Activated partial thromboplastin time (aPTT)  
- Anti‑factor Xa level monitoring  
- Thrombolysis (tissue‑type plasminogen activator, tPA)  
- Fetal intracranial hemorrhage  
- Fetal loss / embryopathy  
- Anticoagulation management in pregnancy  
- Maternal hemorrhage risk  
- Thrombotic complications (stroke, valve thrombosis)  
- Obstetric anticoagulation strategy (e.g., warfarin shift, LMWH use)  
- Mechanical valve thrombosis management during pregnancy  
- Obstetric and anesthesia coordination for anticoagulation  
- Monitoring of anti‑Xa trough levels >0.6 IU/mL  
- Dose‑adjusted LMWH  
- Continuous UFH infusion for low‑dose warfarin replacement  
- Thrombus size criteria (>10 mm) for mechanical valve thrombosis.

Page 103 Extracted Terms:
- Valvular Heart Disease  
- Low‑dose warfarin  
- Low Molecular Weight Heparin (LMWH)  
- Mechanical heart valves  
- Valve thrombosis  
- Maternal thrombotic complications  
- Low‑dose aspirin (pregnancy safety)  
- Preeclampsia prevention  
- Anti‑Xa activity / anti‑Xa levels  
- Dabigatran (direct thrombin inhibitor)  
- Direct oral anticoagulants (DOACs)  
- Warfarin  
- Coronary Artery Disease (CAD)  
- Transcatheter Aortic Valve Implantation (TAVI)  
- Surgical Aortic Valve Replacement (SAVR)  
- Coronary Artery Bypass Grafting (CABG)  
- Aortic Stenosis (AS)  
- Left main coronary artery disease  
- Proximal coronary artery disease  
- Angina  
- Fractional Flow Reserve (FFR)  
- Instantaneous Wave‑Free Ratio (iFR)  
- SYNTAX Score  
- Cardiac cross‑clamp time  
- Cardiopulmonary bypass time  
- Aortic dilation  
- Mitral valve intervention  
- Aortic valve replacement (AVR)  
- Left ventricular (LV) function  
- Pulmonary hypertension  
- Renal injury (post‑operative)  
- Post‑operative adhesions  
- Medial radiation effects on cardiac surgery  
- Re‑operative cardiac procedures  
- Frailty / fragile tissue integrity  
- Concomitant surgical procedures (e.g., maze procedure for AF)

Page 104 Extracted Terms:
- Severe coronary artery disease (CAD)  
- SYNTAX score  
- Revascularization  
- Transcatheter aortic valve implantation (TAVI)  
- Severe aortic stenosis (AS)  
- Obstructive CAD  
- Coronary angiography  
- Coronary CT angiography  
- Fractional flow reserve (FFR)  
- Instantaneous wave‑free ratio (iFR)  
- Percutaneous coronary intervention (PCI)  
- Dual‑antiplatelet therapy (DAPT)  
- Left main coronary disease  
- Coronary artery bypass graft (CABG)  
- Aortic valve replacement (AVR)  
- Mitral regurgitation (MR)  
- Left ventricular (LV)  
- Computed tomography (CT)  

*(All terms are directly related to heart disease and its management as cited in the text.)*

Page 105 Extracted Terms:
- ACC/AHA Guideline  
- Valvular Heart Disease (VHD)  
- Percutaneous treatment  
- Left main disease  
- SYNTAX score  
- Surgical approach  
- Surgical aortic valve replacement (SAVR)  
- Revascularization  
- Coronary Artery Disease (CAD)  
- Significant CAD (>50% stenosis)  
- Valve surgery  
- Invasive coronary angiography  
- Angina  
- Ischemia  
- Left ventricular (LV) systolic function  
- Coronary risk factors  
- Men >40 years  
- Postmenopausal women  
- Chronic severe secondary mitral regurgitation (MR)  
- Contrast‑enhanced coronary CT angiography  
- Pretest probability of CAD  
- Coronary artery bypass grafting (CABG)  
- Proximal CAD (≥70% luminal diameter reduction)  
- Left main coronary artery CAD (≥50% luminal diameter reduction)  
- Physiologically significant CAD  
- Valve repair  
- Valve replacement  
- Coronary imaging in VHD  
- Secondary MR  
- LV reverse remodeling  
- LV remodeling  
- Periprocedural risk  
- Long‑term outcome  
- Percutaneous intervention  
- Sequential intervention  
- Radiation exposure  
- Renal failure (contrast‑related)  
- Diagnostic sensitivity (>90%)  
- Diagnostic specificity (60–90%)  
- Diagnostic accuracy (>90%)  
- Mitral valve disease  
- Aortic valve disease  
- Aortic valve repair/replacement  
- Coronary CT angiography contraindications (active angina, documented ischemia, prior CAD)  
- Cardiac imaging modalities (invasive vs. non‑invasive)  
- Coronary anatomy status  
- Coronary anatomy contribution to risk stratification  
- Coronary risk stratification.

Page 106 Extracted Terms:
- Valvular Heart Disease  
- Valve surgery  
- Myocardial infarction  
- Left ventricular (LV) systolic dysfunction  
- Operative mortality  
- Coronary artery stenosis  
- Left anterior descending artery  
- Left internal thoracic artery graft  
- Hybrid percutaneous coronary intervention (PCI)  
- Surgical valve repair  
- Surgical valve replacement  
- Atrial fibrillation (AF)  
- Atrial flutter  
- Valvular heart disease with atrial fibrillation  
- Arrhythmia surgery  
- Pulmonary vein isolation (PVI)  
- Maze procedure (atrial maze)  
- Left atrial (LA) appendage ligation  
- LA appendage excision  
- LA appendage occlusion/exclusion/amputation  
- Anticoagulation therapy  
- Thromboembolic events  
- Permanent pacemaker implantation  
- Catheter‑based ablation (including cryoenergy or radiofrequency)  
- Mitral valve repair  
- Mitral valve replacement  
- Aortic valve procedure  
- Tricuspid valve procedure  
- Recurrent atrial fibrillation  
- Catheter ablation (for AF)  
- Thrombogenic endocardial lesions  
- Complete revascularization  
- Incomplete revascularization  
- Perioperative complications  
- Bypass surgery (CABG)

Page 107 Extracted Terms:
**Key heart‑disease terms extracted from the text**

- Valvular heart disease (VHD)  
- Atrial fibrillation (AF)  
- Left atrial (LA)  
- Stroke  
- Catheter ablation  
- Surgical ablation  
- Oral anticoagulation  
- Anticoagulation (general)  
- Vitamin K antagonist (VKA)  
- CHA₂DS₂‑VASc score  
- Periprocedural phase  
- Endocardial healing  
- Bioprosthetic valve  
- LA appendage occlusion / exclusion  
- Valvular stenosis  
- Valvular regurgitation  
- Preoperative echocardiography  
- Non‑cardiac surgery in VHD patients  
- Arrhythmia recurrence  
- Valve repair/replacement  

These terms capture the primary themes related to heart disease and its management in the cited clinical guideline.

Page 108 Extracted Terms:
- Valvular heart disease (VHD)  
- Severity of VHD  
- Symptoms (symptomatic disease)  
- Risk of noncardiac intervention  
- Left ventricular (LV) response to overload  
- Right ventricular (RV) response to overload  
- Pulmonary artery systolic pressure  
- Cardiac intervention  
- Valve intervention (replacement, repair)  
- Heart Team  
- Cardiologist  
- Cardiac anesthesiologist  
- Cardiac surgeons  
- Cardiovascular anesthesiologist  
- Invasive hemodynamic monitoring  
- Transesophageal echocardiography (TEE)  
- Pre‑operative resting 12‑lead ECG  
- Transthoracic echocardiography (TTE)  
- Valve stenosis  
- Valve regurgitation  
- Systolic function  
- Diastolic function  
- Left ventricular (LV) size  
- Myocardial structure  
- Right ventricular (RV) size  
- Pulmonary artery pressure  
- Aortic stenosis (AS)  
- Aortic valve replacement (AVR)  
- Surgical aortic valve replacement (SAVR)  
- Transcatheter aortic valve implantation (TAVI)  
- Balloon aortic valvuloplasty  
- Rheumatic mitral stenosis (MS)  
- Mitral valve surgery (repair, replacement)  
- Aortic valve surgery (repair, replacement)  
- Left‑sided regurgitant lesions (mitral regurgitation, aortic regurgitation)  
- High‑risk non‑cardiac surgery  
- Elective non‑cardiac surgery  
- Elevated‑risk non‑cardiac surgery  
- Hemodynamic instability  
- Cardiac complications (10‑30 % rate in undiagnosed severe AS)  
- Pulmonary hypertension (> 50 mm Hg)  
- Coronary artery disease (CAD)  
- Perioperative risk  
- Non‑cardiac procedures  
- Ventricular function assessment  
- Valve pathology evaluation  
- Pre‑operative cardiac imaging  
- Symptomatic severe VHD  

These terms capture the core concepts and conditions related to heart disease discussed in the guideline excerpt.

Page 109 Extracted Terms:
- Valvular heart disease (VHD)  
- Asymptomatic VHD patient  
- Non‑cardiac surgery  
- Aortic stenosis (AS) – moderate or greater, severe  
- Mitral stenosis (MS) – rheumatic, moderate or greater, pulmonary artery systolic pressure < 50 mm Hg  
- Mitral regurgitation (MR) – moderate or greater, normal LV systolic function, pulmonary artery systolic pressure < 50 mm Hg  
- Aortic regurgitation (AR) – moderate or greater, normal LV systolic function  
- Left ventricular (LV) systolic function / left ventricular ejection fraction (LVEF)  
- Coronary artery disease (CAD)  
- Pulmonary hypertension  
- Peripheral artery disease (PAD)  
- Right ventricular (RV) dysfunction  
- Sinus rhythm  
- Hemodynamic monitoring (invasive)  
- Right‑heart catheterization  
- Transesophageal echocardiography (TEE)  
- Preload optimization  
- Forward cardiac output  
- Pulmonary edema  
- Left atrial (LA) pressure  
- Pulmonary capillary wedge pressure  
- Phenylephrine, norepinephrine (vasopressors)  
- Calcium channel blockers (arterial dilators)  
- Epidural/spinal (neuraxial) anesthesia  
- Neuraxial local anesthetic agents  
- Opioids (adjunct)  
- Hemodynamic stability (blood pressure, intracardiac volume)  
- Cardiac complications (myocardial injury, arrhythmias, ischemia, failure, death)  
- Aortic valve replacement (AVR)  
- Risk‑benefit ratio for intervention  
- CT or angiographic imaging for CAD exclusion.

Page 110 Extracted Terms:
- Valvular heart disease (VHD)  
- Acute pulmonary edema  
- Tachycardia  
- Diastolic left‑ventricular (LV) filling time  
- Stenotic mitral valve  
- Left atrial (LA) pressure  
- Rheumatic mitral stenosis (MS)  
- Pulmonary artery systolic pressure  
- Non‑cardiac surgery  
- Mitral regurgitation (MR)  
- LV systolic function  
- Heart failure (HF)  
- Myocardial infarction  
- Neuraxial local anesthetics  
- Opioids  
- Systemic vasodilation  
- General anesthesia  
- Preload  
- Invasive hemodynamic monitoring  
- Intraoperative transesophageal echocardiography (TEE)  
- Fluid balance  
- Ischemic heart disease  
- Hypertrophic cardiomyopathy  
- Aortic regurgitation (AR)  
- Hypotension  
- Arrhythmias  
- Stroke  
- Prolonged intubation (>24 h)  
- Cardiopulmonary complications  
- Mortality  
- Risk factors for valve disease  
- Rheumatic fever  
- Rheumatic heart disease  
- Calcific aortic stenosis (AS)  
- Bicuspid aortic valve (BAV)  
- Lipoprotein(a)  
- Genetic and pathobiological causes of valve dysfunction  
- Prevention of valve disease  
- Artificial intelligence and machine learning in cardiology  
- Imaging and engineering advances for valve diagnosis and treatment.

Page 111 Extracted Terms:
**Key Terms Related to Heart Disease**

- Valvular Heart Disease (VHD)  
- Stage B (Medical Therapy to Treat or Prevent Disease Progression)  
- Stage C (Optimal Timing of Intervention)  
- Stage D (Better Options for Intervention)  
- Early VHD  
- Calcific disease  
- Myxomatous disease  
- Disease progression  
- Patient monitoring  
- Severe disease  
- Symptoms  
- Abnormal cardiovascular function  
- Advanced imaging markers of disease progression  
- Randomized Controlled Trials (RCTs)  
- Valvular involvement  
- Ventricular involvement  
- Vascular involvement  
- Left‑ventricular (LV) dysfunction  
- Pulmonary hypertension  
- Patient education  
- Shared decision‑making  
- LV volumes  
- Systolic function  
- Diastolic function  
- Myocardial performance  
- LV size  
- Chronic severe aortic regurgitation (AR)  
- Strain imaging  
- Strain‑rate imaging  
- Circulating blood markers  
- Older adults  
- Cognitive function  
- Frailty  
- Mobility challenges  
- Women (gender representation)  
- Minorities (racial/ethnic representation)  
- Severe asymptomatic VHD  
- Severe aortic stenosis (AS)  
- Asymptomatic severe AR with normal LV systolic function  
- Severe primary mitral regurgitation (MR)  
- Valve repair  
- Valve replacement  
- Tricuspid regurgitation (TR)  
- Registries  
- Quality of care  
- Prosthetic valve  
- Life‑time risks of valve therapy  
- Transcatheter valve procedures (TAVR, TTVR, etc.)  
- Valve durability (long‑term, >5 years)  
- Mechanical valve replacement  
- Oral anticoagulation  
- Anticoagulant therapy  
- Nonthrombogenic valve surfaces  
- Hemodynamics of valve function  
- Valve substitutes  
- Epidemiology of moderate to severe VHD  
- Surgical procedures for valve disease  
- Clinical trial representation and inclusivity  
- Prediction of outcomes after valve intervention  
- Early markers of myocardial dysfunction  
- Advanced imaging for LV strain and strain‑rate  
- Risk–benefit balance of intervention timing  
- Quality‑of‑life considerations post‑intervention  

These terms capture the primary clinical concepts, therapeutic strategies, patient characteristics, imaging modalities, and research priorities discussed in the guideline excerpt.

Page 112 Extracted Terms:
- Valvular Heart Disease (VHD)  
- Aortic Stenosis (AS)  
- Mitral Regurgitation (MR)  
- Aortic Valve Replacement (AVR)  
- Surgical Aortic Valve Replacement (SAVR)  
- Transcatheter Aortic Valve Implantation (TAVI)  
- Atrial Fibrillation (AF)  
- Left Ventricular (LV)  
- Vitamin K Antagonist (VKA)  
- Randomized Controlled Trial (RCT)  

**Disease / Pathophysiology Terms**  
- Disease mechanisms  
- Rheumatic heart disease  
- Calcific valve disease  
- Ventricular and vascular interactions  
- Valve disease severity  
- Ventricular anatomy and function  

**Diagnostic / Risk Assessment Terms**  
- Advanced imaging endpoints  
- LV size (volumes vs. dimensions)  
- LV strain (function)  
- Nonimaging parameters (serum markers, novel approaches)  
- Decision aids for shared decision‑making  

**Therapeutic & Management Terms**  
- Medical therapy for progressive valve disease (Stage B)  
- Targeted therapy to slow or reverse disease progression  
- Antithrombotic therapy (post‑TAVI, mechanical valves)  
- Alternatives to VKA anticoagulation  
- Anticoagulation during pregnancy  
- Optimal blood pressure targets after valve intervention  
- Medical therapy after AVR (ventricular and vascular function)  
- Prevention of postoperative atrial fibrillation  
- Prevention of complications (e.g., need for permanent pacing, endocarditis, thromboembolic events)  

**Research / Implementation Terms**  
- Patient‑centered research  
- Inclusion of diverse patient groups  
- Decision algorithms for physicians and Heart Valve Teams  
- Evidence gaps & future directions  
- Equity, disparities, and cost‑effective long‑term management in rural settings  
- Access to therapies for valvular dysfunction  

**Procedural / Device Terms**  
- Durable prosthetic valves (TAVI & surgical)  
- Nonthrombogenic valves  
- Lower procedural risk (surgical morbidity & mortality)  

These terms capture the key concepts related to heart disease discussed in the guideline text.

Page 113 Extracted Terms:
**Key terms related to heart disease extracted from the text**

1. Valvular Heart Disease  
2. Heart Disease  
3. Cardiovascular Disease  
4. Cardiac  
5. Valve  
6. Aortic Valve  
7. Mitral Valve  
8. Valve Replacement  
9. Valve Repair  
10. Heart Failure

Page 114 Extracted Terms:
**Key Terms Related to Heart Disease**

- Valvular heart disease  
- Aortic valve stenosis  
- Mitral valve regurgitation  
- Tricuspid valve regurgitation  
- Bicuspid aortic valve  
- Aortic dilatation / dilation  
- Aortic valve regurgitation  
- Prosthetic valve evaluation  
- Hypertrophic cardiomyopathy  
- Congenital heart disease  
- Atrial fibrillation (AF)  
- Heart failure (HF)  
- Antithrombotic therapy  
- Thrombolytic therapy  
- Echocardiographic assessment  
- 2‑D and 3‑D echocardiography  
- Cardiovascular magnetic resonance imaging (MRI)  
- Non‑invasive evaluation of valvular disease  
- Cardiovascular disease during pregnancy  
- ESC/EACTS guidelines for valvular disease  
- ACC/AHA guidelines for valvular disease  
- ACCF/AHA guidelines for hypertrophic cardiomyopathy  
- ESC guidelines for cardiovascular disease during pregnancy  
- Cardiac imaging Committee (American Heart Association)  
- Society of Cardiovascular Echocardiography recommendations  
- Cardiac evaluation of native versus prosthetic valves  

*(This list captures the primary heart‑disease concepts referenced in the cited clinical guidelines.)*

Page 115 Extracted Terms:
Valvular heart disease  
Aortic stenosis (calcific)  
Aortic regurgitation  
Mitral regurgitation  
Mitral stenosis  
Doppler echocardiography  
Stress echocardiography (exercise Doppler)  
Cardiopulmonary exercise testing  
Exercise tolerance  
Left ventricular ejection fraction  
Left ventricular systolic function  
Hemodynamics (cardiac catheterization)  
Dobutamine challenge (dobutamine stress test)  
Watchful waiting (conservative management)  
Valve surgery (timing of aortic/mitral valve surgery)  
Bacterial endocarditis  
Rheumatic fever  
Endocarditis prophylaxis (antibiotic prophylaxis)  
ACC/AHA guideline (2020 Valvular Heart Disease)  
ESC working group on valvular heart disease  
ACC/AHA/HFSA heart failure guideline (2017)  
Secondary prevention (rheumatic fever, endocarditis)  
Primary prevention (cardiovascular disease)  
Heart failure management  
Valve clinic organization and structure  
Echocardiographic quantification of valve disease  
Low‑output low‑gradient aortic stenosis  
Quantitative exercise Doppler echocardiography  
Prognostic significance of exercise testing  
Left‑ventricular remodeling  
Aortic valve disease (overall)  
Valve pathology and diagnostics.

Page 116 Extracted Terms:
- Valvular heart disease  
- Infective endocarditis  
- Atrial fibrillation  
- Mechanical heart valves  
- Bioprosthetic valves  
- Aortic valve disease / aortic valve replacement  
- Mitral valve disease / mitral valve repair  
- Valve replacement  
- Valve repair  
- Anticoagulation (warfarin, NOACs)  
- Dental-related bacteremia (antibiotic prophylaxis)  
- Heart transplantation (orthotopic)

Page 117 Extracted Terms:
- Valvular heart disease  
- Aortic valve replacement  
- Transcatheter aortic valve replacement (TAVR / TAVI)  
- Transcatheter aortic valve implantation  
- Mitral valve repair  
- Mitral valve replacement  
- Valve bioprosthesis  
- Atrial fibrillation  
- Direct oral anticoagulants (DOACs)  
- Warfarin  
- Rivaroxaban  
- Dabigatran  
- Percutaneous mitral valve repair (e.g., MitraClip)  
- Balloon‑expandable prostheses  
- Mitral stenosis  
- Aortic stenosis  
- Mitral regurgitation  
- Aortic regurgitation  
- Heart failure  
- Pulmonary hypertension  
- Transpulmonary gradient  
- Surgical risk  
- Frailty  
- Procedural volume  
- Hospital volume  
- Surgical mortality  
- Stroke  
- Thromboembolism  
- Anticoagulation  
- Cardiac surgery  
- Cardiac catheterization  
- Valve pathology  
- Valve repair rates  
- Valve replacement outcomes


Page 118 Extracted Terms:
- Valvular Heart Disease  
- Mitral Valve Repair  
- Mitral Valve Surgery  
- Mitral Regurgitation  
- Hospital Procedural Volume  
- Hospital Volume  
- Failure to Rescue  
- Transcatheter Aortic Valve Implantation (TAVR)  
- Coronary Artery Bypass Grafting (CABG)  
- Open Aortic Aneurysm Repair  
- High‑Risk Surgery  
- Cardiovascular Surgery  
- Intensive Care Unit (ICU) Organization  
- Heart Team  
- Management of Patients with VHD  
- Periodic Imaging After Valve Intervention  
- Hemodynamic Valve Deterioration  
- Bioprosthetic Surgical Aortic Valve Replacement  
- Aortic Stenosis  
- Echocardiographic Assessment of Valve Stenosis  
- Cardiac Auscultation  
- Asymptomatic Valvular Heart Disease  
- Low‑Flow Low‑Gradient Aortic Stenosis  
- Systemic Hypertension  
- Systemic Vascular Load  
- Dobutamine Stress Doppler Hemodynamics  
- Low‑Dose Dobutamine Echocardiography  
- TOPAS Study  
- CT Aortic Valve Calcium Scoring  
- Electron‑Beam Computed Tomography  
- Multislice Computed Tomography  
- Doppler Echocardiography  
- Computed Tomography (CT)  
- Magnetic Resonance Imaging (MRI) – (implied by imaging discussions)  
- Valve Area Determination  
- Valve Calcification  
- Aortic Valve Calcium Score  
- Left Ventricular Ejection Fraction (LVEF)  
- Left Ventricular Systolic Function  
- Left Ventricular Diastolic Function  
- Vascular Load  
- Stress Testing (Dobutamine)  
- Doppler‑Catheter Correlation  
- Surgical Outcomes  
- Mortality  
- Survival  
- Prognostic Indicators  
- Risk Stratification  
- Echocardiographic Measures (velocity, pressure gradients)  
- Doppler‑Based Valve Area  
- Doppler Flow Velocity  
- Aortic Valve Area**  
- Valve Gradient**  
- Clinical Decision‑Making in Valve Disease  

(These terms capture key concepts, conditions, procedures, diagnostic methods, and outcome measures relevant to heart disease as extracted from the provided guideline excerpt.)

Page 119 Extracted Terms:
**Key heart‑disease related terms extracted from the text**

- aortic stenosis  
- valvular heart disease  
- left ventricular ejection fraction  
- Doppler echocardiography  
- dobutamine challenge / dobutamine echocardiography  
- transcatheter valve implantation (TAVI)  
- surgical prosthetic valve implantation  
- low‑flow, low‑gradient aortic stenosis  
- bicuspid aortic valve  
- exercise testing / exercise‑stress echocardiography  
- cardiac catheterization / angiocardiography  
- blood pressure (systolic and optimal)  
- lipid‑lowering therapy (statins, ezetimibe, rosuvastatin)  
- renin‑angiotensin system blockade (ACE inhibitors, ARBs)  
- hemodyamics / hemodynamic progression  
- valve area / projected valve area  
- leaflet calcification / aortic‑valve calcium  
- myocardial dysfunction / left‑ventricular dysfunction  
- symptomatic versus asymptomatic aortic stenosis  
- risk stratification / prognostic assessment  
- treatment decision / surgical indication  
- hypertension in aortic stenosis  

This list captures the primary clinical concepts and interventions discussed in the cited guideline and related studies.

Page 120 Extracted Terms:
- Aortic valve stenosis  
- Valvular heart disease  
- Transcatheter aortic valve replacement (TAVR)  
- Aortic valve replacement  
- Low‑flow low‑gradient aortic stenosis  
- Low‑output low‑gradient aortic stenosis  
- Calcific aortic valve disease  
- B‑type natriuretic peptide (BNP)  
- Natriuretic peptides  
- Left ventricular ejection fraction (LVEF)  
- Left ventricular systolic function / depressed left ventricular function  
- Symptomatic aortic stenosis  
- Asymptomatic aortic stenosis  
- Dobutamine stress echocardiography  
- Exercise‑treadmill testing  
- Valve disease progression  

Page 121 Extracted Terms:
**Key heart‑disease terms identified in the guideline text**

- Aortic stenosis  
- Valvular heart disease  
- Aortic valve replacement (AVR)  
- Transcatheter aortic valve implantation (TAVI)  
- Low‑flow, low‑gradient aortic stenosis  
- Severe aortic stenosis  
- Mild to moderate aortic stenosis  
- Left ventricular ejection fraction (LVEF)  
- Left ventricular function (systolic & diastolic)  
- Contractile reserve  
- Hemodynamic measurements  
- Doppler echocardiography  
- Dobutamine echocardiography  
- Exercise testing  
- Quantitative exercise Doppler  
- Velocity pressure gradient (VPG)  
- Valve area  
- Valve area index  
- Transvalvular gradient  
- Coronary artery bypass graft (CABG)  
- Coronary revascularization  
- Mechanical prostheses  
- Bioprosthetic prostheses  
- Prosthetic valve durability  
- Anticoagulation risk  
- Reoperation risk  
- Lipid‑lowering therapy  
- Simvastatin  
- Ezetimibe  
- Rosuvastatin  
- Statin treatment  
- Survival  
- Long‑term outcome  
- Prognostic indicators  
- Risk stratification  
- Clinical outcome  
- Symptom onset  
- Asymptomatic patients  
- Symptomatic patients  
- Mortality  
- Surgical risk models (e.g., Society of Thoracic Surgeons)  
- ESC/EACTS guidelines  
- ACC/AHA guidelines  
- Echocardiographic assessment  
- Small valve area  
- Pressure drop/flow slope  
- Invasive hemodynamic characteristics


Page 122 Extracted Terms:
- Valvular Heart Disease  
- Mitral valve replacement  
- Aortic valve replacement (SAVR)  
- Transcatheter Aortic Valve Replacement (TAVR)  
- Bioprosthetic valve  
- Mechanical valve  
- Ross procedure  
- Valve‑in‑Valve implantation  
- Self‑expanding prosthesis  
- Balloon‑expandable valve  
- Carpentier‑Edwards Pericardial bioprosthesis  
- Perimount bioprosthesis  
- Aortic stenosis  
- Severe aortic stenosis  
- Low‑risk patients  
- Intermediate‑risk patients  
- High‑risk patients  
- Propensity‑matched analysis  
- Long‑term outcomes  
- Late outcomes  
- Hemodynamic stability  
- Post‑operative anticoagulation  
- Shared decision‑making  
- Bioprosthetic aortic valve durability  
- Autograft aortic root replacement  
- Homograft aortic root replacement  
- Thoracic cardiovascular surgery  
- Cardiac surgical outcomes.

Page 123 Extracted Terms:
- Aortic valve  
- Aortic stenosis  
- Severe aortic stenosis  
- Low‑flow, low‑gradient aortic stenosis  
- Aortic regurgitation (aortic insufficiency)  
- Acute aortic regurgitation  
- Chronic aortic regurgitation  
- Native valve endocarditis  
- Acute type‑A aortic dissection  
- Transcatheter aortic valve replacement (TAVR / TAVI)  
- Transcatheter aortic valve implantation  
- Balloon‑expandable valve (e.g., SAPIEN 3)  
- Self‑expandable valve (e.g., Evolut R)  
- Balloon aortic valvuloplasty  
- Valve Academic Research Consortium‑2 (VARC‑2) criteria  
- Structural valve deterioration  
- Hemodynamic durability  
- Left ventricular ejection fraction (LVEF)  
- Left ventricular dysfunction  
- Severe left ventricular dysfunction  
- Heart failure  
- Inoperable severe aortic stenosis  
- Decompensated aortic stenosis (emergency treatment)  
- Intra‑aortic balloon counterpulsation  
- B‑type natriuretic peptide (BNP)  
- Echocardiography (including quantitative Doppler)  
- Cardiovascular magnetic resonance  
- Functional outcomes  
- Survival outcomes  
- Pre‑operative left ventricular function  
- Asymptomatic aortic regurgitation  
- Asymptomatic severe aortic regurgitation  
- Long‑term clinical outcomes  
- Surgical aortic valve replacement  
- Propensity‑matched comparison  
- Valve replacement timing criteria**

Page 124 Extracted Terms:
- Valvular heart disease  
- Aortic regurgitation (aortic insufficiency)  
- Chronic aortic regurgitation  
- Severe aortic regurgitation  
- Asymptomatic aortic regurgitation  
- Aortic valve replacement  
- Left ventricular function  
- Left ventricular ejection fraction  
- Left ventricular dysfunction  
- Left ventricular dilation / dilatation  
- Left ventricular volume  
- Left ventricular systolic function  
- Right ventricular function  
- Exercise capacity (pre‑operative)  
- Hemodynamically significant aortic regurgitation  
- Cardiac magnetic resonance imaging (CMR)  
- Cardiovascular magnetic resonance (CMR)  
- Transthoracic echocardiography (TTE)  
- Doppler echocardiography  
- Continuous‑wave Doppler ultrasound  
- Velocity‑encoded cine MR imaging  
- Cine nuclear magnetic resonance (cMRI)  
- Cardiovascular imaging modalities  
- Renin‑angiotensin‑aldosterone system blockade  
- Vasodilator therapy  
- Nifedipine  
- Enalapril  
- Hydralazine  
- Felodipine  
- Beta‑blocker therapy  
- Guideline‑based indications  
- Timing of intervention (surgery)  
- Surgical correction of aortic regurgitation  
- Post‑operative left ventricular function  
- Long‑term prognosis  
- Survival outcomes  
- Functional outcomes  
- Clinical outcome  
- B‑type natriuretic peptide (BNP)  
- Heart failure  
- Cardiovascular disease  
- Primary prevention of cardiovascular disease  
- ACC/AHA guidelines for valvular heart disease  
- ACC/AHA guidelines for heart failure management  
- ACC/AHA guidelines for primary prevention of cardiovascular disease  
- Aortic valve pathology  
- Mitral regurgitation (in combined valvular studies)  
- Valve lesion  
- Cardiac output  
- Pre‑operative criteria for surgery  
- Symptomatic versus asymptomatic status  
- Post‑operative prognosis  
- Guideline adherence in severe aortic regurgitation.

Page 125 Extracted Terms:
- Valvular heart disease  
- Aortic regurgitation / aortic insufficiency  
- Chronic aortic regurgitation  
- Severe aortic regurgitation (native or bioprosthetic)  
- Bicuspid aortic valve (BAV)  
- Aortic root dilation / aortopathy  
- Valvular replacement  
- Valve repair  
- Valve‑sparing aortic root replacement  
- Transcatheter aortic valve replacement (TAVR)  
- Transcatheter valve implantation  
- Transapical valve implantation  
- Bilateral/bioprosthetic valve replacement  
- Cardiovascular magnetic resonance (CMR) imaging  
- Echocardiography (transthoracic, transesophageal, M‑mode, speckle‑tracking)  
- B‑type natriuretic peptide (BNP)  
- Left ventricular ejection fraction (LVEF)  
- Left ventricular end‑systolic dimension (LVESD)  
- Left ventricular end‑diastolic dimension (LVEDD)  
- Left ventricular global longitudinal strain (GLS)  
- Left ventricular dilatation and remodeling  
- Wall stress and ventricular geometry  
- Volume overload from valve regurgitation  
- Preoperative predictors (e.g., fractional shortening, LV dimensions)  
- Intraoperative transesophageal echocardiography  
- Clinical outcome and long‑term survival  
- Mortality and morbidity in aortic regurgitation  
- Symptom‑based therapeutic strategy  
- Hemodynamic predictors of surgical success  
- Early detection of subclinical myocardial injury  
- Biomarkers in asymptomatic aortic valve disease  
- Follow‑up and monitoring of bicuspid aortic valve  
- Valve disease prognosis and re‑operation risks  
- Surgical outcomes for chronic aortic valvular disease  
- Subclinical myocardial damage strategies  
- Cardiac chamber quantification guidelines  
- Heart valve repair classification systems (e.g., bicommissural repair)  
- Bioprosthetic valve durability  
- Aortic root reconstruction techniques (reimplantation, David procedure)  
- Left ventricular performance post‑surgery  
- Clinical laboratory and imaging surveillance of valvular disease

Page 126 Extracted Terms:
- Bicuspid aortic valve (BAV)  
- Aortic dilatation / aortic enlargement  
- Aortic root dilatation  
- Ascending aortic aneurysm  
- Thoracic aortic aneurysm  
- Aortic aneurysm rupture / dissection  
- Aortic insufficiency (regurgitation)  
- Aortic stenosis  
- Aortic valve replacement  
- Aortic valve repair  
- Aortic valve–sparing operations  
- Transcatheter aortic valve replacement (TAVR)  
- Surgical repair of the ascending aorta  
- Mitral stenosis  
- Left ventricular diastolic dysfunction  
- Bicuspidoid aortic valve phenotyping  
- Proximal aortic dilatation  
- Aortic cross‑sectional area / height ratio  
- Sinuses of Valsalva (non‑replaced) management  
- Coronary aortic valve geometry  
- Thoracic aortic disease management guidelines  
- Aortic valve root remodeling  
- Transcatheter aortic valve implantation (TAVI)  

These terms capture the central concepts related to heart disease described in the provided text.

Page 127 Extracted Terms:
- Valvular heart disease  
- Mitral stenosis (MS)  
- Rheumatic mitral stenosis  
- Mitral valve  
- Mitral annular calcification  
- Calcific mitral stenosis  
- Percutaneous mitral valvuloplasty  
- Transseptal mitral balloon valvuloplasty  
- Commissural calcification  
- Commissural calcium score  
- Mitral valve area  
- Transmitral gradient  
- Left atrial appendage thrombus  
- Atrial thrombi  
- Atrial fibrillation (AF)  
- Direct oral anticoagulants (DOAC)  
- Anticoagulant prophylaxis  
- Heart rate control  
- Dobutamine stress echocardiography  
- Transthoracic echocardiography (TTE)  
- Transesophageal echocardiography (TEE)  
- Doppler echocardiography  
- Exercise stress testing  
- Cardiac catheterization  
- Gorlin formula  
- Mitral valve resistance  
- Left ventricular compliance  
- Left atrial compliance  
- Valve stenosis  
- Valve area  
- Valve pressure half‑time  
- Valve calcification  
- Cardiac output reserve  
- Exercise intolerance  
- Ivabradine  
- Metoprolol  
- Atenolol  
- Embolism  
- Stroke  
- Heart failure

Page 128 Extracted Terms:
- Mitral stenosis  
- Mitral valve (and its components: commissures, leaflets)  
- Valvular heart disease  
- Atrial fibrillation  
- Pulmonary hypertension  
- Right ventricular dysfunction  
- Tricuspid regurgitation  
- Left atrial thrombus  
- Left atrial volume / diameter  
- Net atrioventricular compliance (NAC)  
- Left ventricular diastolic dysfunction  
- Rheumatic mitral stenosis  
- Low‑gradient severe mitral stenosis  
- Hemodynamic profile (including transpulmonary gradient)  
- Wilkins score (echocardiographic scoring system for mitral stenosis)  
- Commissural calcium score / calcification  
- Commissural area ratio  
- Echocardiography (including trans‑esophageal and stress Doppler)  
- P‑wave dispersion  
- Atrial electromechanical delay  
- Pulmonary artery stiffness  
- Percutaneous balloon mitral valvuloplasty (PBMV)  
- Percutaneous mitral commissurotomy (PMC)  
- Percutaneous mitral valve dilatation  
- Open mitral commissurotomy (OC)  
- Closed mitral commissurotomy (CC)  
- Balloon mitral valvotomy (BMV)  
- Surgical mitral valvotomy / valve replacement  
- Cardiovascular death  
- Long‑term outcomes (≤ 50 years)  
- Mid‑term outcomes (10–20 years)  
- Short‑term outcomes (early results, immediate results)  
- Predictive scores (e.g., Wilkins, integrated approach)  
- Revascularization / valve replacement options (mitral valve replacement)  
- Echocardiographic predictors of outcome  
- Clinical characteristics (including baseline pulmonary artery pressure)  
- Stress echocardiography in mitral stenosis  
- Pulmonary artery compliance  

These terms capture the principal diseases, anatomical structures, complications, diagnostic modalities, procedural interventions, and prognostic factors discussed in the cited 2020 ACC/AHA guideline and related studies.

Page 129 Extracted Terms:
- Mitral Stenosis  
- Mitral Annulus Calcification  
- Degenerative Mitral Stenosis  
- Nonrheumatic Calcific Mitral Stenosis  
- Rheumatic Mitral Stenosis  
- Valve Stenosis  
- Mitral Regurgitation  
- Acute Mitral Regurgitation  
- Chronic Primary Mitral Regurgitation  
- Mitral Valve Replacement  
- Transcatheter Mitral Valve Replacement  
- Intraoperative Transesophageal Echocardiography  
- Dobutamine Stress Echocardiography  
- Echocardiographic Assessment (2‑D, 3‑D, Doppler)  
- Color Flow Doppler  
- Left Ventricular Function  
- Pulmonary Edema  
- Chronic Kidney Disease  
- Renal Function (glomerular filtration, kidney disease)  
- Aortic Stenosis  
- Aortic Valve Calcification  
- Papillary Muscle Rupture  
- Infective Endocarditis  
- Traumatic Mitral Valve Injury (blunt chest trauma)  
- Vasodilator Therapy (for MR)  
- Annulus Washer Technique  
- Supra‑Annular Prosthesis Insertion  
- Intraatrial Placement of Mitral Prosthesis  
- Post‑infarction Mitral Regurgitation  
- Mitral Valve Area Measurement  
- Mitral Valve Orifice Geometry  
- Signal Void in MRI (mitral regurgitation)

Page 130 Extracted Terms:
Valvular heart disease  
Mitral regurgitation  
Aortic regurgitation  
Tricuspid regurgitation  
Leaflet prolapse  
Valve repair  
Valve replacement  
Transcatheter interventions  
Transesophageal echocardiography (TEE)  
Transthoracic echocardiography (TTE)  
Magnetic resonance imaging (MRI)  
Cine Magnetic Resonance  
Left atrial signal loss  
Left ventricular dysfunction  
Left ventricular performance  
Left ventricular volume  
Left ventricular ejection fraction (LVEF)  
Left ventricular end‑systolic dimension  
Global longitudinal strain (GLS)  
Diastolic function  
Chamber quantification  
Pulmonary hypertension  
B‑type natriuretic peptide (BNP)  
Brain natriuretic peptide (BNP)  
Symptom assessment  
Surgical timing  
Natural history of mitral regurgitation  
Watchful waiting  
Early surgery  
Multimodality imaging  
Echocardiographic quantitative assessment  
Hemodynamics  
Cardiac catheterization  
Prognostic markers  
Survival outcomes  
Clinical outcome  
Native valvular regurgitation  
Organic mitral regurgitation  
Degenerative mitral regurgitation  
Severe mitral regurgitation  
Chronic mitral regurgitation  
Asymptomatic mitral regurgitation  
Aortic regurgitation indication  
Surgical indication  
Valve disease guidelines  
Endocardial imaging  
Valve pathology  
Valve surgery  
Valve repair outcomes  
Valve regurgitation evaluation  
Left ventricular longitudinal strain  
Serial measurement of natriuretic peptides

Page 131 Extracted Terms:
**Key terms related to heart disease**

- Valvular Heart Disease  
- Mitral Regurgitation  
- Mitral Valve Prolapse  
- Rheumatic Mitral Valve Disease  
- Severe Mitral Regurgitation  
- Chronic Mitral Regurgitation  
- Degenerative Mitral Regurgitation  
- Mitral Valve Surgery  
- Mitral Valve Repair  
- Mitral Valve Replacement  
- Left Ventricular Performance  
- Left Ventricular Function  
- Left Ventricular Ejection Fraction  
- Left Ventricular End‑Systolic Diameter  
- Left Ventricular End‑Systolic Volume  
- Left Ventricular Mass  
- Left Ventricular Volumes  
- Echocardiography  
- Exercise‑Induced Mitral Regurgitation  
- Pulmonary Hypertension  
- β‑1 Receptor Blockade  
- Angiotensin‑Converting Enzyme (ACE) Inhibition  
- Losartan (Angiotensin Receptor Blocker)  
- Enalapril (ACE Inhibitor)  
- Captopril (ACE Inhibitor)  
- Afterload Reduction  
- Preoperative Symptoms  
- Postoperative Outcomes  
- Survival  
- Mortality  
- Watchful Waiting  
- Early Surgery  
- Surgical Indications  
- Guideline‑Based Indications  
- Valve Surgery Volume  
- Repair Quality  
- Perioperative Outcomes  
- Surgical Durability  
- Heart Valve Centers of Excellence  
- Percutaneous Valve Repair  
- Long‑Term Survival  
- Long‑Term Outcomes  
- Cardiovascular Imaging  
- Exercise Testing  
- Clinical Statements  
- Guidelines

Page 132 Extracted Terms:
- Mitral valve  
- Valvular heart disease  
- Minimally invasive approach  
- Mitral valve repair  
- Mitral valve replacement  
- Ischemic mitral regurgitation  
- Secondary mitral regurgitation (MR)  
- Chronic secondary MR  
- Severe ischemic mitral regurgitation  
- Moderate ischemic mitral regurgitation  
- Left ventricular dysfunction  
- Left ventricular ejection fraction  
- Heart failure  
- Chronic heart failure  
- Reduced left‑ventricular systolic function  
- Neuroendocrine activation  
- Enalapril (ACE‑inhibitor)  
- Candesartan (angiotensin‑II receptor blocker)  
- Carvedilol (beta‑blocker)  
- Spironolactone (aldosterone antagonist)  
- Cardiac resynchronization therapy (CRT)  
- Angiotensin‑receptor neprilysin inhibitor (ARNI)  
- Functional mitral regurgitation  
- Coronary artery bypass grafting (CABG)  
- Myocardial viability  
- Ischemic cardiomyopathy  
- Transcatheter valve repair  
- MitraClip therapy  
- Echocardiography  
- Magnetic resonance imaging (MRI)  
- Doppler assessment  
- Valvular regurgitation evaluation  
- SCAI/AATS/ACC/STS operator and institutional requirements  
- STS/ACC TVT registry  
- ACC/AHA heart failure guidelines  
- NECT (N/A)

Page 133 Extracted Terms:
- Valvular heart disease  
- Mitral regurgitation (functional/secondary)  
- Ischaemic mitral regurgitation  
- Primary mitral regurgitation  
- Mitral valve repair  
- Mitral valve replacement  
- Transcatheter mitral valve repair (MitraClip)  
- Percutaneous mitral valve repair  
- Mitral valve annuloplasty  
- Cardiac resynchronization therapy (CRT)  
- Left‑ventricular systolic dysfunction  
- Left‑ventricular remodeling (reverse remodeling)  
- Heart failure (HF)  
- Ischaemic heart failure  
- Surgical treatment of valve disease  
- Coronary artery bypass grafting (CABG)  
- Revascularization  
- Ischaemic cardiomyopathy  
- Atrial fibrillation (AF)  
- Functional tricuspid regurgitation  
- Tricuspid valve repair/annuloplasty  
- Right‑ventricular function (ejection fraction, volumes)  
- Systolic and diastolic RV function  
- Echo‑based assessment of valve function  
- Cardiac magnetic resonance imaging (MRI)  
- Three‑dimensional echocardiography  
- Regurgitant volume  
- Quantitative Doppler assessment  
- Prognostic implications of valvular dysfunction  
- Operative and mortality risk in valve surgery  
- Recurrent or residual functional regurgitation  
- COAPT trial outcomes  
- MITRA‑FR trial outcomes  
- RIME (Randomized Ischemic Mitral Evaluation) trial  
- Pathophysiology of functional MR  
- Hemodynamic assessment of valve disease  
- Quality control in echocardiographic measurement  
- Echocardiographic inter‑observer concordance  
- Right‑ventricular mass, volume and function assessment  
- Long‑term outcomes of valve interventions  
- Acute vs. chronic valve disease  
- Structural valve deterioration  
- Valve‑centric hemodynamic metrics (e.g., effective regurgitant orifice area)  
- Clinical statements/ guidelines for valvular management  
- Intervention thresholds for valve repair/replacement  
- Surgical vs. transcatheter strategies for valve disease  
- Functional vs. structural valve causes  
- Valve‑related morbidity and mortality.

Page 134 Extracted Terms:
- Valvular heart disease  
- Ischemic mitral regurgitation  
- Functional ischemic mitral regurgitation  
- Mitral valve repair  
- Mitral valve replacement  
- MitraClip therapy  
- Reverse remodeling (left ventricular/left atrial)  
- Left ventricular remodeling  
- Left atrial remodeling  
- Atrial functional mitral regurgitation  
- Atrial fibrillation  
- Tricuspid valve disease  
- Tricuspid regurgitation  
- Isolated tricuspid regurgitation  
- Functional tricuspid regurgitation  
- Pulmonary hypertension  
- Right heart failure  
- Heart failure (reduced/ preserved ejection fraction)  
- Mortality risk associated with valvular lesions  
- Cardiac implantable electronic devices (CIED)  
- Pacemaker lead–induced tricuspid regurgitation  
- Implantable cardioverter‑defibrillator lead–induced tricuspid regurgitation  
- Device lead‑related tricuspid valve dysfunction  
- Three‑dimensional echocardiography of tricuspid/mitral valves  
- Doppler echocardiography assessment  
- Hemodynamic evaluation (cardiac catheterization)  
- Pulmonary artery pressure measurement  
- Vena contracta analysis  
- Effective regurgitant orifice area (EROA)  
- Proximal isovelocity surface area (PISA)  
- Regurgitant volume quantification  
- Tricuspid valve grading scheme  
- Tricuspid valve repair (surgical / percutaneous)  
- Tricuspid valve replacement (surgical)  
- Right ventricular dysfunction secondary to tricuspid regurgitation  
- Left ventricular ejection fraction (LVEF)   
- Mitral annular dilation and valve adaptation  
- Severe symptomatic tricuspid regurgitation (e.g., due to device leads)  
- Tricuspid valve dysfunction following pacemaker/ICD implantation  
- Functional tricuspid regurgitation secondary to chronic atrial fibrillation  
- Surgical outcomes of tricuspid valve procedures.

Page 135 Extracted Terms:
Valvular Heart Disease  
Right ventricular size  
Right ventricular systolic function  
Pulmonary hypertension  
Right ventricular dysfunction  
Tricuspid regurgitation  
Right‑sided heart remodeling  
Tricuspid valve surgery  
Isolated tricuspid valve surgery  
Severe tricuspid regurgitation  
Moderate tricuspid regurgitation  
Tricuspid annular dilatation  
Tricuspid annular systolic velocity  
Functional tricuspid regurgitation  
Mitral valve surgery  
Mitral regurgitation  
Atrial fibrillation  
Maze procedure  
Tricuspid annuloplasty  
Tricuspid valve replacement  
Left‑heart valve surgery  
Degenerative leaflet prolapse  
Rheumatic mitral disease  
Carcinoid heart disease  
Congestive heart failure  
Tricuspid valve repair  
Transcatheter tricuspid valve interventions  
Tricuspid valve disease  
Pulmonary valve disease  
Cardiac surgery  
Echocardiographic assessment  
Two‑dimensional echocardiography  
Doppler color flow mapping  
Tricuspid valve closure  
Permanent pacemaker leads  
Implantable cardioverter‑defibrillator leads

Page 136 Extracted Terms:
- Valvular heart disease  
- Mixed valvular disease  
- Multi‑valve disease  
- Aortic stenosis  
- Aortic regurgitation / insufficiency  
- Mitral stenosis  
- Mitral regurgitation  
- Prosthetic valve  
- Prosthetic aortic valve  
- Prosthetic mitral valve  
- Mechanical prosthesis  
- Bioprosthetic valve  
- Transcatheter aortic valve replacement (TAVR)  
- Surgical aortic valve replacement (SAVR)  
- Valve replacement  
- Structural valve degeneration (SVD)  
- Hemodynamic valve deterioration  
- Valve gradients  
- Doppler echocardiography  
- Continuous‑wave Doppler  
- Transesophageal echocardiography (TEE)  
- Real‑time 3‑D TEE  
- Pressure recovery  
- Valve performance  
- Valve hemodynamics  
- Valve imaging  
- Valve evaluation  
- Valve selection  
- Valve obstruction  
- Valve dehiscence  
- Valve degeneration  
- Valve design  
- Valve outcomes  
- ACC/AHA guidelines  
- European Observational Research Programme (EURObservational)

Page 137 Extracted Terms:
- Valvular heart disease  
- Aortic valve replacement  
- Mitral valve replacement  
- Valved prosthesis (mechanical)  
- Valved prosthesis (bioprosthetic)  
- Transcatheter aortic valve implantation (TAVI)  
- Transcatheter aortic valve replacement (TAVR)  
- Valve‑in‑valve procedure  
- Ross procedure (aortic root autograft)  
- Stentless bioprosthesis  
- Carpentier‑Edwards pericardial bioprosthesis  
- Perimount pericardial bioprosthesis  
- Mechanical heart valve (bileaflet)  
- Antithrombotic therapy  
- Oral anticoagulation  
- Low‑intensity anticoagulation  
- Dabigatran vs warfarin trials (RE‑ALIGN, ENGAGE, etc.)  
- Thromboembolic complications  
- Bleeding complications  
- Valve durability  
- Valve degeneration  
- Valve failure  
- Valve‑related complications  
- Hemodynamic stability  
- Survival outcomes  
- Mortality outcomes  
- Stroke risk  
- Valve replacement in high‑risk patients  
- Valve replacement in low‑risk patients  
- Valve prosthesis selection (mechanical vs biological)  
- Valve implantation outcomes  
- Clinical guidelines (ACC/AHA) on valvular heart disease  
- Percutaneous valve therapies  
- Valve repair versus replacement  
- Valve position (aortic, mitral)  
- Anticoagulant management in valve patients



Page 138 Extracted Terms:
- Valvular heart disease  
- Intracardiac thrombosis  
- Anticoagulation (warfarin, direct oral anticoagulants)  
- Antiplatelet therapy (aspirin, clopidogrel, dual antiplatelet therapy)  
- Mechanical aortic valve replacement  
- Bioprosthetic aortic valve replacement  
- Transcatheter aortic valve replacement (TAVR)  
- Prosthetic heart valves  
- Thromboembolic complications  
- Bleeding complications  
- Valve thrombosis (including subclinical leaflet thrombosis)  
- Structural valve deterioration / failure  
- Perioperative bridging anticoagulation  
- Low‑molecular‑weight heparin (enoxaparin, dalteparin)  
- Unfractionated heparin  
- Prothrombin complex concentrate  
- Direct oral anticoagulants (dabigatran, rivaroxaban, apixaban, edoxaban)  
- Atrial fibrillation in valvular heart disease  
- Early anticoagulation strategies (short‑term, long‑term)  
- Bioprosthetic valve thrombosis prevention (aspirin, warfarin, low‑dose warfarin)  
- Mechanical valve thrombosis prevention  
- Guideline references (ACC/AHA, American College of Chest Physicians, AHA/NASPE‑CPT)  
- Clinical management of antithrombotic therapy in valve disease  


Page 139 Extracted Terms:
- Anticoagulation  
- Anticoagulant reversal agents  
- Andexanet alfa  
- Bioprosthetic valve  
- Bleeding complications  
- Catheter‑derived imaging  
- Catheter‑guided thrombolysis  
- Computed tomography (CT)  
- Dabigatran  
- Idarucizumab  
- Mechanical valve  
- Mechanical valve thrombosis  
- Multimodality imaging  
- New‑generation anticoagulants  
- Subclinical leaflet thrombosis  
- Pannus formation  
- Prosthetic valve obstruction  
- Prosthetic valve thrombosis  
- Prosthetic heart valve  
- Transesophageal echocardiography (TEE)  
- Transthoracic echocardiography (TTE)  
- Transcatheter heart valve (THV)  
- Transcatheter valve‑in‑valve procedure  
- Vitamin K antagonists (warfarin)  
- Vitamin K1  
- Warfarin  
- Left‑sided prosthetic valve  
- Right‑sided prosthetic valve  
- Thrombolytic therapy  
- Tissue‑type plasminogen activator (tPA)  
- Thrombus vs. pannus differentiation  
- Valve‑in‑valve implantation  
- Valve‑prosthesis interaction  
- Echocardiographic Doppler assessment  
- Clinical decision pathways for anticoagulation  
- Risk assessment for thrombolysis  
- Low‑dose infusion strategies  
- Rebound anticoagulation after cessation  
- Fresh frozen plasma in over‑anticoagulation  
- Anticoagulation monitoring (INR)  
- Cardiac imaging guideline  
- Thrombotic events associated with prosthetic valves.

Page 140 Extracted Terms:
- Valvular Heart Disease  
- Thrombolytic therapy for mechanical pulmonic/tricuspid valves  
- Prosthetic valve thrombosis  
- Bioprosthetic valve thrombosis  
- Subclinical leaflet thrombosis  
- Transcatheter aortic valve replacement (TAVR)  
- Mechanical prosthetic valves  
- Pannus formation  
- Structural valve degeneration  
- Prosthesis–patient mismatch  
- Redo aortic valve surgery  
- Transcatheter aortic valve‑in‑valve implantation  
- Failed surgical bioprosthetic valves  
- Transcatheter heart valve thrombosis  
- Phenprocoumon anticoagulation  
- Echocardiography and Doppler ultrasound in valve assessment  
- Cardiovascular imaging guidelines (American Society of Echocardiography, European Association of Cardiovascular Imaging, etc.)

Page 141 Extracted Terms:
- Valvular heart disease  
- Valvular degeneration  
- Prosthetic valve  
- Bicuspid aortic valve  
- Tricuspid aortic valve  
- Aortic valve stenosis  
- Aortic valve regurgitation  
- Mitral valve stenosis  
- Mitral valve regurgitation  
- Valve replacement (surgical)  
- Valve replacement (transcatheter)  
- Transcatheter aortic valve implantation (TAVI)  
- Valve‑in‑valve procedure  
- Mechanical valve  
- Bioprosthetic valve  
- Paravalvular leak  
- Periprosthetic leak  
- Prosthetic valve regurgitation  
- Valvular insufficiency  
- Infective endocarditis  
- Duke criteria  
- Diagnostic criteria for endocarditis  
- Culture‑negative endocarditis  
- Echocardiography (2‑D, 3‑D, transesophageal)  
- Doppler ultrasound  
- Real‑time 3‑D transesophageal echocardiography  
- Intracardiac echocardiography  
- STS (Society of Thoracic Surgeons) risk calculator  
- Risk factors for infective endocarditis  
- Structural valve degeneration  
- Prosthetic valve evaluation  
- Valve imaging assessment  
- Transcatheter valve repair  
- Surgical valve repair  
- Cardiac imaging guidelines  
- Perioperative valve outcomes  
- Long‑term valve survival  
- Valve reoperation risk  

Page 142 Extracted Terms:
- Valvular heart disease  
- Infective endocarditis  
- Endocarditis  
- Transesophageal echocardiography  
- Transthoracic echocardiography  
- Valve vegetation  
- Prosthetic valve endocarditis  
- Aortic valve  
- Mitral valve  
- Valve regurgitation  
- Valve stenosis  
- Bacteremia  
- Staphylococcus aureus  
- Methicillin‑resistant Staphylococcus aureus (MRSA)  
- Methicillin‑sensitive Staphylococcus aureus (MSSA)  
- Antibiotic therapy  
- Antibiotic duration  
- Surgical treatment of endocarditis  
- Embolization  
- Pacemaker endocarditis  
- Cardiac implantable electronic devices (CIED)  
- Intraoperative echocardiography  
- Appropriate use criteria for echocardiography  
- Duke criteria  
- Diagnostic criteria for infective endocarditis  
- Valve infection  
- Blood cultures  
- Valve prosthesis infection  
- Endocarditis mortality  
- Endocarditis guidelines (ACC/AHA, ESC)  
- Echocardiographic sensitivity  
- Echocardiographic specificity  
- Clinical presentation of endocarditis  
- Valve perforation  
- Valve abscess  
- Cardiac surgery decision‐making  
- Infective endocarditis risk factors  
- Valvular dysfunction  
- Echocardiographic detection of vegetation size  
- Cardiovascular imaging  
- Intravenous catheter–associated bacteremia.

Page 143 Extracted Terms:
- Endocarditis  
- Infective endocarditis  
- Native valve endocarditis  
- Prosthetic valve endocarditis  
- Valve infection  
- Aortic valve  
- Mechanical heart valve  
- Valve obstruction  
- Valvular dysfunction  
- Valvular heart disease  
- Heart valve disease  
- Heart valve prosthesis  
- Heart valve replacement  
- Heart valve surgery  
- Transesophageal echocardiography (TEE)  
- Transthoracic echocardiography (TTE)  
- Echo (echocardiography)  
- Multislice computed tomography (CT)  
- Cardiac CT  
- Coronary angiography  
- Coronary artery disease (CAD)  
- FDG PET/CT  
- 18F‑fluorodeoxyglucose PET/CT  
- Anticoagulation therapy  
- Anticoagulant therapy (warfarin, others)  
- Antithrombotic therapy  
- Antithrombotic and thrombolytic therapy  
- Intracranial hemorrhage  
- Cerebral hemorrhage  
- Stroke (embolic stroke)  
- Cerebrovascular complications  
- Myocardial infarction / infarction  
- Cardiovascular complications  
- Cardiovascular disease  
- Cardiac valve complications  
- Mechanical disc prosthesis  
- Prosthetic heart valve complications  
- Valve-related bacteremia (e.g., Staphylococcus aureus bacteremia)  
- Valve‑related sepsis / septic shock  
- Valve disease imaging (CT, PET/CT, echocardiography)

Page 144 Extracted Terms:
- Valvular heart disease  
- Infective endocarditis  
- Prosthetic valve endocarditis  
- Native‑valve endocarditis  
- Bicuspid aortic valve disease  
- Aortic valve disease  
- Mitral valve disease  
- Right‑sided Staphylococcus aureus endocarditis  
- Left‑sided endocarditis  
- Valve surgery  
- Mechanical valve implantation  
- Bioprosthetic (biological) valve replacement  
- Antiplatelet therapy (e.g., aspirin)  
- Anticoagulant therapy (e.g., warfarin)  
- Aspirin‑induced hemorrhage  
- Warfarin‑associated intracranial hemorrhage  
- Stroke / cerebral hemorrhage  
- Sepsis / septic shock management  
- Multidisciplinary management team (e‑Team)  
- Early surgical intervention  
- Mortality predictors in endocarditis  
- Risk scoring system for prosthetic valve procedures  
- Fungal prosthetic valve endocarditis  
- Chronic infection of pacemaker leads  
- Antimicrobial therapy (e.g., cloxacillin, gentamicin)  
- Prosthetic valve replacement versus medical therapy  

These terms capture the core concepts of heart disease discussed in the guideline text.

Page 145 Extracted Terms:
- Valvular heart disease  
- Infective endocarditis  
- Aortic valve endocarditis  
- Native valve endocarditis  
- Prosthetic valve endocarditis  
- Paravalvular abscess  
- Perivalvular abscess  
- Mitral valve endocarditis  
- Left‑sided endocarditis  
- Right‑sided endocarditis  
- Cardio‑embolic stroke  
- Heart failure  
- Aortocavitary fistula  
- Transesophageal echocardiography  
- Transthoracic echocardiography  
- Vegetation  
- Vegetation size  
- Surgical timing  
- Early surgery  
- Conventional treatment  
- Valve replacement  
- Valve repair  
- Mechanical prosthesis  
- Bioprosthetic valve  
- Allograft  
- Implantable cardiac devices  
- Pacemaker endocarditis  
- Implantable cardioverter‑defibrillator (ICD) infection  
- Device‑related endocarditis  
- Percutaneous lead extraction  
- Endocarditis diagnosis  
- Cardiovascular implantable electronic device infection  
- Drug‑use‑associated endocarditis  
- Injection drug users (IDU)  
- Opioid‑dependent patients  
- Buprenorphine treatment  
- Mortality risk  
- Embolic risk  
- Prognostic value  
- Echocardiographic features  
- Long‑term outcomes  
- Early clinical course  
- Outcome prediction  
- Risk factors  
- Pulmonary hypertension  
- Aortic stenosis  
- Pregnancy outcomes  
- Valvular heart disease in pregnancy  
- Native valves in pregnancy  
- Periprosthetic leakage  
- Transcatheter closure of paravalvular defects  
- ESC guidelines  
- ROPAC registry (Registry Of Pregnancy And Cardiac disease)  
- ESC registry of pregnancy and cardiac disease  
- Multicenter prospective study  
- Multicenter registry  
- Pregnancy outcomes in women with heart disease

Page 146 Extracted Terms:
- Valvular heart disease (VHD)  
- Aortic stenosis  
- Mitral stenosis  
- Rheumatic mitral stenosis  
- Congenital aortic stenosis  
- Mechanical heart valve  
- Valve replacement (mechanical/electronic)  
- Percutaneous balloon aortic valvuloplasty (PBA)  
- Percutaneous balloon mitral valvuloplasty (PBMV)  
- Balloon mitral commissurotomy  
- Balloon dilatation of the aortic valve  
- Balloon dilatation for severe aortic stenosis  
- Peri‑pregnancy intervention for VHD  
- Pregnancy outcomes in heart disease  
- Pulmonary hypertension  
- Exercise Doppler echocardiography  
- Risk stratification of asymptomatic valvular disease  
- ESC guidelines for cardiovascular disease during pregnancy  
- ACC/AHA guidelines for valvular heart disease  
- AHA/ACC/HRS guidelines for atrial fibrillation  
- Beta‑adrenergic blockade in pregnancy with valvular disease  
- Angiotensin‑II receptor antagonists and fetal toxicity  
- ACE inhibitor exposure in the first trimester  
- Anticoagulation management in mechanical valve pregnancy  
- Cardiac medication during pregnancy (ROPAC data)  
- Mechanical aortic valve replacement in women of childbearing age  
- Early surgery for severe aortic stenosis  
- Prognostic importance of quantitative exercise Doppler  
- Multicenter pregnancy outcome registries (ROPAC, Registry of Pregnancy and Cardiac Disease)  
- Perinatal cardiac outcomes in valvular disease  
- Volume overload impact on pulmonary circulation during pregnancy  
- Fetal growth effects of atenolol in pregnancy with hypertension  

Page 147 Extracted Terms:
- Valvular heart disease  
- Mitral stenosis  
- Balloon mitral valvuloplasty  
- Percutaneous balloon valvuloplasty  
- Percutaneous balloon commissurotomy  
- Cardiovascular surgery  
- Intracardiac surgery  
- Cardiac surgery  
- Cardiopulmonary bypass  
- Prosthetic heart valves  
- Mechanical prosthetic valve  
- Biologic prosthetic valve  
- Homograft valve  
- Valve replacement  
- Valve prosthesis  
- Thrombus  
- Prosthetic valve thrombosis  
- Anticoagulation  
- Warfarin  
- Low‑molecular‑weight heparin  
- Enoxaparin  
- Anti‑Xa monitoring  
- Tissue‑type plasminogen activator  
- Thrombolytic therapy  
- Transesophageal echocardiography  
- Echocardiographic evaluation  
- Hemodynamic changes  
- Hemodynamics  
- Pregnancy outcomes  
- Maternal outcomes  
- Fetal outcomes  
- Obstetric outcomes  
- Thromboprophylaxis  
- Thromboembolism  
- Thrombolysis

Page 148 Extracted Terms:
- Valvular heart disease (VHD)  
- Prosthetic heart valve (PHV)  
- Mechanical heart valve  
- Aortic stenosis  
- Aortic valve replacement (AVR)  
- Transcatheter aortic valve replacement (TAVR) / implantation (TAVI)  
- Coronary artery disease (CAD)  
- Angina pectoris  
- Percutaneous coronary intervention (PCI)  
- Coronary artery bypass grafting (CABG)  
- Coronary angiography  
- Computed tomography coronary angiography (CTCA)  
- Instantaneous wave‑free ratio (iFR)  
- Revascularization  
- Valve surgery  
- Valve replacement  
- Valve‑related complications  
- Anticoagulation therapy  
- Warfarin  
- Direct oral anticoagulants (DOACs)  
- Low‑molecular‑weight heparin (LMWH)  
- Enoxaparin  
- Subcutaneous heparin  
- Antiplatelet therapy  
- Thrombosis  
- Mechanical valve thrombosis  
- Thromboembolic events  
- Thrombolytic therapy  
- Tissue‑type plasminogen activator (tPA)  
- Maternal complications during pregnancy  
- Fetal outcomes in pregnancy with prosthetic valves  
- Pregnancy anticoagulation dilemma  
- Hemodynamics  
- Pressure overload  
- Surgical considerations for CAD in VHD  
- Angiographic severity assessment  
- Stroke risk in valvular disease  
- Long‑term survival of valve‑repair patients  
- Valve durability and degeneration  
- Cardioprotective management strategies  

These terms capture the key concepts related to heart disease and its management discussed in the provided guideline text.

Page 149 Extracted Terms:
- Valvular Heart Disease  
- Aortic Stenosis  
- Aortic Regurgitation  
- Severe Aortic Stenosis  
- Mitral Regurgitation  
- Valvular Regurgitation  
- Coronary Artery Disease  
- Coronary Artery Stenosis  
- Coronary Atherosclerosis  
- Ischemic Mitral Regurgitation  
- Radiation‑induced Heart Disease  
- Atrial Fibrillation  
- Intraoperative Atrial Fibrillation  
- Cox Maze Procedure  
- Surgical Ablation of Atrial Fibrillation  
- Pulmonary Vein Isolation  
- Left Atrial Appendage Occlusion / Closure  
- Stroke (associated with atrial fibrillation)  
- Transcatheter Aortic Valve Implantation (TAVI)  
- Transcatheter Aortic Valve Replacement (TAVR)  
- Valve Replacement Surgery  
- Coronary Computed Tomography Angiography (CTCA)  
- Multidetector Computed Tomography Coronary Angiography  
- Coronary Angiography (invasive)  
- Hybrid Cardiovascular Procedures  
- Coronary Artery Bypass Grafting (CABG)  
- Anticoagulation Therapy  
- Novel Oral Anticoagulants (NOACs)  
- Left Ventricular Function  
- Early and Late Survival after Valve Replacement  
- Transesophageal Echocardiography (TEE) for valve assessment  
- Framingham Risk Score (cardiovascular risk profiling)  
- Diamond‑Forrester Probability model (coronary artery disease assessment)  
- Preoperative Coronary Angiography for Cardiac Surgery  
- Surgical Thrombectomy / Atrial Appendage Exclusion  
- Cardiothoracic Surgery (general scope)

Page 150 Extracted Terms:
- Valvular heart disease  
- Aortic stenosis  
- Aortic valve replacement  
- Transcatheter aortic valve replacement (TAVR)  
- Surgical aortic valve replacement (SAVR)  
- Balloon aortic valvuloplasty (BAV)  
- Mitral regurgitation  
- Pulmonary arterial hypertension (PAH)  
- Pulmonary hypertension  
- Coronary artery disease  
- Intrinsic cardiac risks  
- Perioperative cardiovascular evaluation  
- Preoperative cardiovascular evaluation  
- Non‑cardiac surgery (in the context of cardiac risk)  
- Perioperative risk  
- Valve disease prevention (e.g., systolic blood pressure, calcific aortic stenosis)  
- Clinical outcomes related to valvular disease management  

Page 151 Extracted Terms:
- Valvular Heart Disease  
- Aortic Stenosis  
- Calcific Aortic Valve Stenosis  
- Myxomatous Mitral Valve  
- Valvular Calcification  
- Rheumatic Heart Disease  
- Cardiac Fibrosis  
- Matrix Remodeling  
- TGF‑β Signalling  
- Reactive Oxygen Species  
- Multimodality Imaging  
- Renin‑Angiotensin System Inhibition  
- Transcatheter Aortic Valve Replacement (TAVR)  
- Blood Pressure  
- Arterial Load  
- Genetic Associations  
- Patient‑Centered Research  
- Valve Durability  
- Shared Decision‑Making  
- Valve Interventions  
- Cardiovascular Imaging  
- Heart Disease  
- Stroke Statistics  
- Valve Disease Burden  
- Valve Imaging  
- Valve Disease Management

Page 152 Extracted Terms:
- Valvular Heart Disease  
- Heart Disease  
- Cardiovascular  
- Cardiac  
- Adult Congenital Heart Disease  
- Cardiac Surgery  
- Cardiology  
- Interventional Cardiology  
- Cardiovascular Medicine  
- Corrigan Minehan Heart Center  
- ACC/AHA Guideline for the Management of Valvular Heart Disease  

Page 153 Extracted Terms:
- Valvular Heart Disease  
- Heart Failure  
- Infective Endocarditis  
- Cardiovascular  
- Cardiology  
- Heart Disease  
- ACC/AHA (American College of Cardiology/American Heart Association) Guidelines  
- Heart Failure Society of America  
- Valvular  
- Management of Valvular Heart Disease  
- Clinical Guidelines for Heart Disease  
- Cardiovascular Fellowship Program  
- Heart‑related Clinical Practice Guidelines  

Page 154 Extracted Terms:
- ACC/AHA Guideline for the Management of Valvular Heart Disease  
- Valvular Heart Disease  
- Heart Valve  
- Heart Valve Voice  
- Medtronic (device manufacturer for heart valve procedures)  
- Abbott (cardiovascular devices)  
- Edwards Lifesciences (heart valve technology)  
- NeoChord (transcatheter mitral valve repair system)  
- HeartFlow (non‑invasive coronary artery disease assessment)  
- AHA (American Heart Association)  
- STEMI (ST‑segment elevation myocardial infarction)  
- Cardiology / Cardiovascular (clinical disciplines)

Page 155 Extracted Terms:
- **Valvular Heart Disease**  
- **ACC/AHA Guideline for the Management of Valvular Heart Disease**  
- **Clinical Cardiac Electrophysiology**  
- **Adult Congenital Heart Disease Program**  
- **Pulmonary Hypertension**  
- **Cardiovascular** (as a general domain)  
- **National Minority Cardiovascular Alliance**  
- **Cardiac Phoenix**  
- **Boston Scientific** (heart‑device manufacturer)  
- **Medtronic** (heart‑device manufacturer)  
- **Edwards Lifesciences** (heart‑valve manufacturer)  
- **Abbott Vascular** (vascular‑intervention manufacturer)  
- **Bayer Healthcare Pharmaceuticals** (cardiovascular drug manufacturer)  
- **Philips Healthcare** (cardiac imaging equipment)  
- **Siemens Healthineers** (cardiac imaging equipment)  
- **NaviGate** (cardiac navigation system)  
- **V‑Wave Ltd.** (cardiac imaging/diagnostic firm)  
- **Joint Committee on Clinical Practice Guidelines** (guideline‑development body)  
- **American Heart Association (AHA)**  
- **American College of Cardiology (ACC)**  
- **ACC/AHA** (combined guideline and organization abbreviation)  
- **Circulation Journals** (cardiology journal)  

*(These terms were extracted from the provided text and are directly related to heart disease, cardiac care, and cardiovascular medicine.)*

Page 156 Extracted Terms:
- Valvular Heart Disease  
- Heart Disease  
- Cardiovascular Disease  
- Cardiac  
- Heart  
- Stroke  
- Valves  
- Valve Disease  
- Valvular disease  
- Cardiac valves  
- Heart valve disorders  

